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  Abstract 
  
 
Abstract 
 
 
Transporter-mediated uptake is critical for terminating the actions of glutamate, the major 
excitatory neurotransmitter in the central nervous system (CNS), preventing the sustained 
activation of receptors that would otherwise disrupt signaling at synapses and lead to 
excitotoxic neurodegeneration.  At synapses in the CNS, glutamate transporters can 
influence the occupancy of glutamate receptors by reducing the peak concentration of 
glutamate within the synaptic cleft, by accelerating the decay of the glutamate transient, and 
by restricting the diffusion of glutamate to perisynaptic receptors or receptors at adjacent 
synapses. The regulation of these transporters can occur at two levels: transcription and 
synthesis of new protein and by changes in the number of pre-existent transporters at the 
plasma membrane by trafficking mechanisms, but the regulatory mechanisms are poorly 
understood. 
This work characterized the protein expression profile and the functionality of glial 
glutamate transporter GLAST and neuronal glutamate transporter subtypes EAAC1 and 
EAAT4 in HEK-293 cells. The protein expression profiles were established both, by western 
blotting and immunocytochemical localization and the functionality of the glutamate 
transporters was established by high affinity glutamate uptake measurements. 
A massive increase in the glutamate uptake capacity and cell surface expression of EAAC1 
was observed in response to phorbol esters as well as phosphatase inhibitors and the role of 
PKC was conclusively established in the regulated trafficking mechanism and observed 
increase in the surface expression.  
Moreover, it was also shown that the trafficking mechanism for the neuronal glutamate 
transporter EAAC1 also depends on the intracellular calcium, calmodulin and 
Calcium/calmodulin dependent CaM Kinase II for the trafficking. 
All together, activation of PKC is not the only mechanism responsible for the regulated 
trafficking of EAAC1, but also requires the participation of downstream pathway of 
Ca2+/Calmodulin dependent CaM kinase II for the re-distribution of intracellular pools of 
EAAC1 to the plasma membrane. Finally, it was also demonstrated that redistribution of 
glutamate transporter upon stimulation by phorbol esters and phosphatase inhibitors causes 
the transporter to be phosphorylated at a tyrosine residue. 
All together, an involvement of PKC, phosphatase inhibitors, intracellular calcium and 
Ca2+/calmodulin dependent CaM kinase II and tyrosine phosphorylation regulate the 
trafficking of neuronal glutamate transporter EAAC1. 
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1 Abbreviations 
 
aa  Amino acids 
ADP  Adenosine di-phosphate 
ALS  Amyotropic lateral sclerosis 
AMPA  Amino-3-hydroxy-5-Methyl-4-isoxazole Propionic Acid 
APS  Ammonium per sulfate 
ASCT  Alanine Serine Cysteine carrier 
ATP  Adenosine triphosphate 
BAPTA-AM   1, 2-Bis (2-aminophenoxy)-ethane-N, N, N’, N’-Tetra Acetic Acid-Acetoxy 
                        Methyl Ester 
BCA Bichinchoninic acid   
bp  Base pair(s) 
BSA  Bovine serum albumin 
CaM  Calmodulin 
CaMK II calcium /calmodulin dependent kinase II 
cAMP  Cyclic adenosine mono phosphate 
cDNA  Complementary deoxyribonucleic acid 
Ci  Curie 
CLSM  Confocal laser scanning microscopy/microscope 
CNS  Central nervous system 
cpm  Counts per minute 
Da  Dalton 
DAG  Diacylglycerol 
DAT  Dopamine transporter 
dd  Double distilled 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO  Dimethylsulfoxide 
DNA  Desoxyribose nucleic acid 
DTNB  5, 5 dithio-bis-2-nitro benzoic acid 
DTT  Dithiothreitol 
EAAT  Excitatory amino acid transporter  
ECL  Enhanced chemiluminiscence 
E. coli  Escherichia coli 
EDTA  Ethylene diamine tetra acetic acid 
EGF  epidermal growth factor 
FCS  Fetal calf serum 
FGF-2  Fibroblast growth factor-2 
FITC  Fluorescein isothiocyanate 
g  Acceleration due to gravity (9.81 m/s2) 
GABA  -amino butyric acid 
GAT  GABA transporter 
GLAST Glutamate aspartate transporter 
GLT  Glial transporter 
GluR  Glutamate receptor 
GLUT  Glucose transporter 
GSH  Glutathione 
H  Hour(s) 
HEK  Human embryonic kidney cells 
IgG  Immunoglobulin G 
kDa  Kilo Dalton 
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Km  Michaelis Menten constant 
L  liter 
LB  Luria and Bertami 
M  Molar (mol/l) 
mg/ml  Milligram/milliliter 
M  Micro molar 
min  Minute(s) 
MW  Molecular weight 
NGS  Normal goat serum 
NMDA N-methyl-D-aspartate 
O/N  Overnight 
PAGE  Polyacrylamide gel electrophoresis 
PBS  Phosphate buffered saline 
4  -PDD 4  -12,13 phorbol didecanoate 
PDGF  Platelet derived growth factor 
PI3  Inositol tri-phosphate 
PICK  Protein interacting with C kinase 
PIP2  Phosphatidylinositol-4,5-biphosphate 
PKA  Protein kinase A 
PKB  Protein kinase B 
PKC  Protein kinase C 
PLC  Phopholipase C 
PMA  Phorbol 12-myristate 13-acetate 
PMCA  Plasma membrane Ca2+ ATPase 
PNGase Peptide-N-glycosidase 
POD  Peroxidase 
PVP  Polyvinylpyrrolidone 
RACKS Receptor for activated C kinases 
RL  Re-entrant loop 
RyR  Ryanodine receptor 
rpm  Rounds per minute 
SDS  Sodium dodecyl sulfate 
Sec  Seconds 
SERCA Smooth endoplasmic reticulum Ca2+ ATPase 
SERT  Serotonin transporter 
SFM  Serum free medium 
SH  Sulfhydryl 
SNAP  N-ethylmaleimide sensitive attachment protein 
SNARE SNAP receptors 
TEMED N, N, N’, N’-tetramethylethyldiamine 
TGF-  Transforming growth factor- 
TMD  Transmembrane domain 
Tris  Tris-(hydroxymethyl)-aminomethane 
TRITC  Tetramethyl rhodamine isothiocyanate 
U  Unit(s) 
V  Voltage 
VIS  Visible 
v/v  Volume/volume 
vol  Volume 
w/v  Weight/volume 
W  Watt
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2 Introduction  
The brain is the most fascinating organ, capturing and integrating floods of information from 
the environment, and converting it into a form interpretable for us. Most importantly, brain is 
the locus of consciousness, the fundamental characteristic of human beings. Human brain 
contains approximately 1011 (100 Billion) neurons. Each neuron sends out approximately 1000 
cell processes to interact with other neurons at the zones of contact called synapses (Greek: syn 
“together”, hapto “linked with”). Consequently, our brain roughly contains 1014 synapses. This 
illustrates the complexity of the human brain and difficulties in investigating diverse brain 
activities. One approach to learn more about brain function is to explore the mode of operation 
of one or a few neurons in a network.  
In the brain, the smallest functional unit is the synapse. Exchange of information at the 
synapses uses chemical transmitters for communication. These neurotransmitters are released 
from neurons into the synaptic cleft in response to specific stimuli and cause excitatory or 
inhibitory responses in the adjacent neurons, which represent the basic code of the neuronal 
language. In the mammalian central nervous system (CNS), the amino acid L-glutamate is the 
predominant excitatory chemical transmitter. L-glutamate mediates synaptic transmission at a 
majority of synapses in the CNS and has been implicated in several important brain processes, 
ranging from development of synapse formation to learning and memory [2] and thus, is a 
subject of intense investigations in current neuroscience. However, at elevated extracellular 
concentrations, glutamate acts as a powerful neurotoxin capable of inducing severe excitotoxic 
damages to neurons, a mechanism implicated in several neurodegenerative diseases (e.g., 
amylotrophic lateral sclerosis (ALS), Huntington’s disease, and Alzheimer’s disease) and brain 
insults (e.g. ischemia, hypoxia, hypoglycaemia, epilepsy), while low concentrations are 
implicated in schizophrenia [3]. 
2.1 Glutamate in the CNS 
 
L-glutamate is an important amino acid involved in classical biochemical pathways, including 
ammonia detoxification and gluconeogenesis. However, in the mammalian CNS, L-glutamate 
plays an important role as an excitatory neurotransmitter. Glutamate is synthesised and stored 
in specialised glutamatergic neurons and is released upon stimuli (e.g. action potentials) into 
the synaptic cleft. The cycle of neurotransmission is initiated by the fusion of neurotransmitter-
loaded vesicles with the plasma membrane of the presynaptic neuron (Fig.2.1).  
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Within milliseconds, glutamate diffuses across the synaptic cleft and binds to an array of 
glutamate receptors which are situated on the pre- and postsynaptic membranes, and also on 
astroglial processes. The chemical signal is converted into an electrical signal by the transient 
opening of ligand-gated ion channels. This is achieved either directly by ionotropic glutamate 
receptors or indirectly by metabotropic glutamate receptors, which modulate ion channel 
activity by second messenger systems. As a result, the chemical signal is integrated, and 
transformed into an electrical signal, facilitating information transfer from one neuron to 
another. However, to avoid a continuous activation and damage to secondary neurons, 
glutamate has to be removed rapidly from the synaptic cleft. This essential step is accomplished 
by diffusion or enzymatic degradation (e.g. cholinergic transmission) or, by active transport 
into nerve endings or into surrounding glia cells, as in the case of glutamate (Fig.2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2.1 Transport of glutamate from the synaptic cleft  
Triggered by action potentials, synaptic vesicles fuse in a calcium-dependent manner with the 
presynaptic terminal and release glutamate into the synaptic cleft. Glutamate binds to glutamate 
receptors which mediate the signal to secondary neurons. Rapid removal of glutamate from the synaptic 
cleft is achieved by high-affinity glutamate transporters which are located either in glial cells or neurons 
(arrows). Once glutamate is transported into the cell, it can be taken up into vesicles by a different 
family of carriers (indicated by the arrow in the presynapse) or is degraded in glial cells by glutamine 
synthetase into glutamine (Gln). 
 
 
Transmitter accumulated in the cytoplasm of presynaptic cells is sequestered in synaptic 
vesicles, ready for a new cycle of neurotransmission. In contrast, glutamate taken up by glial 
cells passes the so called “Glutamate-Glutamine Cycle”.  
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In the latter case, glutamate is converted to glutamine by the glia-specific enzyme glutamine-
synthetase, released into the extracellular space, and subsequently taken up by glutamatergic 
neurons for a new cycle of transmitter synthesis (Fig. 2.1). Both, neuronal and glial glutamate 
uptake systems are capable of translocating glutamate against several thousand-fold 
concentration gradients, and thus, keep the resting glutamate concentration in the synaptic cleft 
below the level (< 1 µM) that activates glutamate receptors. 
Malfunction of synaptic transmission in the CNS is related to numerous neurological diseases 
and psychiatric disorders. Traditionally, the targets for drugs that interfere with 
neurotransmission are the receptors that are responsible for the generation of the electrical 
signal in post-synaptic neurons.  
This work focuses on a different target in the system: the neurotransmitter transporters, that are 
responsible for the (re)-uptake of the neurotransmitter from the synaptic cleft into neuronal 
cells or surrounding glial cells. The activity of these transporters is known to be essential for 
the temporal and spatial regulation of the neurotransmitter concentration in the synaptic cleft, 
and thus, is crucial for proper neuronal signalling. 
2.2 Glutamate transporter types: an overview 
 
Glutamate transporters can be broadly classified into three categories based upon their affinity 
for glutamate as well as transport dependency on the availability of sodium and potassium ions. 
2.2.1 ‘High-affinity’ Na+/K+-dependent glutamate transporters’ 
 
Originally, these transporters were referred to as the ‘sodium-dependent high-affinity 
transporters’ to distinguish them from the ‘low-affinity transporters’. However, since their 
affinities are not particularly high (Km values being 1–100 M) depending on the transporter 
subtype and the assay system used and because they are driven by the gradients of both Na+ and 
K+, the preferred term is now ‘sodium and potassium coupled glutamate transporters’ or 
‘excitatory amino acid transporters’ (‘EAATs’)[4]  
 
In particular, the high-affinity sodium-and potassium-coupled glutamate transporter contributes 
to the control of the extracellular glutamate concentration. The eukaryotic (EAAT) protein 
family meanwhile consists of 5 members: human EAAT1 (rat homologue: glutamate 
transporter GLAST), human EAAT2 (rat homologue: glutamate transporter GLT), human 
EAAT3 (excitatory amino acid carrier 1 or EAAC1), EAAT4, and EAAT5. 
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The present work concentrates on the high affinity glutamate transporters or the EAAT’s. 
The five cloned glutamate transporters till date i.e. EAAT1 (GLAST), EAAT2 (GLT), EAAT3 
(EAAC1), EAAT4 and EAAT5 catalyze the sodium potassium coupled transport of L-
glutamate as well as L-and D-aspartate. These five transporters share 50-60% amino acid 
sequence identity with the carriers of neutral amino acid carriers such as alanine-serine-cysteine 
carriers: ASCT1 and ASCT2.  
 
2.2.2 ‘Low-affinity’ glutamate transporters 
 
The ‘low-affinity’ uptake exhibits Km values above 500 M and, in contrast to the ‘high 
affinity’ system, is described as sodium-independent [5] and sensitive to inhibition by D-
glutamate and L-homocysteinate [6] This uptake system has been suggested to supply brain 
with amino acids for metabolic purposes, but is poorly characterized.  
 
2.2.3 Sodium-independent uptake and glutamate–cystine exchangers 
 
In addition to the glutamate uptake systems mentioned above, sodium-independent and 
chloride-dependent glutamate uptake has also been described both in brain tissue and in cell 
cultures (for review, see [6]). 
 
2.3 Importance of glutamate uptake 
 
Considering that high extracellular concentrations of glutamate in the CNS can be toxic, it is 
extremely important to have regulatory mechanisms controlling the extracellular glutamate 
concentrations. Since there are no extracellular mechanisms of glutamate conversion, the brain 
needs a very high glutamate uptake capacity in order to protect from the toxic effects of 
excessive glutamate. The normal intact brain is able to maintain the levels of extracellular 
glutamate as long as the energy supply is not compromised. In contrast, unprotected neurons in 
cell culture can be killed in the presence of micromolar concentrations of glutamate. 
These low levels of extracellular glutamate are primarily maintained by glutamate transporters.  
The basic knowledge about the transport mechanism and pharmacology of the sodium and 
potassium-coupled glutamate transporters originates from studies on crude preparations such as 
brain slices, crude homogenates, synaptosomes (pinched off nerve endings) and cell cultures 
[7].  
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The main conclusions of these studies have been confirmed, in combination with more refined 
techniques such as reconstitution of purified transporters in artificial membranes or by 
electrophysiological techniques. The cloning and expression of individual transporters have 
aided detailed characterization of glutamate uptake. It is now possible to study the transporter 
subtypes individually without interference from other proteins and other glutamate transporter 
subtypes. It is also possible to perform electrophysiological recordings from single cells 
expressing a single transporter subtype and thereby to exploit the electrogenic nature of the 
transport to measure both the specificity and the kinetics of the uptake process [8] . 
 
2.3.1 Uptake mechanism and stoichiometry of the process 
 
Glutamate transporters belong to the class of secondary-active, Na+-dependent transporters [9-
11].  In contrast to primary-active transporters which use metabolic energy sources such as 
ATP directly for “uphill” transport [12], secondary-active Na+-dependent transporters are 
energized by the coupling of “uphill” substrate transport to the co-transport of Na+ down its 
own transmembrane concentration gradient [7, 13, 14] which is maintained by the Na+/K+-
ATPase.  In the case of the glutamate transporters, the stoichiometry of this coupling is 
movement of 1 glutamate, 3 Na+, and 1 H+ into the cell, along with 1 K+ out of the cell [15-18], 
as illustrated in Fig.2.2. According to this stoichiometry, glutamate transport is electrogenic 
[19], as two net positive charges are moved into the cell for each completed transport cycle. 
Electrogenic transport is associated with the flow of current [20] which will be referred to here 
as transport current. This current is also sometimes termed coupled transport or uptake current 
to indicate that it is associated with the charge movement that is stoichiometrically coupled to 
glutamate transport. Recording of the transport current represents a highly sensitive functional 
assay for glutamate transporter function, although it is technically not a trivial task. Because of 
the small turnover number of the glutamate transporter (30 s-1 at 0 mV), about 105 transporter 
molecules are necessary to generate the same steady-state current as a typical ion channel with 
a single-channel current of 1 pA. 
In addition to the transport current, the transporters also facilitate anion flux across the 
membrane [21, 22]. Anion flux is associated with a current that will be referred to as anion 
current.  This anion current is kinetically, but not stoichiometrically coupled to glutamate 
transport [23-25]. Therefore, it is sometimes referred to as uncoupled anion current.  
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This anion current is stimulated by the binding of transported substrates and/or Na+-ions to the 
transporter. Finally, glutamate transporters catalyze the leak flux of ions across the membrane 
[19, 23, 26-28]. Leak flux occurs already in the absence of the transported substrate.  Two 
components of the leak ion flux have been identified, one being specific for monovalent cations 
[19, 29], and the other being specific for anions.  The anion component of the leak conductance 
can be inhibited by applying non-transportable inhibitors to the glutamate transporter [23, 26]. 
In other secondary transporters Na+ leaks are caused by uniporter activity [30].  Although it is 
not clear whether the cation leak of glutamate transporters may be caused by a channel activity 
it is more likely that Na+ is imported into the cell by a Na+/K+ exchange mechanism.   
 
 
 
 
 
 
 
 
 
 
 
Fig.2.2 Stoichiometry of glutamate uptake 
 
Three sodium ions along with one glutamate and a proton are transported into the cell in exchange 
for one potassium ion. The net result of this transport is the movement of two positive charges into 
the cell accompanied with cytosolic acidification. 
 
 
2.4 The glutamate transporter topology  
 
Secondary structure prediction algorithms for glutamate transporters unequivocally predict 6 
trans-membrane helices in the N-terminal part of the transporters, but there is no consensus on 
the topology of the C-terminal part. Present structural understanding of the glutamate 
transporter is restricted to topological models. Two such models have recently been proposed, 
one by S. Amara and colleagues [31, 32] and the other by the Kanner and Lolkema groups [33-
35].   
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The latter model is shown in Fig.2.3. Both models predict the N-terminus on the intracellular 
side, six N-terminal transmembrane domains (TMD), and an intracellular C-terminus.  The two 
proposals disagree on the topology of the C-terminal part of the polypeptide sequence.  In the 
model shown in Fig.2.3, there are two pore loop-like structures included (RL = re-entrant loop), 
one which dips into the membrane from the intracellular side (RL1, between TMD6 and 
TMD7, see Fig.2.3) and one from the extracellular side (RL2, between TMD7 and TMD8).  It 
has been proposed that these re-entrant loop sequences, in analogy with ion channels of known 
structure [36, 37], are an essential structural element for the permeation of the neurotransmitter 
and/or the co-transported cations. The model proposed by the Amara group assigns an 
extracellular re-entrant loop to TMD7 and a transmembrane helix to RL1 [31, 32, 38].  Another 
similarity to ion channels is the proposed multimeric structure of the transporter.  The 
functional EAAC1 protein was demonstrated to be a pentamer [39]. However, a recent study on 
bacterial homolog of  glutamate transporter in thermophilic bacterium Pyrococcus horikoshii 
was reported to be a trimer made up of identical subunits [40]. 
                       
 
 
 
 
 
 
 
Fig. 2.3 Topology of glutamate transporters 
 
A transmembrane topology model of the GLT as proposed by Grunewald and Kanner (2000). 
The empty circles depict some of the functionally important amino-acid residues that have been 
identified by using site-directed mutagenesis. The filled circles represent amino acids that have 
been used for topology determination (Grunewald & Kanner, 1995; Slotboom et al., 1999b, 
2001; Grunewald & Kanner, 2000). Adapted from Grewer and Rauen [1] 
  
The structure confirms one of the two topological models with two re
by the Kanner and Lolkema groups
functionally important part of the glutamate transporter is the C
RL1. 
 
2.5  Regulation of glutamate uptake
 
It has been known for a
but subject to regulation, not only during development, but also in the adult brain. A number of 
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The mechanism of regulation of these transporters is an extremely complex and controlled 
sequence of steps involving a large number of signaling pathways. 
Since the events in the brain, upon stimulation of glutamatergic neurons occurs in a short time 
span of minutes, the work in this thesis primarily concentrates on the post- translational 
modulation and regulation of these transporters within a time frame of minutes. 
 
2.5.1 Regulation of glutamate transporters by arachidonic acid 
 
Arachidonic acid (a cis-polyunsaturated fatty acid consisting of a 20-atom long carbon chain 
with four double bonds and a carboxylic group at one end, 20:4) is an effector molecule in its 
own right, as well as the precursor for the cellular synthesis of prostaglandins, prostacyclins, 
thromboxanes and leukotrienes. It is released from both neurons [42, 43] and glial cells upon 
activation of glutamate receptors.  
Free fatty acids, including arachidonic acid, are known to accumulate in the brain under 
pathological conditions such as ischemia and seizures. Arachidonic acid has been reported to 
influence a number of molecules which are indirectly or directly involved in neurotransmission. 
It influences Na+/K+ ATPase [44] which is required for the maintenance of the ion gradients 
driving neurotransmitter uptake, it stimulates glucose uptake in cortical astrocytes [45] and it 
stimulates protein kinase C [46] which regulates a number of widely different molecules, 
including neurotransmitter transporters. Arachidonic acid (as well as other cis-polyunsaturated 
fatty acids) has also been reported to inhibit several sodium coupled amino acid transporters 
including the uptake systems for glutamate, glycine and -amino butyric acid (GABA) [47-49]. 
The inhibition of glutamate uptake induced by phospholipase A2 (which is present in many 
animal venoms) is probably mediated via arachidonic acid [50]. It has also been noted that 
arachidonic acid is a more potent inhibitor of glutamate uptake in the cerebellum and spinal 
cord than in the hippocampus [51]. The effect of arachidonic acid is distinct from and additive 
to the effects of oxidation and of changing the electrochemical gradients across the cell 
membranes.  
All these previous studies have been performed on complex preparations such as synaptosomes 
and neuron and astrocyte cell cultures. Because of the multiple actions of arachidonic acid and 
the complexity of the preparations, it is difficult to distinguish between direct effects of 
arachidonic acid on the transporter proteins and indirect effects via other proteins or signal 
substances influencing the proteins under study.  
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A postsynaptic excitatory amino acid transporter with chloride conductance (EAAT4) is 
functionally regulated by neuronal activity in cultured cerebellar Purkinje cells, and the effect 
may be mediated by Ca2+-dependent activation of phospholipaseA2 releasing arachidonic acid 
[52]. 
 
2.5.2 Redox modulation of glutamate transporters 
 
Oxidation and reduction of sulfhydryl (SH)-groups have been shown to alter the function of a 
number of different proteins. For example, the N-methyl-D-aspartate (NMDA)-receptor 
subtype NR1 has two cysteines (residue numbers 726 and 780) which regulate the receptor 
function [53]. Free radicals differentially affect the members of the Na+/Cl- -dependent 
neurotransmitter transporter family: Dopamine uptake is inhibited [54] while norepinephrine 
uptake is not affected [55].  
It was noted in the mid 1980s that glutamate uptake is sensitive to SH-group oxidants, 
including mercury and that this inhibition is independent of the Na+/K+ ATPase [56] and is 
partly reversible by dithiothreitol (DTT). The phenomenon was further studied by Volterra  et 
al [57] by exposing cortical astrocytic cultures to H2O2 or xanthine-xanthine oxidase (a free 
radical generating ) system. When exposed to these free radical generating systems, the uptake 
fell to 60% of the control value. Free radical scavenger enzymes, however, could offer partial 
protection against the observed effect. The oxidation effect is distinct from and additive to the 
effect of arachidonic acid. It was evident that some of these effects are irreversible and might 
have pathological implications.  
However, it is also reported that the transport activity of GLAST, GLT and EAAC1 
(individually expressed in HeLa cells, solubilized and reconstituted in liposomes) can be turned 
down and up by sequential treatment with 5,5-dithio-bis(2-nitrobenzoic) acid (DTNB, a thiol 
oxidizing agent) and DTT, respectively. These data suggest that the glutamate transporters 
possess an SH-based redox regulatory mechanisms [58].  
The redox interconversion of SH-groups on EAAC reduced Vmax of glutamate transport without 
affecting Km and without affecting the Cl- conductance [59]. This implies that the glutamate 
translocation and the anion-permeation pathways of the EAAC1 molecule are separated and 
undergo independent modulation. However, the role of oxidative modulation of glutamate 
uptake in normal physiology is not known. 
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Additionally, Rice et al have demonstrated that the toxin Tx3-4 from the spider Phoneutria 
nigrienter inhibits glutamate uptake in rat hippocampal synaptosomes and this inhibition is 
dependent on the redox state of cysteine residues [60]. 
 
2.5.3 Glutamate  Transporter regulation by growth factors 
 
A large number of growth factors are known to influence the regulatory mechanisms as well as 
trafficking of neurotransmitter transporters. Growth factors such as Platelet derived growth 
factor (PDGF) are known to stimulate the expression of glutamate transporters at the plasma 
membrane [61], a  mechanism possibly mediated via the phosphatidylinositol-3- kinase (PI3-K) 
pathway.  
The exact cascades involving these regulatory mechanisms have not yet been elucidated. 
However, it has been suggested that the downstream product of PDGF pathway, diacylglycerol 
(DAG) could lead to a direct intervention by acting as a substrate for PKC and hence explain 
the surface expression via the PKC pathway. 
Zelenaia et al have demonstrated recently that the epidermal growth factor receptor (EGF) and 
transforming growth factor 
 
 (TGF-) induce the expression of the glial glutamate transporter 
GLT in primary astrocytes in culture. EGF was observed to increase both, the steady state 
levels of the transporter as well as the high affinity glutamate uptakes [62]. 
Figiel et al [63] have investigated the effect of various growth factors on the expression levels 
of glial glutamate transporters GLT, GLAST. Their results conclude that both GLT and 
GLAST protein expressions are increased dramatically and in a dose dependent manner upon 
exposure to EGF and TGF- . A similar increased protein expression was also observed on 
treatment with cAMP. They also demonstrate stimulation of glial glutamate transporter 
expression by fibroblast growth factor-2 (FGF-2).  
All these findings repeatedly suggest that a large number of signaling cascades regulate the 
expression of glutamate transporters both, at the protein expression level as well as the 
regulation by rapid trafficking mechanisms. Involvement of multiple signal cascades also 
suggests the possibility that these pathways could either work independent of each other, or 
might be convergent at some point. 
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2.5.4 Trafficking mechanism of glutamate transporters: regulation independent 
of protein synthesis 
 
Translocation of membrane proteins between the plasma membrane and intracellular storage 
compartments represents one important mechanism of regulation and may contribute to 
synaptic plasticity. Such changes in cell-surface expression can up or/and down-regulate 
membrane proteins within minutes and at a much faster rate than would be possible by protein 
synthesis. One well-studied example involves the GLUT4 subtype of glucose transporter. After 
release into the circulation, insulin causes a dramatic redistribution of this transporter from an 
intracellular compartment to the cell surface resulting in increased clearance of glucose by 
muscle and adipose tissue (for a review see [64-66]).  
Another example includes the regulated trafficking of membrane receptors, including two large 
families of receptors, G-protein coupled receptors and growth factor receptors [41, 67, 68]. 
Considering all the above cited examples, a relatively common theme for regulation of these 
receptors has emerged. Frequently, binding of agonist accelerates internalization through 
endocytotic pathways thereby decreasing the responsiveness of the cell to subsequent exposure 
to agonist.  
More recently, rapid changes have also been observed in the surface expression of -amino 
butyric acid (GABA), dopamine and serotonin transporters along with the glutamate receptors. 
With this background, it may not be surprising that the trafficking of glutamate transporters to 
and from the cell surface appears to be similarly controlled.  
Using C6 glioma cells, it has been shown that glutamate transport is rapidly increased by 
(phorbol ester mediated) activation of protein kinase C [69] and this is due to mobilization of 
the neuronal glutamate transporter EAAC1 from intracellular stores [70]. Further, a rapid 
decrease in uptake activity and cell surface expression is observed after inhibition of 
phosphatidylinositol-3-kinase [70]. Platelet-derived growth factor (PDGF) increases surface 
expression of EAAC1 in C6 glioma cells through activation of phosphatidylinositol-3-kinase. It 
has also been shown that these (PKC and PI3K) pathways are not additive in their stimulatory 
effects on the trafficking mechanisms, and therefore suggest that the cell surface expression is 
controlled by different but signaling cascades.  
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2.5.5 Effects of direct phosphorylation of the transporter proteins 
 
A number of studies have shown, without having pin-pointed the exact mechanism, that protein 
kinases are able to modulate the transport activities for glutamate. Consensus sites for putative 
protein kinase C and A mediated phosphorylation are present in the predicted primary 
sequences of several neurotransmitter transporters, including transporters for glutamate, 
dopamine, GABA and glycine [71]. These observed protein kinase mediated effects do not 
necessarily imply that the kinases phosphorylate the transporter proteins nor do they imply that 
a phosphorylation of the transporters changes their transport kinetics. Not unexpectedly, there 
are several studies that show different effects of signaling pathway activation on some of the 
transporters. For example, activators of PKC have been shown to increase, decrease, or have no 
effect on the glial glutamate transporter GLT in different studies. At present it is not clear why 
there are such different effects. GLT was originally reported to be stimulated by protein kinase 
C mediated phosphorylation of serine-113, but a recent report by Tan et al [72] questions this 
conclusion.  
In fact, protein kinase C activation in Madin-Darby Canine Kidney cells (MDCK cells) with 
heterologous expression of human GLT leads to a reduced GLT cell surface expression. The 
consequences of phosphorylation vary between different cell types because various cells have 
different intracellular machinery which responds in different ways to phosphorylation.  
It appears that most of the transporter subtypes can be regulated both acutely and chronically 
by the receptor-dependent and receptor-independent mechanisms.  
Among the recently identified mechanisms of transporter regulation is a rapid translocation of 
the carrier proteins from the cytoplasmic compartment to the cell surface and vice versa, a 
process that can be acutely regulated by different stimuli, including the direct interaction of 
glutamate with the transporter molecules and/or protein phosphorylation [73]. Involvement of 
glutamate in the regulation of its own uptake has been further supported by the discovery of the 
fine tuning of transporter expression via ionotropic and metabotropic glutamate receptors [74]. 
These achievements are expected to facilitate further studies on the functional roles of 
individual transporter subtypes and to support the development of new strategies for diagnosis 
and treatment of diseases associated with malfunctioning of glutamate transporters. 
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2.5.6 Regulation of Glutamate transporters by protein kinases 
 
2.5.6.1 Protein kinases C: general overview 
 
The protein kinase C family of enzymes transduces the myriad of signals promoting lipid 
hydrolysis. The prevalence of this enzyme family in signaling is exemplified by the diverse 
transduction mechanisms that result in the generation of protein kinase C’s activator, 
diacylglyerol (DAG). Signals that stimulate members of the large families of G protein-coupled 
receptors, tyrosine kinase receptors, or non-receptor tyrosine kinases can cause diacylglyerol 
production, either rapidly by activation of specific phospholipases or more slowly, by 
activation of phospholipase D to yield phosphatidic acid and then diacylglyerol [75]. In 
addition, fatty acid generation by phospholipase A2 activation modulates protein kinase C 
activity [76]. Thus, multiple receptor pathways feeding into multiple lipid pathways have the 
common end result of activating protein kinase C by production of its second messenger.  
Phorbol esters, potent tumor promoters, can substitute for diacylglyerol in activating protein 
kinase C. Unlike diacylglyerol, phorbol esters are not readily metabolized, and treatment of 
cells with these molecules results in prolonged activation of protein kinase C. As a result, 
phorbol esters have proved invaluable in dissecting out protein kinase C catalyzed 
phosphorylation in vivo. 
In addition to regulation by diacylglyerol or phorbol esters, all isozymes of protein kinase C 
require phosphatidylserine, an acidic lipid located exclusively on the cytoplasmic face of 
membranes, and some isozymes require Ca2+ for optimal activity. 
Protein kinase C (PKC) is a cyclic nucleotide-independent enzyme that phosphorylates serine 
and threonine residues in many target proteins. It was first identified in 1977 in bovine 
cerebellum by Takai et al as a protein kinase that phosphorylated histone and protamine [77]. 
Since then, its involvement in many biological processes has been demonstrated, including 
development, memory, cell differentiation and proliferation and carcinogenesis.  
 
2.5.6.2 Structural arrangement of PKC isozymes 
 
PKC isozymes are synthesized as single polypeptides with an N-terminal regulatory domain 
(20–40kDa) and a C-terminal catalytic domain (~45kDa). Generally, PKC isozymes contain 
four conserved regions termed C1–C4. C1 contains a cysteine-rich motif and forms the 
diacylglyerol binding site [78].  
   2.Introduction 
- 17 - 
 
The auto inhibitory pseudo substrate sequence is upstream of the cysteine-rich motif in the 
same region. C2 contains the recognition site for acidic lipids and, in some isozymes, the Ca2+ 
binding site. C3 and C4 form the ATP and substrate binding lobes of the kinase, respectively. 
The regulatory domain of PKC (Fig.2.4) contains a Ca2+ binding site that is found only in ,  
and -isozymes. The amino terminal half of the regulatory domain of ,  and  isozymes 
contains two conserved regions, C1 and C2, that play a vital role in the regulation of enzyme 
activity. The other PKC isozymes lack the C2 region and do not require Ca2+ for activation. 
The catalytic domain contains C3 and C4 regions which are highly conserved. The C3 region 
contains the ATP binding consensus sequence, whereas the C4 region is responsible for protein 
substrate binding. 
 
       
 
Fig 2.4 Schematic arrangement of regulatory and catalytic subunits of PKC isozymes.                         
 Adapted from Tan et al. [79] 
 
 
Once thought to be a single protein, PKC is now known to comprise a large family of isozymes 
that differ in structure, cofactor requirements and function. At present, 11 isozymes have been 
identified, varying in tissue expression and cellular compartmentalization. 
The PKC family has been divided into three groups, based on the isozymes’ cofactor 
requirements: conventional (c) PKC isoforms comprising , I (also called 2), II (also called 
1 and ) which require calcium and diacylglycerol (DAG) for activation, novel (n)PKC 
isoforms comprising , ,  (also called PKC-L), ,  and  ( the mouse homolog of human 
PKC    is known as PKD) that require DAG and atypical (a)PKC isoforms, namely 	, 
 and I 
(the mouse homolog of human PKC
) that require neither calcium nor DAG. A new PKC 
member has recently been discovered and is referred to as PKC .  
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It contains 890 amino acid residues and exhibits highest sequence similarity to PKC   /PKD, 
thereby posing the possibility of a fourth subfamily of PKC’s, comprising these isoforms.  
The PKC-related kinases (PRKs) have also been classified as members of the PKC 
superfamily. 
Activation of cPKCs involves translocation from the cytoplasm to binding domains at cell 
membranes. Specific anchoring proteins, immobilized at particular intracellular sites, localize 
the kinase to its site of action. These proteins include receptors for activated C-kinase 
(RACKS) and adducins.  
Following an increase in intracellular calcium levels, cPKCs interact with the cell membrane in 
an inactive, but conformationally distinct, form. DAG facilitates penetration of these isozymes 
into the cell membrane. Tumor promoting phorbol esters are used experimentally as synthetic 
DAG analogs. When attached, the affinity of PKC for calcium is increased such that activation 
of the enzyme is achieved, depending on its phosphorylation state. Phosphatidylserine is the 
membrane lipid anchor for both cPKCs and nPKCs, although other membrane phospholipids 
may ultimately link extracellular signals to intracellular events through PKC. 
Increased activity of PKC has been long demonstrated to affect a number of membrane 
proteins. These include both, neurotransmitter receptors as well as transporter. PKC has been 
shown to affect GABA, serotonin, glycine as well as glutamate transporters, but in different 
manner.  
Activation of PKC is shown to have multiple effects on GABA transporter GAT1 mediated 
transport activity. Quick et al have shown a rapid increase of the surface expression of GABA 
transporter upon PKC activation in Xenopus oocytes [80]. However, in primary cultures 
expressing DAT1 endogenously, the opposite effects of phorbol esters have been reported [81].  
Qian et al [82] have reported a decreased surface expression of serotonin transporters SERT 
stably expressed in HEK-293 cells and Huff et al [83] have demonstrated the decrease in the 
surface expression of the dopamine transporter DAT1, accompanied with increased 
phosphorylation of the transporter. 
Considering the differences in the mechanisms of action of PKC in different neurotransmitter 
transporters, the aim of the present work is to analyze the effects of PKC analogs on the 
trafficking and direct phosphorylation of the neuronal glutamate transporter EAAC1. 
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2.5.7 Mechanism of fusion of transporter molecules from the intracellular pools 
to the membrane: role of interacting partners. 
 
It is now shown by various groups that the neuronal glutamate transporter EAAC1 is largely 
localized intracellularly, and these intracellular pools, when stimulated by phorbol esters are 
trafficked to the plasma membrane, increasing the total number of transporters at the membrane 
surface [69, 71, 84]. These mechanisms must involve fusion of the intracellular storage 
elements with the plasma membrane. A classical example of ligand mediated resurfacing of 
transporters is that of the glucose transporter. At steady state, in the absence of insulin, GLUT4 
is almost entirely sequestered within the cell. This is explained by its slow rate of recycling, 
almost 5-fold slower than the transferrin receptor. Insulin increases the exocytosis of GLUT4 
by as much as 5-fold, while its rate of endocytosis from the cell surface may be slowed by 2-
fold to the cell surface [66, 85]. 
It is possible that the formation of specific protein complexes may be involved in the fusion of 
intracellular transporter storage elements with the plasma membrane. Several members of 
neurotransmitter transporter family, including the GABA transporter GAT1 and a choline 
transporter are found in vesicles similar to those in the neurotransmitter containing vesicles.  
Several proteins required for the fusion of intracellular vesicles with the plasma membrane 
have also found to be associated with these neurotransporter containing vesicles. These include 
N- ethylmaleimide-sensitive attachment proteins (SNAPs) and syntaxin 1A [86-88]. Since PKC 
also increases the expression of GAT1 at the surface upon exposure to GABA, PKC may be 
involved in the regulation of the rate at which GAT1 is inserted into the plasma membrane.  
Another protein, protein interacting with C kinase (PICK-1), is known to specifically interact 
with PKC and may as well serve as an adapter protein to recruit PKC to the transporter 
complexes in order to enhance the specificity of PKC dependent effects. 
Similarly, it has also been demonstrated for GABA transporter GAT1 that pre-incubation with 
GABA causes an increased transport activity in primary neuronal cultures [89].GABA 
transporters seem to be regulated by multiple signaling pathways involving PKC dependent 
regulation as well as tyrosine kinase pathways. 
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2.5.8 Regulated exocytosis and involvement of calcium signaling 
 
Calcium (Ca2+) is an important intracellular second messenger in such processes as growth 
factor and hormone signaling, cell cycle regulation, gene expression, and apoptosis among 
numerous others [90]. A resting cell has a cytosolic Ca2+ concentration of roughly 100 nM, a 
concentration approximately 20,000-fold lower than that of extracellular Ca2+, and thus cells 
have an intricate network by which to precisely control cytoplasmic Ca2+ levels [91]. ATP-
dependent Ca2+ pumps shuttle Ca2+ into the two major Ca2+ sinks, the endoplasmic reticulum 
(ER) and the extracellular space.  
Various signals stimulate either waves or spikes of increased intracellular Ca2+ with 
concentrations reaching 1–2 M. The source of Ca2+ depends on the stimulus. Receptor 
tyrosine kinases and G-protein-coupled receptors classically increase Ca2+ levels by producing 
IP3, which induces Ca2+ release from the ER via the IP3 receptor. 
Similarly, cyclic ADP ribose can release Ca2+ from intracellular stores. Ligand gated ion 
channels and voltage-dependent ion channels in the plasma membrane, however, initiate Ca2+ 
entry via extracellular stores. Subsets of each of these types of channels have also been shown 
to cause Ca2+ release from intracellular stores via either the IP3 receptor or the ryanodine 
receptor (RyR). Calcium is an integral part of membrane exocytosis and works in conjunction 
with other calcium binding proteins. 
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Fig.2.5 Schematic representation of calcium homeostasis in a cell 
 Adapted from www.users.aber.ac.uk 
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2.5.9 Calcium regulated proteins: Calmodulin 
 
The information encoded in transient Ca2+signals is deciphered by various intracellular Ca2+-
binding proteins that convert the signals into a wide variety of biochemical changes. Some of 
these proteins, such as protein kinase C, bind to Ca2+ and are directly regulated in a Ca2+-
dependent manner. Other Ca2+-binding proteins, however, are intermediaries that couple the 
Ca2+ signals to biochemical and cellular changes. 
Among this latter group is a family of proteins that is distinguished by a structural motif known 
as the E–F hand. An E–F hand consists of an N-terminal helix (the E helix) immediately 
followed by a centrally located, Ca2+ coordinating loop and a C-terminal helix (the F helix) 
[92].  
One of the key proteins that transduce a signal in response to increases in intracellular Ca2+ is 
calmodulin (CaM). CaM is a 148 amino acid (16.7 kDa) protein comprised of 4 helix-loop-
helix protein folding motifs called E-F hands, with two making up the N -terminal domain and 
two comprising the C-terminal domain. Each of the four E-F hands binds one Ca2+ ion [93].  
Calmodulin (CaM) is a ubiquitous, calcium-binding protein that can bind to and regulate a 
multitude of different protein targets, thereby affecting many different cellular functions. CaM 
constitutes approximately 0.1% of the total cellular protein [92].  CaM mediates processes such 
as inflammation, metabolism, apoptosis, muscle contraction, intracellular movement, short-
term and long-term memory, nerve growth and the immune response.   
CaM is expressed in many cell types and can have different subcellular locations, including the 
cytoplasm, within organelles, or associated with the plasma or organelle membranes.  Many of 
the proteins that CaM binds are unable to bind calcium themselves, and as such use CaM as a 
calcium sensor and signal transducer.   
CaM can also make use of the calcium stores in the endoplasmic reticulum, and the 
sarcoplasmic reticulum. CaM undergoes a conformational change upon binding to calcium, 
which enables it to bind to specific proteins for a specific response.  CaM can bind up to four 
calcium ions, and can undergo post-translational modifications, such as phosphorylation, 
acetylation, methylation and proteolytic cleavage, each of which can potentially modulate its 
actions. Role of calmodulin has recently been implicated in the regulation of GABA 
transporter. Wei et al [94] have demonstrated an increased GABA synaptic transmission 
mediated by the Calcium/calmodulin dependent pathway. Considering these facts, calmodulin 
may as well be an interacting partner for the regulation of other neurotransmitter transporters. 
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2.5.10 CaM KINASES 
 
One of the modes of action of CaM is to activate members of a family of serine /threonine 
protein kinases called Ca2+/CaM-dependent protein kinases or CaM kinases. This family 
includes kinases such as phosphorylase kinase, myosin–light chain kinase (MLCK), and CaM 
kinases I, II, III, and IV [90]. 
These kinases are grouped according to whether they are dedicated kinases having a single 
substrate (phosphorylase kinase, CaM KIII, and MLCK) or whether they are multifunctional 
(CaM KI, II, and IV) and have several substrates. Members of both groups of CaM kinases 
have very similar domain structures [90].  
 From the family of CaM kinases, CaMKII  and CaMKII  are the two major isoforms of 
CaMKII expressed in the brain. These kinases are enriched at synapses and are the main protein 
of the post synaptic density(PSD) [95, 96] 
Both isoforms contain amino-terminal catalytic (260 amino acids) and regulatory (40 amino 
acids) domains that are about 90% identical. The variable size of the carboxy-terminal domain 
(180–240 amino acids) arises from alternative mRNA splicing. 
CaMKII is dependent both, on calcium as well as calmodulin for auto-phosphorylation. Once 
phosphorylated, CaMKII does not require calcium and can be partially active even in the 
absence of calcium. 
Fig.2.6 shows a schematic representation of the activation of CaMKII. 
                                                     
                                            
                                                 
 
Fig 2.6 Schematic representation of interaction of calcium and Calmodulin with CaMKII 
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CaMKII activity and Thr286 auto-phosphorylation are essential for normal N-methyl-D 
aspartate (NMDA) receptor-dependent forms of long term potentiation (LTP) in the 
hippocampal region and hippocampus-dependent behaviors, such as spatial learning and 
memory and also for plasticity in other central nervous system regions. 
LTP in the hippocampal regions is mediated by two pathways: Phosphorylation of 
phosphorylation of GluR1 subunits at Ser831 by CaMKII enhances unitary conductance of the 
receptors, and CaMKII drives synaptic insertion of new receptors [95, 97]. 
The example of glutamate receptor translocation from the cytoplasmic vesicles to the plasma 
membrane in response to calcium as well as a calcium dependent protein calmodulin has 
attracted a lot of interest due to its implications in learning and memory. 
The exocytosis of small vesicles that fuse with plasma membranes is also stimulated by factors 
such as insulin-like growth factor 1 through a pathway involving calcium/calmodulin 
dependent CaM kinase II.  
Considering the involvement of CaM kinases in the regulation of receptors, the transporter 
regulation and trafficking might as well be a subject to similar regulation. 
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3 Objectives 
 
Glutamate, in the brain acts as a major excitatory neurotransmitter. Brain tissue has a 
remarkable ability to accumulate glutamate. This ability is due to glutamate transporter proteins 
present in the plasma membranes of both glial cells and neurons. The transporter proteins 
represent the only (significant) mechanism for removal of glutamate from the extracellular fluid 
and their importance for the long-term maintenance of low and non-toxic concentrations of 
glutamate. In addition to this simple, but essential glutamate removal role, the glutamate 
transporters appear to have more sophisticated functions in the modulation of 
neurotransmission. They may modify the time course of synaptic events, the extent and pattern 
of activation and desensitization of receptors outside the synaptic cleft and at neighboring 
synapses (intersynaptic cross-talk). 
Although it has been more than a decade that these transporters were cloned and characterized, 
information on the regulatory mechanisms governing the rapid modulation of these 
transporters, particularly the neuronal glutamate transporter EAAC1 is rather scarce. 
 
The present investigation focuses on the short term modulation (within minutes) of the 
regulation of the neuronal transporter EAAC1 in heterologous expression system. 
Characterization of the model heterologous system and establishing the functionality of the 
heterologously expressed glutamate transporters is discussed in the first part of the thesis. 
Secondly, the present work aims to characterize the signaling cascades involved in the 
trafficking mechanisms regulating the movement of the glutamate transporter EAAC1 from the 
intracellular storage compartments to the cell membrane and vice versa. 
The signaling pathways focused in the present investigation are the PKC pathways and the 
Ca2+/calmodulin dependent pathways. 
Finally, it needs to be established if the transporter itself is a direct target of the signaling 
cascades involved i.e. if the transporter needs to be directly phosphorylated in response to 
activators of kinases. 
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4 Results 
 
As explained in the introduction to this thesis, glutamate transporters play a crucial role in the 
removal of glutamate from the synaptic cleft after the action potential. In addition to the main 
function of removal of glutamate; these transporter proteins have a more sophisticated role of 
modulation of neurotransmission process. In the first part of this thesis, a more general 
characterization of three heterologous glutamate transporters shall be reported. The second part 
of this thesis concentrates on the post translational modifications and regulation of the neuronal 
glutamate transporter EAAC1 in a heterologous expression system. 
 
4.1 Protein expression profile of glutamate transporters in vivo and in vitro 
 
In the first set of experiments, protein expression profiles of three glutamate transporter 
subtypes expressed heterologously in HEK-293 cells was compared with the native glutamate 
transporters expressed in rat brain. These included the neuronal glutamate transporter EAAC1, 
the glial glutamate transporter GLAST and EAAT4, which is a low capacity neuronal 
glutamate transporter with chloride conducting property. 
Protein expression profile of the glutamate transporter GLAST and EAAC1 (stably expressed) 
and EAAT4 (transiently expressed) was compared with the expression profiles in rat cortex and 
cerebellum. 
For EAAC1 protein, (Fig.4.1A), the expression profile was also compared with that of the C6 
glioma cells which endogenously express EAAC1 [70]. 
Western blot analysis of total cell lysates (Fig. 4.1A) showed the expression of the EAAC1 
protein maximally in the cortex and to a lesser extent in the cerebellum, in line with 
observations of Rauen et al [98]. The heterologous over expression of EAAC1 in HEK-293 
cells is well observed when compared to the C6 glioma cells (compare left panel, lanes 3 and 
4). EAAC1 is observed as a protein with broad electrophoretic mobility centered at 66kDa, in 
agreement with previous reports  [99]. Additionally, higher molecular weight bands are also 
observed in the cortex and cerebellum. According to the findings of Danbolt et al [11], if fresh 
brain tissue is directly homogenized and solubilized in SDS buffer, in the absence of reducing 
agents, only monomeric bands are observed. However, oligomeric bands can be observed upon 
exposure to cross linking agents [100].  
They also report that the use of mercaptoethanol cannot prevent or reverse the formation of 
higher molecular weight aggregates of these transporters. 
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As shown in 4.1A, EAAC1 was observed as a protein with a broad electrophoretic mobility, centered 
around a relative molecular weight of 66kDa in Cortex, cerebellum, HEK-EAAC1 cell line as well as C6 
glioma cell line. The levels of expression in the cortex as well as HEK-EAAC1 cell line were 
comparable. The expression of EAAC1 was more pronounced in cortex when compared to the 
cerebellum. C6 glioma cell line showed an extremely low expression of EAAC1 protein. 
Fig 4.1B shows the expression of GLAST in the rat cortex, cerebellum and the HEK-293 cells stably 
expressing GLAST protein. GLAST is also observed as a protein with a broad electrophoretic mobility. 
Fig.4.1C shows the expression of EAAT4 in cortex and cerebellum. Cortex did not show detectable 
levels of EAAT4 whereas in the cerebellum EAAT4 is seen as a protein with relative molecular weight 
of 66kDa. As expected, EAAT4 protein expression is not observed in the non-transfected HEK-293 
cells whereas the HEK-293 cells transiently expressed with EAAT4 show the protein expressed with 
the relative molecular weight of 66kDa. 
Fig.4.1D shows the immunofluorescence staining of EAAC1 in HEK-293 cells (top left panel), and C6 
glioma cells (bottom left panel). The immunolabeling of GLAST and EAAT4 (transient expression) is 
shown in the top right and bottom right panels respectively. The membrane labeling of respective 
proteins is indicated by white arrows and the shaded arrows indicate cytoplasmic labeling. 
Scale bar 10 m. 
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Fig.4.1. Protein expression profile of 
neuronal glutamate transporter 
EAAC1 (A), Glial glutamate 
transporter GLAST (B) and EAAT4 
(C) by western blotting and 
Innunocytochemistry (D). 
10 g each of total cell protein from rat 
brain cortex, cerebellum, C6 Glioma 
and HEK-293 cells stably expressing 
(EAAC1 and GLAST) or transiently 
expressing EAAT4 were separated by 
10% SDS-PAGE and analyzed by 
immunoblotting with anti EAAC1 
(0.3g/ml), anti-GLAST (0.15 g/ml and 
anti-EAAT4 (0.2g/ml) antibodies 
respectively. 
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Variable electrophoretic mobility of EAAC1 with the higher molecular weight species suggests 
that these transporters organize as oligomers. 
The glial glutamate transporter GLAST is observed as a protein with relative molecular weight 
of 72kDa (middle panel).   
The expression profile of GLAST (Fig.4.1B) revealed a higher expression rate in the 
cerebellum when compared to the expression in the cortex. The stable expression in HEK-
GLAST cell line is also observed. The relative molecular weight of GLAST expressed in 
cerebellum was slightly higher (72kDa) than that expressed in the cortex (68kDa) as 
demonstrated by the findings of Danbolt et al [11]. HEK-GLAST cell line showed a similar 
relative molecular weight as observed for the cerebellum.  
EAAT4 (Fig.4.1C) expression was found primarily in the rat cerebellum and no protein 
expression was observed in the cortex. This is in concordance with the findings of Furuta et al 
[101] . EAAT4 was transiently expressed in HEK-293 cells and the protein expression was 
evaluated 24 hrs post-transfection. The molecular weight of EAAT4 in the cerebellum as well 
as the heterologously expressed protein in HEK-293 cells was calculated as 66kDa. 
Immunocytochemistry of the heterologously expressed EAAC1 and endogenously expressed 
EAAC1 in C6 glioma cells is revealed in Fig.4.1D top left and bottom left panels respectively. 
EAAC1 shows a clear punctuate membrane labeling (white arrow) as well as a cytoplasmic 
staining of EAAC1 (shaded arrow). C6 glioma cells, known for the endogenous expression of 
EAAC1 also label both the membrane (Fig.4.1D bottom left panel, white arrow) as well as the 
cytoplasm (shaded arrow). 
HEK-293 cells show a robust expression of GLAST (Fig.4.1D top right panel) with very strong 
immunolabeling at the plasma membrane (white arrow) as well as an intense labeling in the cell 
cytoplasm (shaded arrow).  
EAAT4 transiently expressed in HEK-293 cells (Fig.4.1D bottom right panel) indicates low 
expression in the membrane (white arrow) and a uniform labeling in the cell cytoplasm (shaded 
arrows). 
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4.2 Functional characterization of glutamate transporters in vitro 
 
In order to establish the functionality of heterologously expressed transporters, sodium 
dependent uptakes for glutamate were performed for each of the transporter subtypes. Crude 
membrane vesicle preparations (see section 7.3.6) were used for all uptake measurements. An 
artificial ion gradient to drive the glutamate transport (similar to the gradient which drives the 
secondary active transport in live cells) was established by loading the membrane vesicles with 
potassium (150 mM) and the transport measurements were carried out in presence of sodium 
(150 mM) and L-glutamate (1M) in the external medium.  
In the presence of an artificially established sodium-potassium gradient, time dependent 
saturable uptake was measured for all the subtypes of glutamate transporters examined 
(Fig.4.2) 
HEK-EAAC1 membrane vesicle uptake reached the saturation within 4 min. of   measurements 
and reached a maximal uptake level of 365±43 pmol glutamate /mg protein.  
HEK-GLAST membrane vesicle uptake however, reached the saturation uptakes after 6 min 
and showed the maximal uptake of 345±50 pmol glutamate/mg protein. 
In contrast to high capacity transport systems EAAC1 and GLAST, EAAT4 is known to 
possess low uptakes and high chloride conductance showed maximal uptake of 14±0.5 pmol 
glutamate/mg protein which was approximately 15-20 folds lower than the maximal uptakes 
shown by EAAC1. 
 
All subtypes of glutamate transporters (EAAC1, GLAST and EAAT4) invariably depend upon 
the presence of extracellular sodium for the transport of glutamate [102].  
To confirm that the uptakes of heterologously expressed glutamate transporters were also 
sodium dependent, parallel experiments were carried out by replacing sodium (150 mM) in the 
external transport medium with equimolar concentrations of potassium (150 mM). 
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Fig.4.2.Functional characterization of 
heterologously expressed EAAC1 (A), GLAST (B) 
and EAAT4 (C) in HEK-293 cells. 
 
Kinetic properties of 3H1glutamate uptake in HEK cells 
stably transfected with EAAC1 and GLAST and 
transiently transfected with EAAT4. Cells were 
cultivated and membrane vesicles prepared. 20 g 
membrane vesicles were taken for each measurement 
and uptake velocity was measured by using 1 Ci 3H1 
(42-57Ci/mmol) supplemented with unlabeled glutamate 
to a final concentration of 1 M. To exclude sodium 
independent transports, uptakes were carried out by 
replacing sodium by equimolar potassium concentration 
in the transport solution. 
The data are the mean ± SD of triplicate determinations 
from three experiments. 
 
 
 
 
No glutamate uptakes were observed in the absence of sodium. In all the cases, levels of 
unspecific binding of anionic glutamate to a maximal level of 8 pmol/mg protein was observed 
which is 30 fold lower than the highest uptakes for EAAC1. These low levels of background 
counts can be accounted for by the unspecific binding of tritiated glutamate to the surface of 
membrane vesicles, without any actual transport taking place. 
 
In order to calculate the kinetic parameters (Km and Vmax) for individual transporter subtypes, 
concentration dependent uptakes were performed using increasing concentrations of unlabeled 
glutamate (1-100 M) as in Fig.4.3. 
The kinetic parameters of Km and Vmax calculated using the Michaelis Menten equation. The 
Km for EAAC1 was calculated as 3.2±0.1 M whereas the Vmax for EAAC1 (Fig.4.3A) was 
calculated as 343±13 pmol glutamate/mg protein/min.  
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The Km for GLAST (Fig. 4.3B) was 7.2±0.2 M glutamate and the Vmax was calculated 
as180±17 pmol glutamate/mg protein/min. 
For transiently expressed EAAT4 (Fig.4.3C), the Km was calculated as 2.5±0.1 M glutamate 
and the Vmax values were 7.8±0.2 pmol glutamate/mg protein/min. 
This data suggests that all the glutamate transporter subtypes analyzed had a very high affinity 
for glutamate, in the range of 2-7 M. 
The above experiments confirm the expression as well as the functionality of the glutamate 
transporters EAAC1, GLAST and EAAT4 in the heterologous expression system. 
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Fig. 4.3. Kinetic properties of 3H1glutamate 
uptake into membrane vesicle 
preparations of HEK-EAAC1 (A), HEK-
GLAST (B) and HEK-EAAT4 (Transiently 
transfected) (C). Uptake velocity was 
measured by using 1Ci (42-57Ci/mmol) of 
3H1 glutamate and increasing concentrations 
of unlabeled L-glutamate at a membrane 
vesicle protein concentration of 20 g. 
Measurements were taken within the linear 
range of uptake (15 and 30s).The data are 
the mean of triplicate determinations from 
three experiments. The Km and Vmax values 
were obtained from the Lineweaver–Burk plot 
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4.3  Kinetic comparison of glutamate uptake for HEK-EAAC1 and C6 Glioma 
cell lines. 
 
In order to characterize the heterologous expression system for EAAC1, direct comparison of 
glutamate uptakes were performed using C6 glioma cell line which endogenously expresses 
EAAC1. 
Comparison of concentration dependent uptakes for HEK-EAAC1 and C6 glioma cell line 
revealed a much lower Vmax for the C6 glioma cell line when compared to HEK-EAAC1.Vmax 
for C6 glioma cell line was calculated as 68±4 pmol glutamate/mg protein when compared to 
343±13 pmol glutamate/mg protein/min for HEK-EAAC1 cell line (Fig.4.4 left panel). 
C6 Glioma cell line had a marginally lower affinity for glutamate as revealed by Km value of 
5.7±1.2 M when compared to the Km of 3.2±0.1 M for HEK-EAAC1 cells (Fig.4.4, right 
panel). 
 
 
  
                                                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.4. Comparison of kinetic behaviour of membrane enriched fractions of HEK-EAAC1 and 
C6 Glioma cell lines. 
Uptake velocity was measured by using 1Ci (42-57Ci/mmol) of 3H1 glutamate and increasing 
concentrations of unlabeled L-glutamate at a membrane vesicle protein concentration of 20 g. 
Measurements were taken within the linear range of uptake (15 and 30s).  
Vmax for HEK-EAAC1 and C6 glioma membrane vesicle preparations (Fig.4.4A) were calculated as 
323±13pmol glutamate/mg protein/min and 68±4pmol Glutamate/mg protein/min respectively. 
The Km value (Fig.4.4B) obtained from the Lineweaver burk plots were calculated as 3.2±0.1M and 
5.7±1.2M Glutamate for HEK-EAAC1 and C6 Glioma cell lines respectively. 
The data is expressed as mean±SD of three independent measurements. 
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The extremely low expression of EAAC1 in C6 glioma cell line as observed in Fig.4.1A 
complements the reduced uptakes (approximately five fold lower) in C6 Glioma cell line. 
The affinity of EAAC1 in C6 glioma and HEK-EAAC1 cell lines for glutamate calculated as 
3.2 M and 5.7±1.2 M for the HEK-EAAC1 cells and C6 glioma cells respectively, was not 
much different as observed from the lineweaver burk plots (Fig.4.4B). 
 
4.4 Post translational glycosylation of neuronal glutamate transporter EAAC1 
 
To investigate whether EAAC1 is post-translationally modified in the heterologous expression 
system, it was decided to look at the glycosylation pattern of EAAC1 as it is one of the 
predominant post translational modifications in membrane proteins. Affinity chromatography 
on wheat germ lectin has been employed for the purification of EAAC1, GLT as well as other 
transporters. The fact that these transporters bind to lectins suggests that they are glycosylated 
proteins. 
In silico analysis of EAAC1 for glycosylation revealed three putative glycosylation sites at 
amino acid positions 85, 178 and 194. Further analysis from the hydropathy plots indicate that 
all these three positions are in the extracellular loops of EAAC1. 
In order to characterize the glycosylation pattern of EAAC1, both, in vitro and in vivo 
deglycosylation were performed. 
The in vitro deglycosylation with an endopeptidase peptide-N-glycosidase F ( PNGase F) led to 
a shift in relative molecular weight of EAAC1 from 66kDa to 56kDa (Fig. 4.5A) within 15 
min. of enzymatic deglycosylation. Increased times of deglycosylation did not have any further 
influence on the electrophoretic mobility of EAAC1. In addition to the deglycosylated 
monomeric 56kDa band, a similar shift in the relative electrophoretic mobility of the 
oligomeric band was also observed. This band may represent the deglycosylated residues of the 
oligomeric EAAC1 bands as described in section 4.1. 
Further confirmation of the glycosylation pattern of EAAC1 was performed by addition of 
tunicamycin. Tunicamycin prevents the glycosylation of newly synthesized proteins in vivo and 
provides a useful tool to analyze the rate of biosynthesis of EAAC1. 
Treatment with tunicamycin (Fig. 4.5B) revealed the appearance of a clear newly synthesized 
non-glycosylated protein with an apparent molecular weight of 56 kDa.  
Increased times of treatment with tunicamycin led to an increase in the band intensity of the 
newly synthesized non-glycosylated protein. 
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4.5 Rates of biosynthesis and degradation of EAAC1 
 
In order to calculate the rates of biosynthesis and degradation of EAAC1 in the heterologous 
expression system, HEK-EAAC1 cells were treated with tunicamycin for the time intervals of 
0.5-24 hrs. 
As seen in Fig 4.6A, increased incubation times with tunicamycin showed a gradual increase in 
the newly synthesized non-glycosylated protein with a corresponding decrease in the band 
intensity of the core-glycosylated protein.  
For the Densitometric evaluations, the total core glycosylated protein, without tunicamycin 
treatment was taken as the control (Fig.4.6A, lane 1, 100%). The band intensities of the newly 
synthesized non-glycosylated protein were expressed as the percent of control for the 
calculation of the rates for biosynthesis. Even after 24 hrs incubation in presence of 
tunicamycin, only 40% of the core glycosylated protein was replaced by the newly synthesized 
protein as analyzed by densitometry. 
A linear fit from the semi-log plot of the time of treatment with tunicamycin versus the % 
intensity of newly synthesized protein revealed the T1/2 Biosynthesis as 22 hrs. 
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Fig.4.5   Deglycosylation of EAAC1  
In vitro deglycosylation (A), 10g of membrane vesicles were denatured and incubated 
without (lane 1) or with PNGase F for 15min-3 hrs. The samples were separated by 10% 
SDS-PAGE and analyzed by immunoblotting with anti-EAAC1 antibody. 
In vivo deglycosylation (B) 5x105 cells were incubated without (lane 1) or with (lanes 2, 3 and 
4) the addition of tunicamycin (10 g/ml) for 2-16 Hrs. SDS probes were then prepared and 
10 g of total lysates (lanes 1, 2, 3 and 4) were separated by 10%SDS PAGE and analyzed 
by immunoblotting with anti-EAAC1 antibodies (0.3g/ml). 
 
B 
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The same blot was also analyzed for the residual mature glycosylated EAAC1 
immunoreactivity after treating with tunicamycin for different time intervals to evaluate the 
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Fig.4.6 Synthesis and Degradation of EAAC1. 
 
5x105   HEK-EAAC1 cells were incubated with tunicamycin 10 g/ml for 0.5-24 hrs. At the end of 
each incubation period the cells were lysed in lysis buffer and SDS probes prepared from the total 
lysates. 10 g of total protein was separated by SDS-PAGE and immunoblotted with anti-EAAC1 
antibody (0.3g/ml). Densitometric analysis of band intensities in A were performed for the newly 
synthesized immature protein and for the mature EAAC1 using Phoretix Total lab software. 
The rate of biosynthesis (B+C) and degradation (D+E) of EAAC1 were calculated by plotting the 
time of treatment with tunicamycin against logarithmic to base 10 log10 densitometry (% of control) 
of the newly synthesized immature protein and the mature protein respectively. 
T1/2(biosynthesis) was calculated by fitting the log10 50 value in the equation 
1.698=0.0454x+0.6907. 
T1/2(Degradation) was calculated by fitting the log10 50 value in the equation  
1.698 = -0.0129x+1.9859. 
Treatment with tunicamycin (Hrs.)
0 5 10 15 20 25 30
lo
g 1
0 
De
n
si
to
m
e
tr
y 
(%
 
o
f C
o
n
tr
o
l )
0.0
0.5
1.0
1.5
2.0
2.5
Treatment with tunicamycin (Hrs.)
0 0.5 1 2 6 15 18 24
De
n
si
to
m
et
ry
 
(%
 
o
f C
o
n
tr
o
l )
0
10
20
30
40
50
lo
g 1
0 
De
n
si
to
m
e
tr
y 
(%
 
o
f C
o
n
tr
o
l )
De
n
si
to
m
et
ry
 
(%
 
o
f C
o
n
tr
o
l )
A
 
Teatment with Tunicamycin (Hrs.)
0 2 6 15 18 24
D
en
si
to
m
et
ry
 
(%
 
o
f C
o
n
tr
o
l)
0
20
40
60
80
100
120
Treatment with Tunicamycin (Hrs.) 
0 5 10 15 20 25 30L
o
g 1
0 
de
n
si
to
m
et
ry
 
(%
 
o
f c
o
n
tr
o
l)  
 
 
 
 
 
 
 
 
 
1.5
1.6
1.7
1.8
1.9
2.0
2.1
D
en
si
to
m
et
ry
 
(%
 
o
f C
o
n
tr
o
l)
Lo
g 1
0 
de
n
si
to
m
et
ry
 
(%
 
o
f c
o
n
tr
o
l)  
 
 
 
 
 
 
 
 
 
D
 
B
 
C 
E
 
   4.Results 
- 35 - 
 
 rates of degradation of the mature core-glycosylated protein. The semi log10 plot of 
degradation kinetics revealed the half life of degradation for EAAC1 as 22.25 Hrs under culture 
conditions.This data suggests that at any given time, the total amount of EAAC1 maintains a 
steady state and any protein degraded is replaced by the newly synthesized protein. 
 
4.6 Cell surface distribution of EAAC1. 
 
The ability of neurotransmitter transporters to remove the neurotransmitter from the synaptic 
cleft depends on the amount of transporter localized at the surface of the nerve terminals or the 
glial cell processes. 
In order to quantify the amounts of EAAC1 present at the cell surface in the heterologous 
expression system, cell surface biotinylation as well as immunocytochemistry were performed 
to gauge the surface expression of EAAC1 (Fig.4.7).  
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Fig. 4.7 Sub-cellular distribution of EAAC1. 
Sub-cellular localization of EAAC1 in HEK-293 cells by 
cell surface Biotinylation assay (A and B) and 
immunocytochemistry (C). 
 
HEK-EAAC1 cells were biotinylated and 100 l of cleared 
lysate (CL) was subjected to avidin precipitation. SDS probes 
were prepared and 10 l each of Total cell Lysate (TCL), 
cleared lysate (CL), cytoplasmic fraction (CF) and 
biotinylated fraction (BF)  were separated by 10% SDS-
PAGE and analyzed by immunoblotting using anti-EAAC1 
antibodies 0.3g/ml). Densitometric analysis of 3 
independent blots (B) was carried out using Phoretix Total 
Lab software. The results are expressed as mean ±SD of 
three independent experiments. 
Immunofluorescence staining of EAAC1 in HEK cells (C) was 
performed to localize EAAC1. Cells were grown on 
coverslips, fixed and labeled with anti EAAC1 antibody and 
visualized with Alexa-488-conjugated secondary antibodies 
(green). Shaded arrow indicates EAAC1 labeling at the 
plasma membrane and the white arrow represents the 
intracellular pools.  
Scale bar 10 m 
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As observed in Fig.4.7A, the biotinylation assay itself did not have any influence either on the 
electrophoretic mobility of EAAC1 or on the banding pattern. 
Fig.4.7A reveals that EAAC1 predominantly localizes in the non-biotinylated cytoplasmic 
fraction of the total lysates indicated by the strong immunoreactivity of EAAC1 in the 
cytoplasmic fraction (CF) and a very weak immunoreactivity in the biotinylated fraction (BF). 
Further quantification of the band intensities (Fig.4.7B) of the cytoplasmic fractions and the 
biotinylated fractions expressed as % of control (Cleared lysate CL) indicated that almost 80% 
of EAAC1 is localized in the cytoplasmic fraction with only 20% in the biotinylated membrane 
fraction. 
This finding was further confirmed by indirect immunocytochemistry (Fig.4.7C). 
Immunocytochemistry of HEK-EAAC1 cells revealed large intracellular pools of EAAC1 
however, a clear but faint membrane labeling was also observed. EAAC1 protein showed clear 
punctate labeling at the membrane, suggesting that the transporter occurs as clusters at the 
membrane. 
In order to investigate the localization of the intracellular pools of the transporter, co-
localization was performed using a Golgi marker protein GM130.  
Immunoreactivity of EAAC1 in HEK-293 cells was found in the cell membrane (Fig. 4.8A, 
white arrow) and in intracellular compartments (Fig. 4.8A, shaded arrow). The membrane 
staining of EAAC1 was not evenly distributed over the membrane but showed distinct puncta 
of intense immunoreactivity, suggesting clustering of the EAAC1 protein in the HEK-293 cell 
membranes. Such a clustered immunoreactivity has been previously described also in vivo by 
Poitry-Yamate et al [73] and Rauen et al [103]. 
GM130 is a 130kDa peripheral protein located on the cytoplasmic side of the Golgi 
membranes. It is part of a cis Golgi matrix and is known to maintain the structural integrity of 
Golgi apparatus [104]. GM130 clearly labeled the Golgi apparatus in the cell cytoplasm as 
shown in Fig 4.8B. 
Double Immunocytochemistry using anti-EAAC1 antibodies (green) and antibodies directed 
against GM130 (red) revealed only partial co-localization of EAAC1 and GM130 in HEK293 
cells. As shown in Fig 4.8C, parts of the EAAC1 protein population is localized in the cell 
membrane and showed no co-localization with GM130.  
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The intracellular fraction of EAAC1 co-localized partly (yellow) with GM130, suggesting 
that the EAAC1 at the cis- phase of Golgi apparatus represents the EAAC1 mature 
glycosylated protein from the endoplasmic reticulum indicating co-translational 
modification.  
Another fraction of the intracellular EAAC1-pool clearly did not co-localize with GM130.  
Post translationally modified proteins can be either present in the endoplasmic reticulum, 
golgi apparatus, or other intracellular storage elements, which store the newly synthesized 
protein, until it is required by the cell. The fact that EAAC1 intracellular protein did not 
completely co-localize with the Golgi marker proteins indicates the existence of EAAC1 
intracellular storage pools which could be trafficked to the membrane when required. 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.7 Impact of substrate on trafficking of Glutamate transporter EAAC1 
 
 
For transporter proteins to function there has to be a mechanism of interaction between the 
transporter and the ligand. In the first instance, the effect of glutamate itself on the regulated 
trafficking mechanism was studied. In the first set of experiments, where the cells were 
subjected to addition of glutamate (1-100M) for 15 min in serum containing medium 
(Fig.4.9A), no significant change in pattern of the cell surface expression was observed.  
Fig.4.8 Co-localization of EAAC1 and Golgi marker protein GM130. 
 
HEK-EAAC1 cells were grown on coverslips, fixed with 4% Paraformaldehyde, labeled with anti-
EAAC1 antibodies and Golgi marker antibodies GM130.EAAC1 was visualized with Alexa-488-
conjugated secondary antibodies (green) and GM130 was visualized by alexa-546- conjugated 
secondary antibody (red). Shaded arrow in 4.8A represents the intracellular pools of EAAC1 
whereas white arrow represents the membrane localization. The arrow in4.8B indicates Golgi 
apparatus staining. The arrow in 4.8C represents the co-localized EAAC1 and Golgi apparatus 
(yellow). Scale bar 10m 
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Fig.4.9 Effect of glutamate on surface expression of HEK-EAAC1 
Cells were treated with L-Glutamate for 15 min. at 37ºC in 5% CO2 air mixture in serum 
containing medium (A) or in serum free medium (B) before cell surface biotinylation. 
SDS probes were prepared from the avidin precipitated samples and 10 l of each 
sample was separated by 10% SDS-PAGE and immunoblotted with anti-EAAC1 
antibodies.  
As observed in A), addition of glutamate in serum containing medium did not have any 
influence on the surface expression. However, when glutamate (1-100M) was added 
to serum free medium, there was a drastic increase in the surface biotinylated fraction 
up to 5 M, followed by a gradual decrease in the surface labeled EAAC1 from 20-100 
M glutamate supplementation. 
 
 
The reason that glutamate addition, under these experimental conditions showed no effect 
might be that serum itself contains high concentrations of free glutamate. Serum contains 
approx 3.5 mM glutamate [105], which would dilute the effects of any further addition of 
glutamate. Therefore, it was decided to repeat the experiments adding external glutamate under 
serum free conditions.  
When glutamate was supplemented in serum free medium (Fig. 4.9B), a rapid increase in the 
surface expression of EAAC1 was observed even at an external glutamate concentration of        
1 M. However, with increasing concentrations of glutamate, above the range of the Km value 
(above 20 M), an opposite effect on the surface localization was observed. Increased 
concentrations of extracellular of glutamate (above 20 M) led to a consistent gradual decrease 
in the biotinylated surface expression.  
This experiment suggests that addition of ligand itself causes a drastic change of the transporter 
expression at the cell surface.  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
However, any further addition of glutamate at higher concentrations gradually reduced the 
surface expression of EAAC1, suggesting the presence of an endogenous homeostatic 
mechanism, which, after stimulation brings the levels of EAAC1 back to those seen in non-
stimulated cells. 
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4.8 Post-translational regulation by phosphorylation : Influence of  phorbol 
esters on the glutamate uptake by EAAC1 
 
Translocation of membrane proteins between the plasma membrane and intracellular storage 
compartments represents one important mechanism of regulation and may contribute to 
synaptic plasticity [106]. Such changes in cell-surface expression can up and down-regulate 
membrane proteins within minutes and much faster than would be possible by protein 
synthesis. It is still an open question how the trafficking mechanism is regulated.  
The activity of a large number of Na+/K+ dependent neurotransmitter transporters have been 
shown to be regulated by activators of protein kinases [107]. In the heterologous over-
expression system, the effect of phorbol esters, the general activators of protein kinase C (PKC) 
[78] which mimic diacylglycerol (DAG) was analyzed. 
In order to determine the appropriate concentration of (phorbol 12-myristate 13- acetate) PMA 
to be used for HEK-EAAC1 cells, cells were treated with PMA (10-300nM) for 30 min. and the 
rates of glutamate uptake were measured in the membrane vesicle preparations. With the 
addition of increasing concentrations of PMA (10-300nM), the glutamate uptake for HEK-
EAAC1 membrane vesicles showed a saturable, concentration dependent increase. The uptake 
increased dramatically in a concentration dependent manner up to 100nM PMA. Higher 
concentrations of PMA did not further increase the glutamate uptake (Fig. 4.10A).  
There was an evident increase in the uptake velocity in HEK-EAAC1 membrane vesicles 
treated with phorbol esters ranging from 150 pmol glutamate/mg protein/min in absence of 
PMA to a maximal value of 350 pmol glutamate/mg protein/min for 100 nM PMA. 
Since maximal uptakes were observed for a PMA concentration of 100nM, all further 
experiments were performed with a PMA concentration of 100 nM. 
To investigate time dependent effect of PMA on uptakes, the membrane vesicles were prepared 
from cells treated with 100nM PMA for times ranging from 2 min to 20 hrs. 
Treatment with PMA with increasing time revealed biphasic behavior for glutamate uptake 
(Fig.4.10B). In the time range between 2-15 min, a rapid increase in the uptake rates was 
observed followed by a rapid decrease in the uptake up to 3 hrs of PMA treatment. 
The maximal uptake was observed at 15 min, which led to the increase of uptake up to 250% of 
the control.  
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Data is represented as mean±SD of 
triplicate measurements from three 
independent experiments. 
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Fig.4.10 Effect of phorbol myristate acetate (PMA) on uptake of glutamate in HEK-
EAAC1 membrane vesicles.  
Effect of PMA concentration (A) Cells were treated with PMA at different concentrations (10-
300nM) and rates of glutamate uptakes (pmol/mg protein/min) measured. 20 g membrane 
vesicle protein was used for each measurement.  
The increased concentration of PMA addition caused a concentration dependent increase of 
glutamate uptake. Maximal uptake was observed for a PMA concentration of 100nM. 
The glutamate uptake was found to be 150pmol Glutamate/mg protein/min in control (no PMA) 
when compared to the uptake of 350 pmol Glutamate/mg protein/min for PMA treated 
samples.  
Influence of time of treatment with PMA and PDD, an inactive phorbol ester (B) HEK-
EAAC1 cells were treated with 100nM PMA for different times (2-1200 min.) and glutamate 
uptakes were performed using 20 g membrane protein for each measurement.  
The addition of PMA caused a dramatic increase in the glutamate uptake in the time scale of 
2-15 min., Further increase upto 180 min with PMA caused a decrease in the glutamate 
uptake.  
Addition of 4-alpha PDD also had a similar effect as PMA on the glutamate uptake. However, 
the effect of PDD was not as pronounced as in the case of PMA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this experiment, 4,12,13 phorbol-didecanoate (PDD) was used as an inactive PMA 
analogue in the control experiments; however, recent data from Watanabe et al [108] suggests 
that PDD affects TRPV4 channels. In line with these observations, PDD also showed a time 
dependent effect on the glutamate uptake. The effect mediated by PDD was not as pronounced 
as in presence of PMA. 
Maximal effect was observed for PMA after 15 min, reaching 500 pmol glutamate/mg protein, 
whereas in presence of PDD, the maximal glutamate uptake only 300 pmol glutamate/mg 
protein was observed. 
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The results obtained with PDD confirm the observations of Watanabe et al that PDD is not a 
useful PMA analogue. However, differences in the effects of PMA and PDD on the glutamate 
transport suggest i) specific effect of PMA and ii) suggest a possible effect of calcium on 
glutamate transporter regulation as TRPV channels are known to activate the influx of 
extracellular calcium into the cells, thereby increasing the overall cytoplasmic calcium 
concentration in the cell and possibly affecting the EAAC1 kinetics through an unknown 
signaling pathway..   
Further investigations on rapid trafficking mechanisms were carried out only in the initial phase 
of the biphasic response to PMA, in the time spans of up to 1 hr.  Since the uptake rates for 
glutamate were maximal at 15 min (250% of the control), it was taken as a standard time for 
treatment with PMA for all further investigations. 
 
4.9 Influence of phorbol esters on the kinetics of EAAC1. 
 
The increased uptake of glutamate upon exposure to PMA could arise either from the increased 
surface expression of EAAC1 or changes in the intrinsic properties of the transporter i.e. 
increased turnover rates of the transporter [109]. 
To evaluate the possibilities, concentration dependent uptakes were carried out in order to 
calculate the Michaelis-Menten kinetics of the uptake. 
To investigate the possible changes in the turnover rates, laser pulse photolysis experiments to 
determine the micro-kinetics of EAAC1 were performed by Dr. Christof Grewer, Miami, USA, 
revealing that the turnover rate of EAAC1is not effected by treatment with PMA (personal 
communication with Carsten Mim). 
However, kinetic analysis of glutamate uptake (Fig. 4.11) revealed a three fold increase in Vmax 
for the cells treated with PMA (1012±32pmol glutamate/mg protein/min) with respect to 
control (343±13pmol glutamate/mg protein/min). 
In contrast, the Km value of EAAC1 was not affected by PMA treatment. The Km value of non-
treated cells was determined to be 3.4±0.4 M and that of PMA treated cells was 3.3±0.2 M 
glutamate  
In comparison to PMA, PDD showed a much lower effect on glutamate uptake, increasing the 
Vmax only by 1.5 fold (500±49 pmol glutamate /mg protein/min). In line with PMA, there was 
no effect on the Km value. The Km values for PMA and PDD treated cells were calculated as 
3.3±0.2 M and 3.5±0.4 M glutamate respectively (Fig. 4.11). 
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In summary, these experiments suggest that phorbol ester treatment neither changes the 
turnover rate of the transporter nor affects the affinity of the transporter for glutamate, but has a 
strong influence on the Vmax value of EAAC1. 
The increase in Vmax of glutamate uptake might indicate the high density expression of EAAC1 
in the cell membranes while lower Vmax values might represent the low density expression of 
glutamate transporters at the membrane.   
 
 
 
 
 
 
Fig.4.11 Influence of PMA on EAAC1 Glutamate uptake.  
Kinetic properties of glutamate uptakes in membrane vesicles of HEK-EAAC1 treated with PMA 
(100nM/15 min). Uptake velocity was measured by using 1Ci (42-57Ci/mmol) of 3H1 glutamate and 
increasing concentrations of unlabeled L-glutamate at a membrane vesicle protein concentration of 
20 g. Measurements were taken within the linear range of uptake (15 and 30s).The data are the 
mean of triplicate determinations from three experiments. The Km and Vmax values were obtained 
from the Lineweaver–Burk plot. As a control, 4-PDD, an inactive phorbol ester was used at a 
concentration of 100nM for 15 min.  
As observed in 4.11A, the control cells (HEK-EAAC1) showed a Vmax of 323pmol/mg protein/min 
when compared to 500pmol glutamate/mg protein/min and 1000pmol/mg protein /min for PDD and 
PMA treated cells respectively. 
The calculation of Km value from the Lineweaver Burk plots (Fig.4.11B) revealed a V max of 3.4M, 
3.5 M and 3.3 M for control, PDD treated and PMA treated cells respectively. 
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4.10 Influence of phorbol esters on localization of EAAC1 
 
In order to investigate the phorbol myristate acetate (PMA) effect on the cell surface expression 
of EAAC1, immunocytochemistry was performed to localize EAAC1 in presence and absence 
of PMA (Fig. 4.12). 
 
                      
 
 
 
 
 
 
 
 
 
 
In the untreated cells (Fig. 4.12A), EAAC1 was predominantly observed in the intracellular 
pools, with a faint membrane labeling as indicated by the shaded and white arrows respectively. 
However, upon treatment with increasing concentrations of PMA, the immunolabeling of 
EAAC1 at the membrane strongly increased (Fig.4.12 B, C and D, white arrows). The EAAC1 
is not homogenously distributed at the membrane, but showed a punctuated labeling pattern, 
suggesting clustering of the EAAC1 proteins in the membrane.  
 
B 
C 
A 
D 
Fig. 4.12 Confocal microscopy of HEK-EAAC1 cells in presence and absence of 
PMA. 
The cells were treated without (A) or with 25nMPMA (B), 50nM PMA (C) and 100nM 
PMA (D) for 15min at 37ºC in  5% CO2 air mixture supplemented with 10% serum  
and labeled with anti-EAAC1 antibodies (0.3g/ml). For visualization, Alexa Fluor 488 
conjugated secondary antibodies were used. 
White arrows represent EAAC1 localized at the plasma membrane whereas the gray 
shaded arrows represent intracellular pools of EAAC1. 
Scale bar 10m. 
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Although, membrane staining of EAAC1 increased in the presence of PMA, still intracellular 
labeling was observed (shaded arrows), indicating that PMA does facilitate trafficking of 
EAAC1 from the intracellular compartments to the plasma membrane only partially, which 
intracellular labeling of EAAC1 still observed. 
Treatment with PMA did not have any detrimental effects on the cell morphology of HEK-
EAAC1 cells. All together, these immunocytochemical experiments suggest that PMA caused a 
redistribution of EAAC1 to the membrane. This explains the observed increase in the Vmax 
(Fig.4.12A) as increased density of the transporter in the membrane is expected to increase the 
transport rate (Vmax) of EAAC1. 
A common feature of several ion channels, receptors and transporters is the trafficking 
mechanism, which causes rapid redistribution from the intracellular compartments to the 
membrane [71]. To confirm the trafficking mechanism of EAAC1 in HEK-293 cells, cell 
surface biotinylation experiments were performed. 
 
4.11 Cell surface biotinylation assay : Influence of phorbol esters and 
 phosphatase inhibitors on cell surface expression of EAAC1 
 
In order to assert the trafficking of EAAC1 to the membrane, cell surface biotinylation was 
performed after treating the HEK-EAAC1 cells with PMA. Phorbol esters are general 
activators of PKC which finally phosphorylate their target proteins. In order to avoid 
simultaneous dephosphorylation of PMA induced PKC phosphorylation of the downstream 
targets, the effect of phosphatase inhibitors was also determined in presence and absence of 
PMA (Fig.4.13). 
A broad specificity phosphatase inhibitor cocktail (phosphatase inhibitor cocktail II, Sigma) 
was used for this study which inhibited tyrosine phosphatases, acid as well as alkaline 
phosphatases.  
As shown in Fig.4.13 (left panel), treatment with either phosphatase inhibitors (lane 2), PMA 
(lane 3), or PMA and phosphatase inhibitors (lane 4) did not have any effect on the expression 
of EAAC1 in HEK-293 cells compared with lane 1 (control, without addition of PMA or 
phosphatase inhibitors). The total amount of EAAC1 protein expression was not changed.  
Addition of the PMA solvent dimethyl sulfoxide (DMSO) alone does not change the EAAC1 
protein expression pattern.  
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Fig.4.13 Influence of PMA and phosphatase inhibitors on cell surface expression of 
EAAC1 
HEK-EAAC1 cells were treated with DMSO alone (lane 1), phosphatase inhibitors (10l/ml 
medium) (lane 2), 100nM PMA (lane 3) and 100nM PMA + phosphatase inhibitors (10l/ml 
medium) (lane 4) for 15 min. before cell surface biotinylation. 10 l SDS probes were separated 
by 10% SDS PAGE and analyzed by immunoblotting with anti-EAAC1 antibodies. To confirm 
equal protein loading in each lane as well as complete separation of non-biotinylated and 
biotinylated fractions, blots were also probed with anti-actin antibodies. The blots are 
representative of 5 independent experiments. 
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Thus, PMA, phosphatase inhibitors, or both in combination did not influence EAAC1 protein 
expression or degradation in HEK-EAAC1 cells in the time range of 15 min. used in these 
experiments. 
Treatment with phosphatase inhibitors alone (lane 1) led to a slight increase (values) in the 
surface biotinylated fraction (right panel) and decrease in the cytoplasmic fraction (middle 
panel). PMA treatment alone (middle panel, lane3) showed a drastic increase in the surface 
biotinylated fraction of EAAC1 with a strong decrease in the non-biotinylated fraction. 
When the cells were treated with both, PMA and phosphatase inhibitors (right panel, lane 4), 
there was a cumulative increase in the surface biotinylated fraction of EAAC1 with a decrease 
in the non-biotinylated cytoplasmic fraction. At this point however, it should be clarified that 
the increased labeling of the surface biotinylated fraction of EAAC1 was more sensitive to the 
densitometric analysis compared to the decrease in the cytoplasmic fractions. This difference 
could be explained due to the saturation levels of protein detection by the EAAC1 antibodies 
for the cytoplasmic fraction. 
In all the three fractions, EAAC1 was labeled as a 66 kDa protein as well as the higher 
molecular weight protein of approximately 175 kDa. To ensure complete separation of the 
biotinylated fraction from the non biotinylated fraction, the blots were also labeled for the 
cytoskeletal protein, actin. Actin was observed as a 45kDa protein, as expected, only in the 
total lysates and the cytoplasmic, non-biotinylated fraction but not in the surface biotinylated 
fraction. 
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In summary, these experiments confirm the trafficking of EAAC1 from the intracellular pools 
to the cell membrane in response to PMA as well as by phosphatase inhibitor treatment. 
Thus, increasing protein phosphorylation (PMA) or decreasing protein dephosphorylation 
(phosphatase inhibitors) increases the surface expression of EAAC1. Furthermore, these 
experiments indicate a direct influence of protein kinases on the trafficking behavior of 
EAAC1. However, the more pronounced effect of PMA on EAAC1 trafficking in comparison 
to that of the phosphatase inhibitors might suggest multiple regulatory mechanisms in the 
redistribution of EAAC1.  
 
4.12 Endocytosis of EAAC1 
 
The observation that phorbol esters increased intracellular calcium and protein phosphorylation 
lead to an increased cell surface expression of EAAC1 and that the uptakes of glutamate 
increase up to 15 min. and decrease thereafter led to the hypothesis that either the transporter, 
after stimulation undergoes the degradation pathway, or alternatively enters the recycling 
pathway. 
Recycling of EAAC1 should involve the regulated trafficking of the protein to the membrane, 
the coordinated removal of the protein from the membrane into internal storage elements and 
finally back to the membrane again. 
In order to analyze this hypothesis, the endocytotic process was investigated employing a 
membrane cleavable cell surface biotinylation assay. 
Using this assay, membrane proteins were generally labeled with sulfosuccinimidyl-2-
(biotinamido) ethyl-1, 3-dithiopropionate (NHS-SS-biotin). NHS-SS-biotin includes a 
cleavable disulfide bridge, so that reducing conditions are able to cleave biotin from the 
previously biotinylated protein. 
In order to investigate the endocytotic process, HEK-EAAC1 cells were labeled with NHS-SS-
Biotin, and incubated up to 30 min at 37ºC to allow EAAC1 endocytosis. The residual biotin 
still attached to the membrane proteins were removed by reducing buffer (containing 50mM 
reduced glutathione). The biotin tagged endocytosed EAAC1 was affinity precipitated by 
avidin precipitation. The rate of EAAC1 endocytosis was analyzed by WB analysis and 
subsequent densitometry of avidin precipitated EAAC1 (Fig 4.14 B) 
The experiments were carried out in HEK-EAAC1 cells stimulated with PMA in order to check 
the endocytosis of the PMA stimulated EAAC1.   
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For this purpose, membrane impermeant, cleavable biotin was used to label the surface 
proteins. The cells were re-transferred to serum free medium at 37ºC/5% CO2 for different time 
intervals (1-30 min). The endocytosed proteins, being inaccessible to reducing glutathione, still 
remained tagged with biotin and the surface proteins (not-endocytosed) were cleaved in 
glutathione containing buffer. 
In order to check the efficiency of glutathione cleavage for the validation of the experiments, 
the surface biotinylated membrane proteins were cleaved in presence of reduced glutathione for 
15 min (Fig.4.14A, lane 1). 
Fig. 4.14A, Lane 2 shows the total membrane biotinylated EAAC1 without PMA addition. The 
increase in the surface biotinylated EAAC1 upon treatment with phosphatase inhibitors (Fig. 
4.14A, lane 3), PMA (Fig 4.14A, lane 4) and phosphatase inhibitors plus PMA (Fig. 4.14A, 
lane 5) is observed compared to the untreated cells (Fig. 4.14A, lane 2).  
The endocytosed EAAC1 after time intervals of 2min-30 min incubations are depicted by lanes 
7-11. As seen in the Fig.4.14, lanes 3-11, the EAAC1 endocytosis increases from 2min until a 
time period of 10 min, after which, a gradual decrease in the biotin labeled EAAC1 is observed 
till 30 min. 
Since a maximal amount of EAAC1 was endocytosed in the time interval of 10 min, it was 
decided to check for the surface labeled EAAC1 after 10 min of endocytosis (Fig. 4.14, lane 6). 
Theoretically, the addition of the surface biotinylated EAAC1 and the endocytosed EAAC1 
after 10 min time span should add up to the total biotinylated EAAC1 at the surface after PMA 
stimulation (Fig. 4.14, lane 5). 
In order to quantify the amounts of protein, Densitometric evaluation of the band intensities 
was performed. The plot of %EAAC1 internalized with respect to time (Fig.4.14B) indicates 
that 27-30% of EAAC1 at the membrane, after stimulation to the surface upon PMA 
stimulation, is internalized within a time span of 10 min. 
These results indicate that after stimulation to the surface following PMA treatment, rapid 
internalization follows, once PMA is removed from the medium. 
However, after the internalization time span of 10 min, followed by decreased EAAC1 
immunolabeling was observed for further time spans of 20 min and 30 min. This suggested two 
possibilities.  
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After internalization, either the transporter was directed towards the degradation pathways or 
the internalized EAAC1 rapidly came back to the plasma membrane surface and was hence 
cleaved by the glutathione cleavage buffer and therefore escaped the detection by avidin 
precipitation. 
Fig.4.14 Endocytosis of EAAC1. 
 
A) EAAC1 was biotinylated without (Lane 2) or with stimulation with PMA (lane 1, 3-11) in 
presence of phosphatase inhibitors. Lane 1 shows the efficiency of biotin cleavage by 
glutathione. Lane 2 shows the expression of EAAC1 in non-stimulated cells (no PMA added). 
Lane 3-5 depict the increased surface expression of EAAC1 on exposure to PMA alone, 
phosphatase inhibitors and PMA plus phosphatase inhibitors respectively. Lane 6 shows the 
surface biotinylated EAAC1 fraction after 10 min. endocytosis at 37ºC. Lanes 7-11 show the 
surface biotinylated fraction of EAAC1 after 2, 5, 10, 20 and 30 min. incubations in serum free 
medium post stimulation. 
B) Densitometric analysis of the band intensities of lanes 7-11 with respect to control (lane 5, 
100%) 
Data is represented as mean±SD of 2 independent experiments. 
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To confirm the possibilities the total protein fractions before and after transporter endocytosis 
were checked for EAAC1 protein. There was no evidence the degradation of EAAC1 after 
stimulation with PMA even after 1 hour (data not shown). 
 
4.13 Recycling of EAAC1: Is endocytosed EAAC1 reused for a new membrane 
 trafficking series/round and recycled back to the membrane  
 
In order to follow if EAAC1 undergoes a complete cycle from the membrane to intracellular 
compartments and back to the membrane (recycling), modification of the previous experiment 
was performed. 
In order to analyze the recycling kinetics of EAAC1, the cells were stimulated with 100 nM 
PMA plus phosphatase inhibitors and surface biotinylated. Thereafter, a 20 min. time was 
allowed for endocytosis before cleavage of surface biotin with reducing buffer. The cells were 
incubated at 37ºC in serum free medium supplemented with glutathione for a second time for 
different time intervals in presence of PMA, to allow for a second round of stimulation. 
The samples were cleaved again of any biotinylated proteins resurfacing before subjecting to 
lysis and avidin precipitation. 
As observed in Fig. 4.15A, lane 1 represents the total biotinylated EAAC1 endocytosed after 20 
min. of PMA stimulation. Lane 2 represents the efficiency of cleavage of surface biotin using 
glutathione cleavage buffer.  
Fig.4.15A, lanes 3-7 represent the amount of endocytosed EAAC1 still tagged with biotin or in 
other words, the amount of EAAC1 which did not recycle back to the membrane, and hence the 
biotin label was not cleaved by the glutathione cleavage buffer. 
As seen in the Fig.4.15A, lanes 3-7 represent the increase in recycling of EAAC1 with respect 
to time of recycling of 2-30 min, in comparison to the non recycled sample (Fig. 4.15A, lane 1). 
Densitometric analysis of the non-recycled EAAC1, and hence still tagged with biotin plotted 
against the recycling time revealed that after a time period of 30 min, only 25-30% of EAAC1 
still remained localized intracellularly, however, majority of the EAAC1 endocytosed (70-
75%), was recycled back to the membrane upon re-stimulation with PMA. 
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Fig.4.15 Recycling of EAAC1. 
 
HEK-EAAC1 cells were cultured in 15mm culture dishes and treated with PMA (100nM/15 min. 
before cell surface biotinylation. The cells were incubated at 37ºC to allow for endocytosis of the 
surface protein. After 20 min. incubation, the remaining non-endocytosed, surface biotin was 
cleaved by incubation with glutathione cleavage buffer at 4ºC. The cells were stimulated again with 
PMA and the surface biotinylated EAAC1 recycled to the plasma membrane was cleaved with 
glutathione cleavage buffer for a second time. Thereafter, the cells were lysed in lysis buffer and 
non-recycled biotinylated EAAC1 was precipitated using avidin and analyzed by immunoblotting. 
Densitometric evaluation of the non-recycled EAAC1 fraction was performed using Phoretix Total 
lab software. 
A) Lane 1 represents the total EAAC1 endocytosed after 20 min. lane 2 (G) represents the 
efficiency of biotin cleavage by glutathione. Lanes 3-7 represent the amount of EAAC1 not 
recycled and hence still tagged with biotin after 2, 5, 10, 20 and 30 min of recycling times 
respectively. 
B) Densitometric plot of transporter not recycled vs the recycling time. 
Data is a representative of 2 independent experiments. 
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The values obtained from the densitometric analysis of EAAC1 after recycling reveals that 
almost 40 % of EAAC1 stimulated to the surface after PMA treatment is recycled back to the 
intracellular compartments in the cytoplasm. Moreover, re-stimulation of EAAC1 with PMA 
causes 75% of this 40% protein to resurface at the membrane. 
This data, in conjugation with the half life calculations for the degradation of EAAC1 protein 
suggest that the protein is not degraded after stimulation with PMA and re-internalization, but 
possibly undergoes multiple cycles of internalization and resurfacing before being degraded.  
 
 
4.14 Effect of PKC inhibitor staurosporine membrane permeable calcium 
chelator BAPTA-AM on cell surface expression of  EAAC1 
 
Phorbol esters are general stimulators of protein kinase C. PKC’s are classified into three 
subtypes: the conventional, the atypical and the novel subtypes [78].  Protein kinase C isoforms 
are ubiquitously expressed in mammalian cells. Protein kinases are classified as conventional 
PKC’s(PKC ,  and ) which require both calcium and diacylglyerol (DAG) for their action, 
novel PKC’s (PKC , ,  ,  and ) which require DAG for their function and atypical PKC’s 
(	 and 
) which do not require calcium or DAG for their action. 
To discriminate between conventional and atypical/novel PKC’s, cell surface expression of 
EAAC1 was investigated in presence of PMA (DAG analog) and BAPTA-AM, a cell 
permeable calcium chelator. As shown in Fig. 4.16A (upper panel), addition of phosphatase 
inhibitors (Lane 2), PMA (lane 3) or PMA plus phosphatase inhibitors (lane 4) increased the 
expression of EAAC1 in the biotinylated fraction when compared to the unstimulated cells 
(lane 1). Addition of BAPTA-AM alone caused a drastic decrease in the surface labeled 
EAAC1 (lane 5).  
However, addition of PMA along with BAPTA-AM caused a partial recovery of EAAC1 at the 
surface (lane 6) but the surface EAAC1 levels never reached the basal level under these 
conditions (compare lane 1 and lane 6).  
Addition of 100nM staurosporine (lane7, upper panel), a general PKC inhibitor, for 15 min 
caused a moderate decrease in the surface expression of EAAC1. 
More importantly, addition of both, staurosporine and BAPTA-AM caused a dramatic decrease 
in the surface expression of EAAC1 (lane 8), comparable to that of lane 5 (only BAPTA-AM).  
 
 
   4.Results 
- 52 - 
 
The cytoplasmic fractions (lower panel) exhibited a corresponding increase or decrease 
whenever the surface biotinylated fraction decreased or increased respectively.  
                                                           
  
                                         
 
 
 
 
             
 
 
 
 
 
 
 
The electrophoretic mobility and the immunoreactive band pattern of EAAC1 was identical 
under all experimental conditions chosen here (see Fig.4.16). 
All together, these data indicate the involvement of a calcium dependent PKC for membrane 
trafficking of EAAC1. 
 
Non-biotinylated 
Cytoplasmic fraction 
 
Biotinylated 
fraction 
 
 
Fig.4.16 Effect of cell permeable calcium chelator BAPTA-AM and a general PKC inhibitor, 
staurosporine on surface expression of EAAC1.  
HEK-EAAC1 cells (80% confluence) were treated with DMSO alone (lane 1), phosphatase 
inhibitors (10l/ml medium) (lane2), 100nM PMA/15 min at 37ºC/5% CO2 (lane 3), 100nM PMA + 
phosphatase inhibitors (lane 4) for 15 min. and taken as controls for PMA mediated increase of 
surface expression. Additionally, cells were treated with BAPTA-AM (10 M/1hr pre-incubation) 
(lane 5) and BAPTA-AM plus PMA (lane 6) and staurosporine (lane7) as well as staurosporine 
and BAPTA-AM (lane 8) before cell surface biotinylation. 10 l SDS probes were separated by 
10% SDS-PAGE and analyzed by immunoblotting with anti-EAAC1 antibodies (0.3g/ml). 
Addition of Phosphatase inhibitors (lane 2) and PMA (lane 3) or both phosphatase inhibitors plus 
PMA (lane 4) an expected increase in the surface expression (see upper panel). Addition of 
BAPTA-AM caused a drastic decrease in the surface expression of EAAC1 upper panel, lane 5. 
Upon treating the cells with both BAPTA-AM plus PMA caused a partial recovery of the surface 
labeled EAAC1 (upper panel, lane 6). 
Addition of staurosporine marginally caused a marginal decrease in the surface EAAC1 (upper 
panel, lane 7) whereas addition of both, staurosporine plus BAPTA-AM again caused a drastic 
reduction of surface EAAC1 protein (upper panel, lane 8). 
The lower panel shows corresponding cytoplasmic fractions of the investigated samples. 
The blots are representative of three independent experiments. 
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4.15 Influence of intracellular calcium on PMA mediated EAAC1 trafficking 
 to the membrane 
 
In order to further evaluate the effect of calcium on EAAC1 membrane trafficking, the 
concentration dependence of BAPTA-AM was determined in the presence of PMA (Fig. 4.17). 
Addition of BAPTA-AM to HEK-EAAC1 cells did not have any influence on the total EAAC1 
protein content as shown in Fig.4.17A. Equal loading of protein was ensured by 
immunoblotting the same membrane with anti-actin antibodies. The cytoplasmic, non- 
biotinylated fraction shows a decreased immunolabeling of EAAC1 in the cytoplasmic fraction 
upon treatment with PMA (Fig.4.17B, lane 2) when compared to the untreated cells (Fig.4.17B, 
lane 1). A corresponding increase in the surface biotinylated fractions of EAAC1 was also 
observed as shown in Fig.4.17C lane 2.  Addition of increasing concentrations of BAPTA-AM 
(co-incubation) (Fig 4.17B, lanes 3-5) showed increased intensity of EAAC1 labeling in the 
cytoplasmic fraction with a corresponding decrease in the surface biotinylated fractions of 
EAAC1 (Fig.4.17C, lanes 3-5). 
Increasing concentrations of BAPTA-AM almost completely eliminated the PMA effect in the 
cells co-incubated with PMA (100nM) and BAPTA-AM. As for the control (only PMA), a 
drastic increase in the surface expression of EAAC1 was observed. Corresponding 
densitometric calculations for the non-biotinylated cytoplasmic fractions and the surface 
biotinylated fractions are shown Fig.4.17D and 3.17E respectively. Addition of the highest 
concentration of BAPTA-AM (50 M) caused a decrease in the surface labeling of EAAC1 in 
presence of PMA from 230% of control, non-stimulated cells to 125% of control. 
This experiment suggests that BAPTA-AM decreases the PMA mediated increase in the cell 
surface expression of EAAC1, however, the levels of EAAC1, upon treatment with the 
intracellular calcium chelator also decrease the levels of EAAC1 below those of the untreated 
cells. 
Intracellular calcium can have a variety of effects on cellular signaling. Since chelation of 
intracellular calcium led to a concentration dependent decrease in the PMA mediated 
trafficking of EAAC1. This implies that calcium may be a pre-requisite for the trafficking 
mechanism of EAAC1.  
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Fig.4.17 Influence of intracellular 
calcium chelator BAPTA-AM on 
rapid trafficking of EAAC1. 
 
HEK-EAAC1 cells (80% confluence) 
were treated with DMSO alone 
(lane1), 100nM PMA/15 min at 
37ºC/5% CO2 (lane 2) or 100nM 
PMA + BAPTA-AM (lanes 3, 4, 5 
and 6) for 15 min. before cell surface 
biotinylation. 10 l SDS probes were 
separated by 10% SDS PAGE and 
analyzed by immunoblotting with 
anti-EAAC1 antibody. To confirm 
equal loading in each lane as well as 
complete separation of non-
biotinylated and biotinylated 
fractions, blots were also probed 
with anti-actin antibody. The blots 
are representative of three 
independent experiments. 
Densitometric analysis of cell 
surface biotinylation was performed 
using Phoretix Total Lab software. 
 
 
 
To investigate the calcium effect on EAAC1 trafficking in more detail,   two basic mechanisms 
of intracellular calcium signaling were investigated. 
a) Calcium as an important requirement for exocytosis of the intracellular storage elements 
of EAAC1. 
b) Calcium as a cofactor required for the PKC signaling cascade. 
 
Before investigating the calcium effect in detail, the specific protein kinase involved in 
EAAC1 trafficking was determined using a variety of PKC inhibitors  
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4.16 Influence of Non-specific and specific PKC inhibitors on regulated 
trafficking of EAAC1 
 
The previous set of experiments (section 4.14) demonstrated the role of a calcium dependent 
conventional kinase. Hence it was decided to identify the specific protein kinase involved in 
EAAC1 trafficking. Therefore, various specific inhibitors for conventional PKC ,  and   
have been used. 
Four different kinase inhibitors, staurosporine, rottlerin, BIS I and BIS II were used (Fig.4.18).  
The use of a conventional PKC inhibitor, staurosporine, led to a moderate decrease in the 
surface expression of EAAC1 (Fig.4.18C, lane 5, Fig. 4.18E lane 5, 160% of control) 
suggesting the possible involvement of a conventional PKC. 
However, the cells preincubated with staurosporine plus phosphatase inhibitors, and then 
treated with PMA exhibited a similar increase in the surface expression of EAAC1 (200% of 
control, Fig.4.18C, lane 6), as the cells treated only with PMA (230% of control) (Fig.4.18C, 
lane 4). This indicates that staurosporine cannot block the PMA effect. This might suggest that 
the specificity of staurosporine for conventional PKC’s is questionable, as also suggested by 
Davies et al [110] . 
Rottlerin, another PKC inhibitor, previously acknowledged as a highly specific PKC  (atypical 
PKC) inhibitor [111], was used as a control. 
Using rottlerin, it was expected that if a conventional PKC is involved in EAAC1 trafficking, it 
should not affect the PMA mediated increase in the EAAC1 surface expression.   
Surprisingly, upon addition of rottlerin (10 M), a moderate decrease in the surface expression 
of EAAC1 was observed (60% of control). However, rottlerin was not able to contradict the 
PMA effect and a drastic increase in EAAC1 surface labeling was observed in samples treated 
with PMA plus rottlerin. The latter data indicates that conventional PKC’s and not atypical 
PKC’s are involved in EAAC1 trafficking. But the observed decrease of EAAC1 surface 
expression in presence of rottlerin might suggest a possible involvement of atypical PKC’s. 
As recently reported by Davies et al [110], rottlerin not only inhibits atypical PKC, but also 
affects conventional PKC’s. Thus, the observed rottlerin effect might be due to inhibition of 
PKC or PKC. 
To address this problem, it was decided to use, in a similar experimental setup, the specific 
PKC inhibitors bisindoylmaleimide I (BIS I) and additionally BIS II which also inhibits 
protein kinase A (PKA)[110].  
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Administration of BIS I, a potent and highly selective inhibitor of PKC  completely inhibited 
the PMA mediated increase in biotinylated cell surface fraction of EAAC1 (Fig 4.18E, lane 9-
10, 110% of control) (Fig. 4.18C, lanes 10-11). This experiment clearly demonstrated the 
involvement of PKC in the regulation of cell surface expression of EAAC1. 
In line with this experiment, BIS II showed the same affect as BIS I (Fig. 4.18E, lanes 11-12) 
indicating again the involvement of PKC. However, BIS II additionally inhibits the activity of 
PKA [110] . However the inhibition of PKA by BIS II does not appear to influence EAAC1 
trafficking. If PKA would be involved in the trafficking mechanism of EAAC1, we would 
expect a decrease in the basal levels of EAAC1 at the surface. The experimental data do not 
show a decrease in the surface expression and thus, we conclude that PKA is not directly 
involved in the trafficking mechanism of EAAC1.  
Total fractions of the above samples (Fig.4.18A, lanes 1-12) were also evaluated for any 
change in the protein expression upon treatment with various inhibitors. As shown in 
Fig.4.18A, no change in the total EAAC1 protein content was observed. Furthermore, equal 
protein loading for all samples was confirmed by immunoblotting with anti-actin antibodies. 
The cytoplasmic fraction of the samples showed a corresponding decrease or increase 
whenever an increase or decrease in the biotinylated surface fraction was observed (Fig.4.18 B, 
D). 
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This set of experiments suggests the role of PKC in the regulation of rapid trafficking of 
EAAC1 from the intracellular pools to the plasma membrane. 
It was then decided to check the effect of PMA on the localization of PKC. Indirect 
immunocytochemistry indicated that in unstimulated cells, PKC is uniformly distributed in 
the cytoplasm of HEK-cells, but upon stimulation of cells with PMA, the localization of PKC 
is altered, with more concentrated labeling at the membrane. 
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Fig.4.18 Influence of PKC inhibitors on 
the cell surface expression of EAAC1. 
Cells were treated with phosphatase 
inhibitors (10l/ml 1hr pre-incubation, PMA 
(100nM/15 min), staurosporine (100nM/15 
min), rottlerin (10M/15min pre-
incubation), BISI (5 M/15 min) and BISII 
(5M/15min) before cell surface 
biotinylation. Biotinylated proteins were 
separated from the non-biotinylated 
fraction by avidin precipitation. 10l each 
of total lysate (A), non-biotinylated fraction 
(B) and biotinylated fraction (C) was 
separated by 10 % SDS-PAGE and 
analyzed with anti-EAAC1 antibody. 
Complete separation of non-biotinylated 
and biotinylated fractions as well as equal 
protein loading was ensured by 
immunoblotting with anti-actin antibody. 
The Densitometric analysis of the 
cytoplasmic fraction (D) and the 
biotinylated fractions (E) was performed 
using Phoretix Total Lab software after 
normalizing the protein content against 
actin. The data is representative of 2 
independent experiments. *Significantly 
different p>0.05 
C 
 E 
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To confirm the involvement of PKC in the regulated trafficking of EAAC1, co-localization 
with EAAC1 was performed in unstimulated as well as PMA stimulated cells. 
As observed in Fig 4.19A, PKC is stained as evenly distributed protein, localized in the 
cytoplasm in non-stimulated cells. EAAC1 staining is observed primarily in the intracellular 
compartments and a faint punctuate labeling is also observed at the plasma membrane (4.19B). 
The overlay for PKC and EAAC1 does not show any co-localization (4.19C).  
 
       
 
 
Fig.4.19 Co-localization of PKC and EAAC1 in unstimulated cells. 
HEK-EAAC1 cells were grown on coverslips and fixed with 4% paraformaldehyde. The cells were 
labeled with anti-PKC and anti-EAAC1 antibodies. PKC and EAAC1 were visualized using Alexa 546 
and Alexa 488 conjugated secondary antibodies respectively. 
A) Represents the PKC labeling, uniformly distributed throughout the cytoplasm. 
B) Shows the EAAC1 labeling, both, as punctuate labeling at the membrane and as intracellular 
pools 
C) Shows the overlay of A and B. 
As observed, in the unstimulated cells, there is no co-localization of PKC and EAAC1 
Scale bar 10M. 
 
 
 
However, when PMA was added to the cells, a change in the distribution pattern of PKC was 
observed. PKC redistribution was observed upon addition of PMA and it was localized close 
to the cell membrane (4.20A). The change in the distribution pattern of EAAC1 is also 
observed with a more prominent labeling at the membrane (4.20B). The overlay of PKC and 
EAAC1 showed co-localization of the two proteins (Fig.4.20C), however, a total co-
localization of PKC and EAAC1 was not observed. 
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Fig.4.20 Co-localization of PKC and EAAC1 in stimulated cells. 
HEK-EAAC1 cells were grown on coverslips and treated with 100nM PMA/15 min at 37ºC in 5% CO2 
and 95% air before fixation with 4% paraformaldehyde. The cells were labeled with anti-PKC- and anti-
EAAC1 antibodies. PKC and EAAC1 were visualized using Alexa 546 and Alexa 488 conjugated 
secondary antibodies respectively.  
As shown in Fig.4.20 A, PKC distribution shows a punctate labeling, especially at the membrane 
surface, as indicated by the arrow. 
EAAC1 staining pattern (Fig.4.20B) shows a clear membrane labeling (white arrow) as well as 
intracellular localization (gray shaded arrow). 
Double immunocytochemistry reveals areas of yellow labeling, indicated by arrows, demonstrating co-
localization of PKC and EAAC1 at the membrane (Fig.4.20C). Scale bar 10M. 
 
 
4.17 Influence of Ophiobolin (calmodulin inhibitor) on the cell surface 
 expression of EAAC1 
 
In the previous chapter (see section 4.16), the role of conventional protein kinase C (PKC) 
was evaluated in the regulated trafficking of EAAC1. Since requirement for calcium is 
indispensable for the activity of conventional PKC’s, demonstrated by the use of intracellular 
calcium chelator BAPTA-AM (see section 4.14 and 4.15), the role of calcium regulated 
proteins and PKC activation on the regulated membrane trafficking of EAAC1 was 
investigated.  
Deriving an analogy from receptor trafficking mechanisms, it was decided to check the 
influence of a ubiquitous calcium regulatory protein, calmodulin. 
Calmodulin, the most ubiquitous calcium-binding protein which regulates proliferation, cell 
growth, and cell movement [93, 112]. In recent years, several reports have suggested that 
calmodulin is also involved in membrane trafficking, in both endocytic and exocytic pathways 
[113].  
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To investigate the effect of calmodulin on EAAC1 membrane trafficking, ophiobolin, a 
membrane permeable inhibitor of calmodulin was used.  Ophiobolin is an irreversible 
antagonist of calmodulin and binds to the calcium binding domain of calmodulin [114], thereby 
blocking the activity of calmodulin. In a concentration range of 5 µM, Leung  et al. [115] have 
shown that ophiobolin quantitatively blocks the activity of recombinant calmodulin in vitro. 
The treatment of cells with ophiobolin did not have any affect on the banding pattern of 
EAAC1 total lysates as shown in Fig. 4.21A. Equal loading of the total protein was confirmed 
by immunoblotting of the same gel with anti-actin antibodies. 
Using the concentration range of 1-20 M, addition of ophiobolin to HEK-EAAC1 cells 
resulted in a quantitative inhibition of calmodulin. Performing biotinylation experiments to 
determine the ratio of cellular and intracellular distribution of EAAC1 in presence of 
ophiobolin revealed a decrease in the surface labeled EAAC1. 
At an ophiobolin concentration of 1 M, decreased the surface intensity of EAAC1 in the 
presence of PMA from 250% of control to 200 % of control. 
Moreover, increased concentration of ophiobolin (5 M), decreased the intensity of surface 
labeling in PMA stimulated cells (Fig. 4.21 C, lane 4) to 20 %  of the control cells treated with 
PMA (250% of control). 
Further addition of  20 M ophiobolin showed no detectable band in the western blot analysis 
(Fig 4.21C, lane 5), but the Densitometric evaluation of the blot revealed minor levels of 5% 
intensity ( Fig 4.21 E, lane 5) compared cells stimulated with PMA (Fig. 4.21E,lane 2) . 
The decrease in the intensity of EAAC1 in the surface biotinylated fractions was accompanied 
with a corresponding increase in the non-biotinylated cytoplasmic fractions (Fig.4.21 B). 
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4.18 Influence of CaM kinase II inhibitor KN-93 on the trafficking of EAAC1 
 
The effect of calcium as well as the effect of calmodulin (section 4.17) demonstrated the 
significance of calcium signaling in the rapid trafficking of EAAC1. 
Several classes of protein kinases depend on calcium calmodulin complex for function and the 
role of various calcium/CaM dependent kinases has been implicated in synaptic plasticity.  
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Fig.4.21 Influence of Calmodulin 
antagonist Ophiobiolin on the cell 
surface expression of EAAC1. 
Cells were treated with vehicle alone 
(0.1%DMSO) lane 1, PMA (100nM/15 
min) lane 2 and PMA and Ophiobolin 
(co-incubation), lanes 3, 4 and 5 
before cell surface biotinylation. 
Biotinylated proteins were separated 
from the non-biotinylated fraction by 
avidin precipitation. 10l each of total 
lysate (A), non-biotinylated fraction 
(B) and biotinylated fraction (C) was 
separated by 10 % SDS-PAGE and 
analyzed with anti-EAAC1 antibody. 
Complete separation of non-
biotinylated and biotinylated fractions 
as well as equal protein loading was 
ensured by immunoblotting with anti-
actin antibody. The Densitometric 
analysis of the cytoplasmic fraction 
(D) and the biotinylated fractions (E) 
was performed using Phoretix Total 
Lab software after normalizing the 
protein content against actin. The data 
is representative of 3 independent 
experiments.  
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The most extensively studied kinase in this respect is the calcium/calmodulin dependent CaM 
kinase II [116]. It is ubiquitously expressed in the neurons, emerged as a possible target for the 
regulation of EAAC1.  
In order to analyze the role of Ca/CaM dependent CaM kinase II, KN-93, a cell permeable 
inhibitor of CaM kinase II was used. KN-93 inhibits the association of CaM with CaM kinase 
II, thereby inhibiting the CaM modulated affects on CaM kinase II. 
The trafficking of neuronal glutamate transporter EAAC1 in the presence of both PMA and cell 
permeable CAM Kinase II inhibitor KN 93 was evaluated. 
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Fig.4.22 Influence of CaM Kinase II 
inhibitor KN-93 on the cell surface 
expression of EAAC1. 
Cells were treated with vehicle alone 
(0.1%DMSO) lane 1, PMA (100nM/15 
min) lane 2 and PMA and KN-93 (co-
incubation), lanes 3, 4 and 5 before 
cell surface biotinylation. Biotinylated 
proteins were separated from the non-
biotinylated fraction by avidin 
precipitation of 100g total protein 
from each sample with 50l of 50% 
avidin bead slurry. 10l each of total 
lysate (A), non-biotinylated fraction 
(B) and biotinylated fraction (C) was 
separated by 10 % SDS-PAGE and 
analyzed with anti-EAAC1 antibody. 
Complete separation of non-
biotinylated and biotinylated fractions 
as well as equal protein loading was 
ensured by immunoblotting with anti-
actin antibody. The Densitometric 
analysis of the cytoplasmic fraction 
(D) and the biotinylated fractions (E) 
was performed using Phoretix Total 
Lab software after normalizing the 
protein content against actin. The data 
is representative of 3 independent 
experiments.  
 Biotinylated 
Fraction 
C 
B 
E 
A 
Lane Number           1    2   3   4   5    
D 
Non-Biotinylated 
Fraction 
175
84
47
62
175
84
47
62
175
84
47
62
kDaPMA
KN- 93 ( M) 0   0     1   5   20
EAAC1
Actin
EAAC1
EAAC1
EAAC1
EAAC1
EAAC1
Actin
- +    +    +   +
   4.Results 
- 63 - 
 
As shown in Fig 4.22A, the total EAAC1 protein content and the EAAC1 banding pattern was 
not influenced by the addition of KN-93.  
The decrease in surface expression upon treatment with KN-93 (1-20M) was not as 
pronounced as seen with the addition of the calmodulin inhibitor ophiobolin (compare Fig 
4.21C with Fig 4.22C). 
As shown in the experiments with HEK-EAAC1 cells treated with PMA alone (Fig.4.22C, 
lane2), compared with non-stimulated cells (Fig. 4.22C, lane 1, no PMA addition), an increased 
cell surface expression of EAAC1 was observed. When the cells were co-incubated with 
100nM PMA and increasing concentrations of CaM kinase II inhibitor KN-93, the PMA 
mediated increase in the surface expression (230% of control) decreased substantially upon 
incubation with highest concentration of KN-93.  
In presence of 1M KN-93, the surface labeled EAAC1 decreased marginally to 210% of the 
control compared to the PMA treated cells (Fig 4.22C,E, lane 3, 230% of control).In contrast, 
when the concentration of KN-93 was increased to 5 M (Fig. 4.22C, lane 4), a drastic drop in 
the surface labeled EAAC1 was observed (Fig 4.22C,E, lane 4, 140% of control)  in 
comparison to the cells treated with PMA alone (Fig 4.22C,E, lane 3, 230% of control). Further 
increase in the concentration of KN-93 up to 20 M did not cause a further decrease of EAAC1 
surface expression (Fig. 4.22C, E, lane 5). 
The increase or decrease in the immunolabeling of EAAC1 surface fraction was accompanied 
by a corresponding increase or decrease in the cytoplasmic non-biotinylated fractions of 
EAAC1 as shown in Fig.4.22B.  
This data clearly demonstrates the role of CaM kinase II involvement in the trafficking of 
EAAC1 by PMA. 
Taken together, the regulation of  EAAC1 trafficking involves the activity of PKC second 
messenger systems, DAG and  presence of intracellular calcium, calmodulin activity as well as 
the role of CaM kinase II, suggesting diverse signaling pathways involved in EAAC1 
trafficking.   
In summary, PMA acts as a trigger for the EAAC1 intracellular pools to be trafficked to the 
membrane. However the fusion of intracellular pools of EAAC1 cannot be accomplished in the 
absence of intracellular calcium, calmodulin or CaM kinase II. 
At present it seems likely that stimulation of EAAC1 trafficking to the membrane requires the 
involvement of additional downstream signaling cascades for the increased cell surface 
expression of EAAC1  
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4.19 Direct phosphorylation of EAAC1 
 
Previous investigations revealed the role of protein kinases, phosphatases as well as CaM 
kinase II mediated signaling in the rapid trafficking of EAAC1. However, no evidence of direct 
phosphorylation of EAAC1 has yet been reported. Further investigations were carried out to 
check whether EAAC1 is itself phosphorylated or the trafficking is a result of indirect 
involvement of kinases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.23 In silico analysis of putative phosphorylation sites for EAAC1  
 
A) The putative sites for serine phosphorylation (S), threonine phosphorylation (T) and 
tyrosine phosphorylation (Y) are listed below 
S6, S7, S42, S45, S87, S115, S137, S333, S404, S465, S475, S501, S508, S512, S516 
T121, T133, T164, T180, T354, T447, T498 
Y199, Y502. 
B) The arrangement of putative intracellular phosphorylation sites for EAAC1 in the topology 
model. 
According to the topology model, S6, S7, S42, S45, S87, S115, S501, S508, S512, S516, 
T121, T498 and Y 502 were predicted to be located in the intracellular domain of EAAC1 
 
A 
B 
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Fig.4.24 Evaluation of specificity of phospho antibodies 
 0.1g each of phosphotyrosine-BSA (Lane1), phosphothreonine-BSA (Lane 2) and 
phosphoserine BSA (Lane 3) were loaded on 10% SDS gel and immunoblotted with 
anti-phosphoserine(0.25 g/ml, anti-phosphothreonine (0.25 g/ml) and anti 
phospho tyrosine (0.12 g/ml) antibodies. 
Left panel: the anti-phosphoserine shows no cross-reactivity with the phospho 
tyrosine-BSA (lane 1) but a moderate cross reactivity of anti-phosphoserine 
antibodies is observed for phosphothreonine-BSA (lane 2). A clear and much 
stronger immunoreactivity is observed for phospho-serine BSA. 
Middle Panel: anti-phosphothreonine antibodies show a negligible cross-reactivity 
with phospho-tyrosine BSA (Lane 1). A very strong reactivity of anti-phospho 
threonine antibodies is observed for phosphothreonine-BSA, as both, the 
monomeric 66kDa band as well as the higher molecular weight bands of BSA can 
be observed (lane 2). Anti-phosphothreonine antibodies, however, also react with 
phosphoserine BSA (lane 3). 
Right Panel: the immunoblotting of phosphotyrosine-BSA, phosphothreonine-BSA 
and phosphoserine-BSA with anti-phosphotyrosine antibodies shows a highly 
specific reaction only with phosphotyrosine-BSA (lane 1). No cross-reactivity of the 
anti-phosphotyrosine antibodies is observed for phosphothreonine-BSA (lane 2) or 
phosphoserine-BSA (lane 3). 
IB            p-Ser                 p-Thr p-Tyr
1     2      3         1      2     3         1    2    3 kDa
175
84
62
 
In silico analysis of EAAC1 sequence predicted numerous putative sites of phosphorylation for 
serine, threonine as well as tyrosine phosphorylation as depicted in Fig.4.23A. 
The phosphorylation prediction software predicted 15 serine, 7 threonine and 2 sites for 
tyrosine phosphorylation in EAAC1 sequence. 
The arrangement of the predicted phosphorylation sites of EAAC1 in the predicted topology 
model is represented in Fig 4.23B. 
According to the topology model, 9 serine moieties, 3 threonine moieties and one tyrosine 
moiety is predicted to occur intracellularly, and therefore are more likely to be phosphorylated 
by kinases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   4.Results 
- 66 - 
 
To evaluate the phosphorylation status of the neuronal glutamate transporter EAAC1 in 
absence and presence of 100nM PMA, immunoprecipitation experiments using anti-EAAC1 
antibodies, followed by western blot analysis with anti-phosphoserine, anti phosphothreonine, 
and anti-phosphotyrosine antibodies of total cell lysates derived from HEK-EAAC1 cells.  
Prior to the EAAC1 phosphorylation experiments, the specificity of the phosphoserine, 
phosphothreonine and phosphotyrosine-antibodies were analyzed. 
As shown in Fig. 4.24 (Left panel, lane 3), the anti-phosphoserine antibody intensely labeled 
the phosphoserine coupled BSA (66kDa monomeric band and higher molecular weight 
oligomeric bands). The same anti-phosphoserine antibodies also labeled phosphothreonine-
coupled BSA (Fig.4.24, left panel, lane 2), although with less intensity. The anti-
phosphothreonine antibodies predominately reacted with the phosphothreonine-coupled BSA 
(Fig.4.24, middle panel, lane 2), however, also showed cross reactivity with phosphoserine-
BSA and phosphotyrosine-BSA (Fig.4.24, middle panel, lanes 1 and 3). Only the anti-
phosphotyrosine antibodies exhibited specific labeling (Fig.4.24, left panel, lane 1) and no 
cross-reactivity with each of the other phosphorylated BSA. 
In the following experiments, investigating the phosphorylation state of EAAC1, HEK-EAAC1 
cells cultured for 15 min in absence and presence of 100 nM PMA. Cell lysates of these cells 
were used for anti-EAAC1-Immunoprecipitation experiments (anti-EAAC1-IP) combined with 
Western blot analysis (WB) using anti-phosphoserine, anti-phosphothreonine or anti-phospho 
tyrosine antibodies. 
As shown in the Fig. 4.25, immunoprecipitation of EAAC1 with anti-EAAC1 antibodies and 
subsequent western blot analysis with anti EAAC1 antibodies revealed the typical banding 
pattern of EAAC1 with the labeling of both, the monomeric 66kDa band as well as the higher 
molecular weight oligomeric bands. 
In addition to the EAAC1 immunoreactive bands, a 50 kDa band was also observed. The 50 
kDa band was contributed by the immunoglobulin heavy chains (IgG) of the anti-EAAC1 
antibodies used for the IP experiments. 
The banding pattern of the Protogold blot, Fig.4.25A shows the original western blot membrane 
with the protein staining is identical to that of WB of immunoprecipitated EAAC1 blotted with 
anti-EAAC1 antibodies.  
Treating the cells for 15 min with PMA solvent DMSO (Fig.3.25 B lane 1) or with phosphatase 
inhibitors (Fig.4.35B, lane 2) or phosphatase inhibitors plus PMA (Fig.4.25B lane 3), the 
banding pattern was identical indicating that the immunoprecipitation of EAAC1 protein was 
successful under all conditions used in this experimental setup. 
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The immunolabeling pattern of EAAC1 immunoprecipitates with anti-phosphoserine 
(Fig.4.25C), anti-phosphothreonine (Fig.4.25 D) and anti-phosphotyrosine antibodies               
(Fig.4.25E) revealed a different labeling pattern. 
The anti phosphoserine antibody (Fig. 4.25 C) did not stain the EAAC1 protein, however, 
labeling of the IgG fraction was observed, which may be labeled by the phosphoserine 
antibodies directly or most likely by the anti rabbit secondary antibodies. 
 
 
IP-anti- EAAC1
IB   Protogold staining   anti- EAAC1      anti- p-Ser       anti- p-Thr anti- p-Tyr
A                      B                C                     D                       E
1      2      3        1     2     3         1  2    3         1     2      3        1      2      3        kDa
175
84
62
47
EAAC1
IgG
Heavy chain fraction
 
Fig.4.25  Immunoprecipitation of EAAC1 and immunoblotting with phospho specific antibodies. 
 
5x106 cells were treated with vehicle alone (DMSO) (lane 1), phosphatase inhibitor cocktail 
(10l/ml) (lane 2) and PMA 100nM/15 min+ phosphatase inhibitors (lane 3) before lysis. 
750 g of total lysates were subjected to immunoprecipitation with 20 l of dynabeads coated with 
anti-EAAC1 antibody for 1 hour at room temperature. After subsequent washing steps, the proteins 
were eluted directly in SDS buffer. 
Each lane was loaded with 10 l of eluted proteins and separated by 10% SDS-PAGE and 
immunoblotted with anti-EAAC1 antibody (B), anti-phosphoserine antibodies (C), anti-
phosphothreonine antibodies (D) and anti-phosphotyrosine antibodies (E). 
 
 
The anti- phosphothreonine antibodies WB (Fig.4.25 D) revealed a faint labeling of a 66 kDa 
band  and additional labeling of the 50 KDa band under all experimental conditions ( PMA 
solvent, lane 1, phosphatase inhibitors, lane 2 and PMA plus phosphatase inhibitors , lane 3). 
The 50 kDa band represents the staining of the heavy chain of the anti-EAAC1 antibodies, most 
likely due to the staining by the secondary anti-rabbit peroxidase coupled secondary antibodies.  
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The immunolabeled 66kDa band, which might represent the EAAC1 monomeric band, 
exhibited increased staining intensity in presence of both PMA and phosphatase inhibitors 
(Fig.4.25 D lane 3). 
However, the missing oligomeric EAAC1 immunoreactive bands for the anti-phosphothreonine 
immunostaining suggest the absence of threonine phosphorylation in EAAC1. However, our 
experiments shown here do not exclude the threonine phosphorylation, only of the monomeric 
EAAC1 transporter protein. 
In contrast to the anti-phosphothreonine antibody WB, the anti-phosphotyrosine WB revealed 
labeling of the monomeric 66 kDa bands and additionally the labeling of the high molecular 
weight oligomeric bands of EAAC1 suggesting specific labeling of phosphotyrosine residues in 
EAAC1. In absence of PMA and /or phosphatase inhibitors, the immunolabeling of EAAC1 is 
not as intense as that of HEK-EAAC1 cells treated with phosphatase inhibitors and PMA plus 
phosphatase inhibitors Fig.4.25E, lane 2 and 3 respectively. 
Highest labeling intensity was revealed in HEK-EAAC1 cells treated with both PMA and 
phosphatase inhibitors.  
Taken together, it was shown for the first time that EAAC1 is phosphorylated directly and the 
target site for the protein kinases is most likely a tyrosine residue. 
As shown in Fig.4.23, EAAC1 contains 2 putative tyrosine phosphorylation sites which are 
localized at the amino acid residues 199 and 502.  
However, according to the membrane topology model, the tyrosine residue at the amino acid 
position 199 is located in the extracellular domain of EAAC1 protein, suggesting that it may 
not be the likely residue for phosphorylation. 
The tyrosine amino acid residue 502, seems to be the most likely to be phosphorylated. These 
data suggest that phosphatase inhibitors as well as PMA modulate the tyrosine phosphorylation 
of EAAC1.  
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5 Discussion 
 
In this study, the posttranslational modifications regulating the membrane trafficking 
mechanism of a neuronal glutamate transporter EAAC1 were investigated. 
Neurotransmitter transporters are required for the rapid clearing of the glutamate at the 
synaptic clefts after the synaptic event. In this respect, since a synaptic event lasts in the 
time scale of  milliseconds, rapid protein targeting from the intracellular storage 
compartments play a significant role in the synaptic plasticity rather than new protein 
synthesis.  
The primary results of this study report regulatory cascades involving PKC, phosphatase 
inhibitors, direct phosphorylation, calmodulin, intracellular calcium and the CaM kinases 
as regulatory mechanisms which control the levels of the glutamate transporter EAAC1 at 
the cell membrane surface. 
The studies reported in this thesis were performed in a heterologous expression system, 
where the neuronal glutamate transporter EAAC1 was stably expressed in Human 
Embryonic Kidney cells (HEK-293). HEK cells exhibit epithelial morphology and were 
modified by Frank Graham in 1977 [117, 118] using adenovirus DNA to form a cell line 
used with a common notation HEK-293 and are extensively used as a model heterologous 
system to study a large number of transmembrane proteins. 
 
5.1 Need for a model system for expression and regulation of  glutamate 
transporters in vitro 
 
The brain is an extremely complex organ with a myriad of interactive networks and several 
cell types, most of which are either neuronal or glial. The brain expresses all five subtypes 
of glutamate transporters; however, their distribution in different regions is highly specific. 
The distribution of the glutamate transporters in the brain can broadly be classified as 
neuronal (EAAC1 and EAAT4) or glial (GLT and GLAST), however, this classification is 
not rigid in its definition.  
The neuronal glutamate transporter EAAC1 is primarily found in the hippocampus and 
cerebellum of the mammalian CNS. Studies by Conti et al [119] also showed EAAC1 
presence in the astrocytes in the cortex and the oligodendrocytes.  
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EAAT4 is known to be localized in neurons of the cerebellum, the purkinje cells [120] 
whereas the  glial glutamate transporter GLAST is localized in all the regions of adult 
mammalian CNS, but in different concentrations.  
GLT is described as a major glutamate transporter present in the forebrain in the glial cells. 
Besides, during the development of rodent brain, GLT has been shown to be expressed in 
several neuronal populations as well as in growing axons. 
Presence of all subtypes of glutamate transporters in vivo makes it almost impossible to 
study the regulation of a single subtype of these proteins. The challenge to best mimic the 
in vivo situation in the brain and to study individual transporters drives the need to develop 
model systems to study the expression and regulation of these transporters. 
In order to study the regulation of a single protein in vitro, it is extremely essential that the 
properties of the individual protein are exclusive and these characteristics are not, in any 
manner, influenced by other similar proteins. 
Although the primary cell culture system is closest possible representation of the in vivo 
situation, effects of artificial environment and culture conditions cannot be discounted. 
Another disadvantage of the primary cell culture system is the contamination of neurons 
with other cell types such as glial cells do allow for the study of individual transporter 
subtypes. 
There have been several studies in the past decade, reporting the regulation of glutamate 
transporter subtypes in different cell lines as well as in the primary cell cultures of neurons. 
Several groups have tried to identify the best model system for the study of glutamate 
transporters in vitro.  
The glial glutamate transporters GLT and GLAST have been extensively studied in mouse 
cortical astrocytes , fetal astrocytes, cerebellar astrocytes as well as in Xenopus oocytes  by 
Gegelashvili et al [121], Fine et al, [122], Dreier et al,[123] and Zerangue et al[124] 
respectively.  
The neuronal glutamate transporter EAAC1, however, has generally been studied in the rat 
C6 glioma cell line [71]. The neuronal glutamate transporter EAAC1 is generally not 
expressed in the glial cells in adult animals, but may occur in the glial cells during 
developmental stages. 
Although it was earlier believed that the C6 glioma cell line does not express any other 
glutamate transporter subtypes, a study by Casado et al [125] has demonstrated that the 
glial glutamate transporter GLT is expressed in the C6 glioma cell line. 
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These results were further substantiated by  Imura et al who reported the expression of 
GLT and GLAST along with EAAC1 in C6 glioma cells [126]. 
The conclusions reported from the studies mentioned above call for a careful selection of 
expression systems to study glutamate transporters in vitro as EAAC1 regulation and 
expression in C6 glioma would certainly be a subject to influence by the other subtypes of 
glial transporters. 
The heterologous model expression system used in this study was developed by Michael 
Wiessner [127]  and uses the easy expression system of Human Embryonic kidney (HEK-
293) cell line to study in individual properties of the glial or neuronal transporter subtypes 
exclusively. The stable cell lines provide better controlled system to study the regulatory 
aspects of these transporters and was therefore preferred model system for this study.  
 
5.2 Expression profile of Glutamate Transporters in vivo and in vitro. 
 
The comparison of the protein expression profile of the glutamate transporters EAAC1, 
GLAST and EAAT4 with that of the protein expression in the brain cortex and cerebellum 
indicated a similar rate of protein expression in vivo and in vitro. 
Glutamate transporters appear as proteins with a broad electrophoretic mobility, possibly 
due to heterogeneity of the N-linked glycosylations. The heterologously expressed 
EAAC1, GLAST and EAAT4, all appeared as broad bands , in concordance with previous 
reports [11]. Moreover, the expression of EAAC1 and GLAST also showed higher 
molecular weight bands. These higher molecular weight, possibly oligomeric bands have 
been reported to be dependent on the method of preparation of the samples. According to 
Danbolt [11], exposure of the  protein extract  to mild oxidants before detergent 
solubilization results in the appearance of the higher molecular weight bands. If however, a 
reducing agent such as DTT is directly added to the solubilization buffer, the higher 
molecular weight bands are not observed. 
The heterologously expressed transporters showed the similar pattern of electrophoretic 
mobility as observed in vivo. 
According to  Conti et al [119], EAAC1 protein is found in the highest amounts in the 
hippocampus and the cerebellum. Comparison of western blots from cortex and HEK-
EAAC1 cell line indicated comparable protein expression as indicated by the western 
blotting. 
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The glial glutamate transporter GLAST is known to be expressed throughout the CNS, 
most strongly in the cerebellum [128], in line with the findings of the present study.  
Lehre et al have also calculated the number of GLAST transporters in the Bergmann glia 
of cerebellum as 18000 molecules per square m of the glial plasma membrane. The 
molecular weight of GLAST in the cortex was moderately lower than that of the 
cerebellum. These findings were also concordant with the in vivo expression profile 
reported by other groups (for review, see [11]). 
Although no EAAT4 was detected by western blots of rat cortex in this study, Dehnes et al 
report that the concentration of EAAT4 in the forebrain is extremely low, but not absent 
[120].  The absence of EAAT4 detection in the cortex could possibly be accounted for by 
either the low sensitivity of the antibodies to the protein or the extremely low levels of 
protein expression, undetected by the antibodies. 
The localization studies of the heterologously expressed transporters revealed a punctuate 
membrane localization for EAAC1 in HEK-293 cells. Moreover, large intracellular pools 
of EAAC1 were also observed. The localization of EAAC1 showed a similar pattern as 
observed for the C6 glioma cell line (endogenously expressing EAAC1) and is concordant 
with the findings of Davis et al [70] and He et al [129]. 
Immunocytochemical localization of GLAST also showed an intense membrane labeling. 
EAAT4, transiently expressed in HEK-293 cells showed a moderately strong membrane 
labeling accompanied with a uniform punctae in the cytoplasm. Dehnes et al[120] have 
shown that EAAT4 is primarily localized in the plasma membranes of the cerebellar 
purkinje cells. However, they also report labeling of vesicular structures in the cytoplasmic 
region.  
The functional characterization of the heterologous expression system used in this study 
was performed by measuring high affinity glutamate uptake in the membrane vesicle 
fractions prepared from the stably transfected cells. 
This method offers another advantage that the radiolabelled glutamate used for uptakes 
cannot be further modified by enzymes such as glutamate dehydrogenase and the artificial 
gradient established by this method is sufficient to drive glutamate uptakes for short time 
spans of up to 30 min, which is long enough time to reach saturation levels for glutamate 
uptake. 
Sodium independent studies showed no glutamate uptake in the absence of sodium in the 
transport solution, indicating the functionality of the heterologously expressed EAAC1 was 
the same as the native EAAC1. 
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In general, the affinity of glutamate transporters for glutamate, represented by the 
Michaelis Menten constant Km is dependent on the method of preparation used for the 
assays. The apparent affinities for the dorsal root ganglia have been reported as 20 M by 
Roberts and Watkins [130]. Westphalen et al  [131] have reported the Km for glutamate 
uptake in synaptosomes to be 14 M for the cortical nerve terminals. Robinson [132] has 
reported the Km values for the brain synaptosomes between 1-5 M. 
In the C6 glioma cell line expressing EAAC1, Dowd and Robinson [133] have reported a 
Km value of 13 M. The heterologous expression system used in this study shows a similar 
range of Km (2-7 M) for the glutamate transporters. 
The kinetics of glutamate transporters establish the functionality of the glutamate 
transporters expressed in the heterologous expression. 
Together, the western blot analysis, immunocytochemistry and the high affinity glutamate 
uptake data for the neuronal glutamate transporter EAAC1, the glial glutamate transporter 
GLAST and the neuronal glutamate transporter EAAT4 (with chloride conducting 
properties) suggest that the heterologous expression system is a promising tool to study the 
regulation and expression of individual transporter subtypes. 
Followed by the characterization of the heterologous expression system, it was decided to 
carry out further studies on the regulatory mechanisms governing the neuronal glutamate 
transporter EAAC1.  
 
5.3 Regulation of EAAC1 
 
EAAC1 is a 523 amino acid (aa) protein, first cloned by Kanai and Hediger in 1992 [99]. 
EAAC1 is co-translationally glycosylated and the in silico glycosylation prediction 
software predicts 3 asparagine residues which could be glycosylated. These sugar residues 
possibly account for the broad electrophoretic mobility of the EAAC1 protein. In general, 
N-linked glycosylations are constitutive signals for the protein trafficking to the plasma 
membrane after synthesis 
In the case of Glutamate transporters, Trotti et al [134] reported a decreased uptake 
capacity as well as reduced trafficking in a naturally occurring GLT mutant where the N-
glycosylated asparagine is mutated to serine.  
However, contrary to the above report, no function of glycosylation has yet been found for 
the glial glutamate transporter GLAST [135]. Nevertheless, studies on the relevant 
function of glycosylation of the EAAC1 protein still remain to be investigated. 
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Molecular weight calculation of EAAC1 from the amino acid sequence reveals a molecular 
weight of 57.6 kDa. However, EAAC1 is always observed as a protein with a broad 
electrophoretic mobility and a relative molecular weight centered at 66 kDa. This indicates 
that the glycosylation of EAAC1 adds approximately 10 kDa to the relative molecular 
weight of the protein.  
Deglycosylation of EAAC1 caused an increased electrophoretic mobility of EAAC1, 
possibly due to the loss of the sticky sugar residues and a band with the apparent molecular 
weight of 56 kDa, consistent with the molecular weight calculated on the basis of the 
amino acid sequence.  
Both, in vivo and in vitro deglycosylation procedures yielded the same molecular weight 
deglycosylated protein with a relative molecular weight of 56kDa. 
The deglycosylation of EAAC1, in vivo, also allowed for the calculation of the rates of 
biosynthesis and degradation of EAAC1. 
Examining the rates of biosynthesis and degradation of EAAC1 revealed a half life of 
biosynthesis as 22hrs. Yang and Kilberg [136], in their studies employing the C6 glioma 
cell line as a model system reported that the total pool of EAAC1 protein has a half life of 
approximately 12 hrs. This difference in the calculation of half life of the transporter may 
result from the different expression systems used for the study. Yang and Kilberg also 
suggest that the newly synthesized EAAC1 has the same degradation kinetics as the mature 
glycosylated EAAC1 [136].  
This supports the finding in this study that the total EAAC1, in the steady state remains 
constant and the rate of biosynthesis of the new protein is the same as the rate of 
degradation of the mature protein.  
EAAC1 is found in several neuronal subtypes and a large part of EAAC1 appears to be 
localized in the cytoplasmic structures in contrast to the clear membrane labeling of the 
glial transporters GLAST and GLT. A study by He et al [129] suggests that EAAC1 is 
primarily localized in the peri-synaptic membrane and not the synaptic membrane. 
Localization studies on the EAAC1 transporter protein performed by cell surface 
biotinylation assay revealed that most of the transporter protein is localized intracellularly.  
These biochemical observations were also confirmed by immunocytochemistry. These 
findings are consistent with those reported by Conti et al [119], Kugler and Smidt [137], 
Rothstein et al [138] and Shashidharan et al [139], where they report a predominant 
cytoplasmic staining of EAAC1 in the neurons.  
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One can argue that the transporters, for function should ideally be localized at the 
membrane for rapid quenching of the glutamate after the action potential. However, 
intracellular localization of transporter pools, provide a readily available pool of 
transporter, which can be rapidly mobilized whenever and as the need arises. 
As the transport process mediated by these transporters is electrogenic in nature [1], 
presence of all the transporter molecules at the plasma membrane may grossly disturb the 
electrochemical gradient of a living cell. Hence, the large intracellular storage elements 
may as well be a mechanism to avoid the detrimental effects of these transporters on the 
fragile electrochemical balance of the cell. 
Since large pools of EAAC1 were observed intracellularly, to confirm the localization of 
EAAC1 intracellularly, co-localization was performed to check if the intracellular EAAC1 
was localized with the Golgi apparatus. 
The presence of EAAC1 in Golgi apparatus was performed in order to check if the 
intracellular EAAC1 was the newly transcribed protein passing through the Golgi or if 
EAAC1 was localized in specialized storage organelles.  
However, the result of the co-localization studies revealed that the intracellular pools were 
only partially localized with the Golgi apparatus. The lack of information about the 
characterization of the intracellular pools of EAAC1 drives the comparison with other 
receptors, which show similar localization characteristics. 
Chieregatti et al  [140] suggest that Amino-3-hydroxy-5-Methyl-4-isoxazole Propionic 
Acid (AMPA) receptors, which are localized in the cytoplasmic vesicles fuse with the 
plasma membrane upon membrane depolarization. These cytoplasmic vesicles, in case of 
glutamate receptors have been suggested to be of the endosomal origin [141, 142].  
The data from AMPA receptors as well as other neurotransmitter transporters i.e. serotonin 
transporters (SERT) and dopamine transporters (DAT1) suggests the presence of similar 
intracellular pools of EAAC1, possibly of endosomal origin which are readily available for 
fusion with the plasma membrane upon stimulus. 
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5.3.1 Trafficking of EAAC1  
 
There have been ample investigations on the glial glutamate transporters but the 
information on the regulation of the neuronal glutamate transporter is still obscure.  
It has been more recently that there have been reports of regulation of EAAC1 by growth 
factors and protein kinase C (PKC) [70] and most of the investigations on EAAC1 
regulation have been performed in the C6 glioma cell line. 
Being a neuronal glutamate transporter, EAAC1 can have a strong impact on the re-uptake 
of glutamate in the synaptic cleft and hence on the efficacy of neurotransmission. 
A recent study by Otis et al [74] , shows the enhancement of long term depression upon 
inhibition of glutamate transporters, suggesting that post-synaptic glutamate can influence 
the strength of the strength of the signal transmitted at the synapse or in other words, is a 
modulator of synaptic plasticity. 
Glutamate transporters are known to shape receptor responses by two different 
mechanisms: binding and active uptake. Binding of glutamate to transporters contributes to 
a fast removal of glutamate from the synaptic cleft. This mechanism requires the presence 
of high density of transporter molecules surrounding the synaptic cleft, which modulate the 
glutamate concentration in order to buffer the activity of glutamate receptors.  
Although active transport is considered to be a slow process in comparison to the rapid 
kinetics of ion channels, it is fast enough , with a turnover time of 100ms to shape the 
activation of other glutamate receptors [143-145] 
This new data emphasizes the need to study the regulatory aspects of the neuronal 
glutamate transporter EAAC1 and therefore, in this study, the mechanisms regulating the 
expression of EAAC1 at the membrane were investigated. 
 
5.3.2 Cell surface expression of EAAC1 
 
Trafficking, in general, is defined as the regulated movement of proteins from their site of 
synthesis (ER and Golgi) to the destination in the form of vesicles, and furthermore, into 
specialized organelles for temporary storage or degradation. 
Neurotransmitter transporters generally exhibit a cellular distribution consistent with their 
function. Na+- dependent transporters involved in transmitter re-uptake usually reside at 
the plasma membrane. However, the trafficking pathways and mechanisms responsible for 
the steady-state localization of these proteins remain largely unknown.  
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In addition, the members of the transporter family vary in their sub-cellular location, and 
these differences presumably contribute to synaptic transmission [106]. The observed 
differences in sub-cellular location also suggest potential mechanisms for the regulation of 
neurotransmitter transport.  
In the Na+/Cl-–dependent family of plasma membrane transporters, the GABA transporter 
GAT-1 resides specifically in axonal rather than somatodendritic membranes, consistent 
with a role in the clearance and recycling of synaptic GABA.  
The PKC family of kinases has long been associated with the regulation of GABA, 
serotonin, nor epinephrine, dopamine as well as glutamate transporters [106]. 
PKC has different effects on different types of neurotransmitter transporters. Activation of 
PKC has been shown to decrease dopamine transporter (DAT) activity and increase the 
extent of DAT phosphorylation [71, 83]. Qian et al [146] have demonstrated that PKC 
causes a rapid decrease (within 30 min.) of the serotonin transporter (SERT) expressed in 
human embryonic kidney cells (HEK-293) activity, attributed to a decreased Vmax. A 
similar regulation by PKC has also been reported for GABA transporter GAT1. PKC 
activation causes a decreased GAT1 cell surface expression.  
For the glutamate transporters, the effects of PKC have varied depending upon the cell 
system used for investigation.  
The neuronal glutamate transporter EAAC1 has been shown to be shuttling between the 
intracellular organelles and the plasma membrane in response to activation by PKC [70]. 
Trotti et al [147] report a significant decrease in EAAC1 activity upon stimulation of PKC 
by phorbol esters in cells  transfected with EAAC1 in Xenopus oocytes. A similar decrease 
was also observed by the same group in MDCK cell line stably transfected with EAAC1.  
The endogenously expressed EAAC1 in C6 glioma cells, however, has been shown to 
increase the glutamate uptake as well as surface expression in response to PKC activation 
by phorbol esters [133].  
The contradictory reports on the effect of phorbol esters on EAAC1 expressed in different 
systems, it was decided to check the effects of phorbol esters on EAAC1 in the 
heterologous expression system used in this study. 
The investigations of phorbol esters on the uptakes of glutamate led to a conclusion that 
the activation mediated by phorbol esters, does not, in any way cause a change in the 
affinity of the transporters for glutamate, but only increases the Vmax. This further indicates 
that the increased uptake do not result from the change in turnover rate of the transporter, 
but due to the increase in the total amounts of EAAC1 at the surface. 
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These findings are in agreement with the findings of Dowd and Robinson [133] where they 
report a similar effect in the C6 glioma cell line. 
In conclusion, the heterologous expression system behaves in a similar manner as the 
endogenously expressed EAAC1 in the C6 glioma cells. 
 
5.3.3 Effects observed with 4-PDD  
 
4-12,13 phorbol-didecanoate (4-PDD) is widely claimed to be a physiologically inactive 
phorbol ester and widely used as a negative control for experiments involving stimulation 
with phorbol esters [148] . In this study however, it was observed that 4- PDD also 
caused an increase in the glutamate uptakes for EAAC1, but to a much lesser extent than 
PMA. The increase in the uptakes caused by 4-PDD was significantly higher than the 
non-stimulated cells. 
A recent report by Watanabe et al [108] suggests that the phorbol ester 4-PDD, thought to 
be biologically inactive, is a potent activator of the TRPV4 channels which cause the 
influx of calcium into the cells. The increased uptakes in the HEK-EAAC1 cells treated 
with 4-PDD may be an indirect effect, possibly because of the influx of calcium.  
 
5.3.4 Endocytosis and recycling of EAAC1 
 
The rationale that EAAC1 could be trafficked to the surface led to the hypothesis that the 
levels of transporter at the surface must recede back to basal levels once the stimulating 
agent is removed. 
Considering compelling data on other transporters especially the glucose transporter 
GLUT4 [66] and receptors such as AMPA [149], all have been shown to be endocytosed 
post-stimulation.  
The experiments demonstrated for the first time that indeed, EAAC1 was endocytosed 
after PMA was removed from the surrounding medium.  
These results substantiate the fact that glutamate uptake was decreased after an initial 15 
min. period of stimulation mediated by PMA. 
The time scale of observed endocytosis was extremely short. Approximately 40 % of total 
transporter at the surface was endocytosed within a time frame of 10 min, revealing 
extremely fast turnover rates of EAAC1. 
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Fournier et al [150] have demonstrated rapid endocytosis for EAAC1 followed by 
treatment with PMA within a time span of 5-7 min. in C6 glioma cells. However they also 
report a turnover rate of EAAC1 basal levels, without any stimulation. 
This indicates that EAAC1 is constitutively trafficked between the membrane and the 
cytoplasmic organelles. Furthermore, analysis of total amounts of EAAC1 after stimulation 
did not indicate any degradation of the transporter protein. 
 
The observed endocytosis of EAAC1 prompted the question whether EAAC1 endocytosed 
can be stimulated again to the surface, or it follows only a single cycle to the plasma 
membrane. 
Recycling of receptor proteins, ion channels as well as neurotransmitter transporters is well 
documented it is known that the transferrin receptor can recycle several times before it 
undergoes degradation [151]. There have been differences in the behavior of the members 
of neurotransmitter transporter family. Daniels and Amara [152] have demonstrated the 
internalization and recycling or degradation of dopamine transporter DAT after stimulation 
with phorbol esters whereas a recent study by Deken et al [88] has demonstrated rapid 
recycling of GABA transporters (50% transporter recycling within 10 min).  
It was therefore decided to find evidence for a further possibility of EAAC1 recycling at 
the membrane, on stimulation with PMA again. 
Recycling kinetics revealed that the almost 80% of the internalized protein is recycled back 
to the surface after 30 min. the recycling kinetics of EAAC1 is found to be comparable 
with that of GABA transporters reported by Deken et al [88]. However, unlike the 
observations of Daniels and Amara [152] regarding the degradation of dopamine 
transporter upon stimulation, no degradation of EAAC1 was observed in this study.. 
 
Having observed the PMA related increased EAAC1 trafficking to the surface, it was 
decided to evaluate the influence of substrate on the surface expression of EAAC1. 
The use of serum supplemented medium did not show any increase in the levels of the 
transporter at the surface, as detected by cell surface biotinylation. No changes in the 
surface expression of EAAC1 in the serum supplemented medium may be due to the effect 
of serum proteins, which may, in some way maintain the homeostasis of the system. 
Serum contains approximately 3.5mM glutamate [105], which is extremely high, if the 
effects of external glutamate are to be observed.  
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It is possible that the extracellular glutamate added in the serum containing medium was 
far below the levels already existent in the medium. 
Therefore, same experiment was carried out in serum free medium.  
First the increase, followed by a radical decrease in the surface expression of EAAC1 upon 
exposure to extracellular glutamate (1-100M)  could be explained either due to the  rapid 
internalization of the transporter after stimulation to the surface or due to an intrinsic 
homeostatic mechanism, which causes no further response to the increased extracellular 
substrate concentrations. 
 
The behavior observed for EAAC1 is analogous to that observed by Bernstein and Quick 
[89] where they observe the regulation of GABA transporter GAT1 by extracellular 
GABA, in serum free media. Serotonin transporter has also been shown to respond to the 
extracellular agonist concentrations. Ramamoorthy and Blakely [153] suggest that the 
serotonin transporter substrates effect both, the phosphorylation state as well as the surface 
distribution of the serotonin transporter (SERT). 
Since the time scale of the experiment was very short (15 min.), the increased surface 
expression of EAAC1 cannot be accounted for by synthesis of new protein and therefore, 
has to be due to increased mobilization of fully glycosylated, matureEAAC1 from the pre-
existing intracellular pools of cytoplasmic origin. 
It thereby strongly supports the hypothesis that there exists a feedback mechanism in 
which, the transporter molecules extracellular neurotransmitter concentrations as a signal 
for the dynamic control of the neurotransmitter levels at the synapse. 
 
5.3.5 Influence of phosphatase inhibitors on trafficking of EAAC1 
 
The rationale for the use of phosphatase inhibitors in the experiments carried in the 
presence of PMA was to inhibit the activity of phosphatases which could possibly 
dephosphorylate the proteins phosphorylated by the activation of PKC upon administration 
of phorbol esters. However, it was observed in the surface biotinylation experiments that 
the phosphatase inhibitors alone could cause an increase in the cell surface labeling of 
EAAC1. 
This is the first documented evidence of the role of phosphatase inhibitors in the regulation 
of EAAC1.  
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The fact that the use of phosphatase inhibitors alone never increased the surface expression 
of EAAC1 to the extent observed with PMA alone or with PMA and phosphatase 
inhibitors in conjugation indicates the converging cascades and a combined roles of 
phosphatases and kinases involved in the regulatory mechanism of EAAC1. 
Since these phosphatase inhibitors employed for the study specifically targeted the 
tyrosine, acid and alkaline phosphatases, the role of tyrosine phosphorylation could be 
speculated as being the cause for the increased surface expression of EAAC1. 
 
5.3.6 Influence of staurosporine and cell permeable calcium chelator on 
trafficking of EAAC1 
 
Considering the fact the phorbol esters primarily activate protein kinases, in order to 
classify the kinase involved, calcium dependency of kinase was evaluated by introduction 
of a cell permeable calcium chelator, BAPTA-AM. 
Addition of BAPTA-AM alone drastically reduced the surface expression of EAAC1. This 
result confirmed the role of calcium availability as a requirement for regulated trafficking 
of EAAC1, upon stimulation by phorbol esters. 
To classify further, if calcium was required only for the maintenance of basal levels of 
EAAC1, or was exclusively required for the functioning of a conventional kinase, 
BAPTA-AM was added in conjugation with PMA.  
Here also, a huge drop in the surface expression of EAAC1 was observed. This data further 
indicated two mechanisms, one possibly maintaining basal EAAC1 levels, regulating 
fusion of intracellular EAAC1 with the plasma membrane, and another mechanism, 
possibly dependent on cPKC, which required calcium for its in order to rapidly  traffic 
EAAC1 upon stimulation. 
Staurosporine, a general protein kinase C inhibitor, inhibits the action of kinases by 
binding to the ATP binding site of the kinase [154]. The addition of staurosporine to the 
HEK-EAAC1 cells decreased the surface expression of EAAC1in non-stimulated cells. To 
further confirm one of the above possibilities of the role of calcium, staurosporine was 
used along with BAPTA-AM. In this case, a drastic decrease in the levels of biotinylated 
EAAC1 confirmed that calcium is required for maintenance of basal EAAC1 at surface as 
well as rapid trafficking by PKC. 
Since a large number of exocytic processes require calcium as a prerequisite, it is plausible 
that calcium plays an important role in the trafficking of EAAC1. 
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Calcium triggered exocytosis regulates the fusion of vesicles containing neurotransmitter 
as well as hormones upon stimuli [155]. Apart from these mechanisms, calcium mediated 
regulation of synaptic plasticity has also been reported in the case of AMPA receptors.  
Maher et al [156] examined the effects of intracellular calcium in the modulation of 
synaptic transmission as well as synaptogamin-SNARE dependent exocytosis of AMPA 
receptors. Their findings indicate that calcium is required for the rapid trafficking of 
AMPA receptors.  
The inhibitory effect of BAPTA-AM, even in the presence of general PKC inhibitor 
staurosporine suggests a confirmed the involvement of intracellular calcium in EAAC1 
trafficking from the cytoplasmic storage elements to the plasma membrane.  
The calcium dependency of EAAC1 trafficking was further confirmed by the concentration 
dependent decrease of the cell surface biotinylated EAAC1 upon addition of increasing 
concentration of BAPTA-AM when co-incubated with PMA. 
It is well documented that elevated calcium levels are required for regulated exocytosis.  
This can occur either by calcium entry through the plasma membrane or by mobilization of 
internal calcium stores or both [157]. BAPTA-AM is known to inhibit several intracellular 
fusion events. It has also been reported that the rate of calcium binding to BAPTA-AM is 
similar to that of calmodulin, which is one of the important components of the vesicular 
fusion machinery in the cells [158]. 
Hence BAPTA-AM can compete with calmodulin for the initial binding of calcium. 
Depletion of luminal calcium has been shown to inhibit  fusion of endosomes [159], 
endosome-lysosome fusion [160] and intra-Golgi transport [161], leading to an idea that 
fusion requires local release of luminal calcium during the process of membrane fusion.  
Regulation of EAAC1 by calcium, would possibly involve one or more of the above 
mechanisms, which explain the role of calcium in regulated trafficking of EAAC1.   
 
5.3.7 Influence of kinase inhibitors on PMA mediated increase of EAAC1 
surface expression. 
 
Use of various kinase inhibitors facilitates the identification of kinases involved in the 
signal transduction pathways. 
The choice of kinase inhibitors employed for the study distinguished general kinase 
inhibitors from the highly specific inhibitors for PKC subtypes.  
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In addition, since the effect of calcium was already observed, the protein kinase C subtype 
involved had to be a conventional kinase.  
The effect of staurosporine, a broad specificity kinase inhibitor; rottlerin, earlier claimed to 
be a highly specific kinase inhibitor for PKC but now found to have a broader specificity; 
BIS1, a highly potent inhibitor of PKC and BISII, a general inhibitor of conventional 
PKC’s were examined in the present study.  
In this study, both broad specificity inhibitors, staurosporine as well as rottlerin were not 
able to inhibit the effect of PMA related increased trafficking of EAAC1 to the plasma 
membrane. Although both staurosporine as well as rottlerin decreased the basal levels of 
EAAC1 when added alone, the co-incubation with PMA showed a similar (250%) increase 
in the surface labeling of EAAC1. 
The effect of decreased basal levels of EAAC1 upon addition of staurosporine as well as 
rottlerin can possibly be explained by inability of these inhibitors to counter the PMA 
mediated increase upon excessive stimulation. 
Staurosporine is also known to inhibit the activity of PKA as well as PKB. Whether the 
effect mediated by staurosporine is due to the influence on these enzymes, still needs to be 
investigated. 
Davies et al [110] report  Bis-indoylmaleimideII as a highly selective inhibitor of PKC 
alpha
 
 (it inhibits 96% of PKC activity). In this study, BIS I caused no decrease in the 
basal levels of EAAC1 at the surface when added alone, and completely prevented the 
PMA mediated increase of EAAC1 when co-incubated with PMA. A similar effect was 
also observed for BISII. These results strongly indicate the role of PKC in the PMA 
mediated trafficking of EAAC1. studies of Gonzalez et al [162], using C6 glioma as a 
model system have demonstrated indirectly, that PKC may be involved in the increased 
surface EAAC1 upon PMA mediated PKC activation. However, they also suggest the role 
of PKC  in a PMA independent regulation of EAAC1; possibly by increasing the catalytic 
efficiency of EAAC1, although, there is no direct evidence of such a mechanism. 
 
5.3.8 Influence of calmodulin on cell surface expression of EAAC1 
 
Over the past few years a large amount of information has been obtained concerning the 
trafficking of AMPARs, from their synthesis and dendritic trafficking to their membrane 
insertion and removal [141, 163]. In most cases of rapid receptor trafficking, a large 
number of kinases have been shown to be involved. 
   5.Discussion 
- 84 - 
 
The use of BAPTA-AM, an intracellular calcium chelator asserted the role of calcium in 
the trafficking mechanism.  
Since there are a large number of proteins regulated by calcium, and calmodulin, being one 
of the predominant calcium modulatory proteins, the role of calmodulin in EAAC1 
trafficking was evaluated. 
As suggested earlier (see section 5.3.6), BAPTA-AM can affect the binding of calcium to 
calmodulin. To investigate if calmodulin was an interacting partner in the calcium 
mediated regulation, the effect of calmodulin antagonists on EAAC1 regulation was 
evaluated. 
Ophiobolin, an irreversible inhibitor of calmodulin, shows its inhibitory effect by reacting 
with the lysine residues of calmodulin [115, 164]. The effect of ophiobolin on the activity 
of calmodulin is attributed to covalent binding further effects binding of calmodulin to 
other target proteins. 
In the present study, incubation of HEK-EAAC1 cells with ophiobolin completely 
abolished the expression of EAAC1 at the surface.  
When the cells were co-incubated with increasing concentrations of ophiobolin, it led to 
the reversal of the PMA effect and a decrease in the cell surface expression of EAAC1 was 
observed. More surprisingly, EAAC1 was completely absent in the biotinylated membrane 
fractions when higher concentrations of ophiobolin were used. 
Comparing these results with those obtained after addition of BAPTA-AM, BAPTA-AM 
never caused a complete absence of EAAC1 at the cell surface, as seen with ophiobolin. 
These results suggest that the interaction between calcium and calmodulin is an extremely 
important step in the trafficking of EAAC1 to the surface.  
The concentrations of ophiobolin required for the inhibitory action on calmodulin is 
suggested as 10 M by Peters et al [165], are similar to those used in this study.  
There have been several reports of the role of calmodulin in phagocytosis, receptor 
recycling and transcytosis [166]. There is also a consensus regarding the general 
trafficking machinery in the cells, which is considered to be similar to the mechanism of 
the release of neurotransmitters. The work in this thesis, demonstrates, for the first time, 
the effect of calmodulin on the trafficking of EAAC1. 
Calmodulin may directly effect the trafficking of EAAC1 or the effect observed on the 
trafficking of EAAC1 could be indirect, affecting one or more members of the proteins 
involved in the vesicular fusion mechanism. 
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5.3.9 Regulation of surface expression of EAAC1 by Ca2+/CaM dependent 
kinase (CaM kinase II)  
 
Calcium calmodulin dependent CaM kinase II has diverse roles in all cell types. However, 
CaMKII is present in the forebrain and hippocampus at the highest concentration of 
approximately 1% of the total protein[167]. Local changes in calcium concentration drive 
calmodulin binding and CaM kinase II activation. CaM Kinase II drives the synaptic 
insertion of new receptor subunits and phosphorylates the receptor subunits in order to 
directly enhance channel conductance [116]. 
Having observed the effect of both, calcium as well as calmodulin indicated the possible 
role of kinases involving the two in regulated protein mobilization for EAAC1.  
The use of KN-93, which is a highly potent CaM kinase II inhibitor (completely inhibits 
CaM kinase II activity [110]), revealed that KN-93 could only inhibit only the effect of 
PMA mediated increase in the surface expression of EAAC1.  
There was no change in the basal levels of EAAC1, even upon usage of 20 M inhibitor, 
which is twice as much required for the inhibition of CaM kinase II.  
This data suggests that CaM kinase II is required along with PKC for the rapid trafficking 
mechanism of EAAC1 and is a downstream effector in the PMA mediated trafficking of 
EAAC1. 
CaM kinase II is also regulated by a number of phosphatases. It may be exposed to 
different levels of phosphatase activity, and possibly distinct phosphatases in discrete sub- 
cellular locations. 
The regulation of EAAC1 seems to occur at two different levels. One pathway, involving 
calmodulin, CaM kinase II as well as PKC seems to be essential in the rapid trafficking of 
EAAC1 and on the other hand, calmodulin and calcium seem to be required for the 
maintenance of the basal levels of EAAC1 at the membrane. 
 
5.4  Direct phosphorylation of EAAC1 
 
It was observed during the course of this work that EAAC1 is affected by protein kinase 
activators, inhibitors, CaM kinase II as well as phosphatase inhibitors. All these 
observations lead to a speculation that a number of different pathways are involved in the 
extremely complex rapid regulation and trafficking of EAAC1. 
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The study on direct phosphorylation of EAAC1 was prompted due to all the kinase 
mediated effects. 
It was evident from the immunoprecipitations, followed by immunoblotting with phospho 
specific antibodies, that EAAC1 could be phosphorylated at tyrosine residues upon 
stimulation by PMA or by phosphatase inhibitor addition. 
The role of tyrosine phosphorylation in regulating EAAC1 transporter function has yet to 
be elucidated, although there is reasonable evidence to suggest that this form of regulation 
of the transporter might occur: 
(i) protein phosphorylation of tyrosine residues acutely regulates neurotransmitter 
receptors [168] and ion channels  
(ii) the primary amino acid sequence of the rat brain neuronal glutamate transporter 
EAAC1 contains two putative tyrosine phosphorylation sites, one of which lies in 
the C-terminal intracellular domain  and 
(iii) pharmacological manipulation of tyrosine kinases acutely regulates other 
neurotransmitter transporters such as serotonin and dopamine transporters [169, 
170], although the mechanism underlying the modulation is not known.  
 
 
In this study, no influence was observed on the serine and threonine phosphorylation 
status. This study however, cannot assert that there is no serine or threonine 
phosphorylation on EAAC1, as the signal obtained for serine/threonine phosphorylation 
was very weak.  
Quick et al [171] have recently reported that GABA transporter GAT1 is phosphorylated 
by PKC at a serine residue but this phosphorylation status can be revealed only if the 
tyrosine phosphorylation of GAT1 is completely eliminated or is greatly reduced, 
suggesting that tyrosine phosphorylation on the GABA transporter, somehow influences 
the detection of the status of serine phosphorylation on GAT1. They also suggest the roles 
of differential phosphorylation on the localization of GAT1.  
Apart from the neurotransmitter transporters, the tyrosine phosphorylation mediated 
regulation has also been investigated in the regulation of AMPA receptors, involving Src 
family tyrosine kinases. A recent report by Hayashi et al [172] explores the involvement of 
tyrosine phosphorylation of the C terminus domain of AMPA receptors in their 
localization and trafficking. They report that the tyrosine phosphorylation of GluR2 
regulates its trafficking to the cell surface and helps to maintain the surface expression. 
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Considering these facts, it may not be surprising that the glutamate transporter EAAC1, is 
also, possibly regulated by a similar cryptic mechanism. 
It could also be possible that PKC stimulation involves other downstream interacting 
partners, possibly activation of other tyrosine kinases, which regulate the trafficking of 
EAAC1. The mechanisms involving the change in status of the phosphorylation states of 
serine, threonine and tyrosine residues therefore needs further investigations.  
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6 Conclusion 
 
In summary, this work describes multiple regulatory pathways involved in the rapid 
trafficking mechanisms of the neuronal glutamate transporter EAAC1 expressed 
heterologously in HEK-293 cells. Main focus of this investigation was the regulation of 
this important intracellular shuttle process in response to phorbol esters and more 
importantly, the increased cell surface expression of EAAC1 in response to the substrate 
(glutamate) as well as phosphatase inhibitors Characterization of the involved signaling 
pathway revealed the dynamics between phosphatases, intracellular calcium concentration, 
calmodulin and the activation of CaM kinase II. 
In detail, the role of activation of CaM kinase II in presence of calcium as well as 
calmodulin, in conjunction with the PKC pathway in the increased levels of surface 
expression of EAAC1 has been shown. It was also made evident that the CaM Kinase 
pathway is localized downstream of the PKC pathway, as indicated by the investigations 
involving co-incubation of PMA with various inhibitors of the Ca2+/calmodulin dependent 
CaM Kinase pathway. 
Moreover, the direct phosphorylation of EAAC1 at a tyrosine residue was confirmed by 
the immunoprecipitation experiments. Analysis of the putative tyrosine phosphorylation 
sites points towards two tyrosine residues at the amino acid positions 199 and 502. The 
topology model of the transporters predicts the tyrosine phosphorylation site 199 in the 
transmembrane domain, and therefore unlikely to be phosphorylated. Therefore, the most 
likely target of tyrosine phosphorylation in response to PMA stimulation is the tyrosine 
residue 502. This residue is a part of the C-terminal intracellular domain of EAAC1, which 
has been shown in other transporter subtypes to be responsible for the trafficking 
mechanism. However, further confirmation of importance of this tyrosine residue in the 
regulation of EAAC1 trafficking needs future investigations.  
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SCHEMATIC REPRESENTATION OF EAAC1 REGULATION 
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7 Materials and Methods 
 
7.1 Materials 
 
 
Acetic acid      Merck (Darmstadt, Germany) 
Acrylamide / bis-acrylamide (37.5/1)  Sigma-Aldrich (Deisenhofen, Germany) 
Agar      Sigma-Aldrich (Deisenhofen, Germany) 
Agarose      ROTH (Karlsruhe, Germany) 
Ampicillin      Sigma-Aldrich (Deisenhofen, Germany) 
APS       Sigma-Aldrich (Deisenhofen, Germany) 
BAPTA-AM     Sigma-Aldrich (Deisenhofen, Germany) 
BCA       Sigma-Aldrich (Deisenhofen, Germany) 
BD™ phospho protein enrichment kit BD Biosciences (Palo Alto, CA, USA) 
BIS I      Merck (Darmstadt, Germany) 
BIS II      Merck (Darmstadt, Germany) 
Bradford reagent     Sigma-Aldrich (Deisenhofen, Germany) 
Bromophenol blue     ICN Biochemicals (Eschwege, Germany) 
BCA       Sigma-Aldrich (Deisenhofen, Germany)  
BSA       Sigma-Aldrich (Deisenhofen, Germany) 
CaCl2       Merck (Darmstadt, Germany) 
Calf serum      PAA (Pasching, Austria) 
CuSO4  4%      Sigma-Aldrich (Deisenhofen, Germany) 
Cycloheximide     Sigma-Aldrich (Deisenhofen, Germany) 
DMEM      Biochrom(Berlin, Germany) 
D-Manntol      Sigma-Aldrich (Deisenhofen, Germany) 
DMSO      Sigma-Aldrich (Deisenhofen, Germany) 
Dynabeads® M-280 Tosyl activated   Dynal Biotech (Oslo, Norway) 
ECL Kit™      Amersham Biotech (Uppsala, Sweden) 
EDTA      Merck (Darmstadt, Germany) 
Ethanol      Merck (Darmstadt, Germany) 
EZ-link sulfo-NHS-SS-Biotin   Pierce (Rockford USA) 
FCS       PAA (Pasching, Austria) 
Filtersafe Scintillation cocktail   Zinsser analytic (Frankfurt, Germany) 
Formaldehyde (37%)     Merck (Darmstadt, Germany) 
Glucose      Sigma-Aldrich (Deisenhofen, Germany) 
3H1 Glutamic acid     Amersham biosciences (Buckinghamshire, 
     England) 
KN-93      Alexis chemicals (San Diego, USA) 
Leupeptin      Sigma-Aldrich (Deisenhofen, Germany) 
LipofectamineTM 2000    Invitrogen (Karlsruhe, Germany) 
L-glutamine      Seromed (Berlin, Germany) 
L-Glutathione (reduced)    Sigma-Aldrich (Deisenhofen, Germany) 
Glycerol      Merck (Darmstadt, Germany) 
Glycine      Sigma-Aldrich (Deisenhofen, Germany) 
Goat anti-mouse IgG (Alexa Fluor 546) Mobitech (Göttingen, Germany) 
 
Goat anti-rabbit IgG (Alexa Fluor 488)  Mobitech (Göttingen, Germany) 
HCl       Sigma-Aldrich (Deisenhofen, Germany) 
Hyperfilm ECL     Amersham Biotech (Uppsala, Sweden) 
Isopropyl alcohol     Merck (Darmstadt, Germany) 
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Kanamycin      Sigma-Aldrich (Deisenhofen, Germany) 
KCl       Merck (Darmstadt, Germany) 
KH2PO4      Merck (Darmstadt, Germany) 
K2HPO4      Merck (Darmstadt, Germany) 
 
-Mercaptoethanol     Sigma-Aldrich (Deisenhofen, Germany) 
Methanol      Merck (Darmstadt, Germany) 
MgCl2       Merck (Darmstadt, Germany) 
Milk powder      Merck (Darmstadt, Germany) 
NaCl       Merck (Darmstadt, Germany) 
Na glutamate      Merck (Darmstadt, Germany) 
Na2HPO4      Merck (Darmstadt, Germany) 
NaH2PO4      Merck (Darmstadt, Germany) 
NaN3       Sigma-Aldrich (Deisenhofen, Germany) 
NaOH       Sigma-Aldrich (Deisenhofen, Germany) 
Nitrocellulose-Membrane    Amersham Biotech (Uppsala, Sweden) 
Normal goat serum (NGS)   Sigma-Aldrich (Deisenhofen, Germany) 
Ophiobolin      Sigma-Aldrich (Deisenhofen, Germany) 
Paraformaldehyde     Merck (Darmstadt, Germany) 
Paramount      Polysciences Inc. (Warrington, PA/USA) 
4   PDD      Sigma-Aldrich (Deisenhofen, Germany) 
Penicillin/streptomycin    Seromed (Berlin, Germany) 
Peptone      Life Technologies (Eggenstein, Germany) 
Phenol red      Sigma-Aldrich (Deisenhofen, Germany) 
Phosphatase inhbitor cocktail II   Sigma-Aldrich (Deisenhofen, Germany) 
PMA       Sigma-Aldrich (Deisenhofen, Germany) 
PNGase F      Sigma-Aldrich (Deisenhofen, Germany) 
Polyvinylpyrrolidone 20    Sigma-Aldrich (Deisenhofen, Germany) 
Polyvinylpyrrolidone 40    Sigma-Aldrich (Deisenhofen, Germany) 
Polyvinylpyrrolidone120    Sigma-Aldrich (Deisenhofen, Germany) 
Ponceau S solution     Sigma-Aldrich (Deisenhofen, Germany) 
Prestained protein marker    New England Biolabs (Beverly, MA, USA) 
Protease inhibitor cocktail    Roche (Basel, Switzerland) 
Protogold Detection Kit™    BBI International (Plemington, NJ, USA) 
Rabbit anti-glutamate transporter EAAC1  Biotrend (Köln, Germany) 
Rabbit anti-glutamate transporter GLAST Biotrend (Köln, Germany) 
Rabbit anti-glutamate transporter EAAT4     Biotrend (Köln, Germany) 
Rabbit anti-phospho threonine   Zymed Laboratories (San Francisco, USA) 
Rabbit anti-phospho serine    Zymed Laboratories (San Francisco, USA) 
Rabbit anti-phospho tyrosine    Zymed Laboratories (San Francisco, USA) 
Rottlerin      Sigma-Aldrich (Deisenhofen, Germany) 
SDS       Sigma-Aldrich (Deisenhofen, Germany) 
SOC-medium      Clontech (Palo Alto, CA, USA) 
Staurosporine      Sigma-Aldrich (Deisenhofen, Germany) 
Sucrose      Sigma-Aldrich (Deisenhofen, Germany) 
TBOA      Tocris (Bristol,UK) 
TEMED      Sigma-Aldrich (Deisenhofen, Germany)  
TOP10F´E.coli cells     Clontech (Palo Alto, CA,USA) 
Triethanolamine     Sigma-Aldrich (Deisenhofen, Germany) 
Trizma base      Sigma-Aldrich (Deisenhofen, Germany) 
Triton X-100      Sigma-Aldrich (Deisenhofen, Germany) 
Trypsine      Belger (Kleinmachnow, Germany) 
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Tunicamycin      Sigma-Aldrich (Deisenhofen, Germany) 
Tween®- 20      ICN Biochemicals (Eschwege, Germany) 
Ultralink immobilized Biotin   Pierce (Rockford USA) 
Yeast extract      Life Technologies (Eggenstein, Germany) 
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7.2 Devices 
 
Cell culture 
Laminar flow hood Flow BSB 6A and BSB 4A  Gelaire (Meckenheim, Germany) 
Water bath GFL 1004     GFL (Burgwedel, Germany) 
Incubator IG 150      Astel (Chateau Gontier, France) 
Incubator Revico Ultimo     Hettich (Tuttlingen, Germany) 
Autoclave -steam sterilizer 3870EL    Jürgens (Münster, Germany) 
Sterilizer UT 6120      Heraeus (Hanau, Germany) 
 
Centrifuges 
 
Avanti 300       Beckman (München, Germany) 
Centrifuge 5415 D      Eppendorf (Hamburg, Germany) 
Centrifuge 5804 R      Eppendorf (Hamburg, Germany) 
Sepatech Megafuge 1.0     Heraeus (Hanau, Germany) 
Ultra centrifuge Optima-L70 with rotor JA-14  Beckman (München, Germany) 
 
Electrophoresis and blotting 
 
Electrophoresis Power Supply EPS1000 Amersham Biotech (Uppsala, Sweden) 
Power Pac 200      BioRAD (Hercules, California/USA) 
Semi-dry blotting equipment     Sigma (Steinheim, Germany) 
SDS-Gelelektrophorese (Minigel 10 x 10 cm)  Sigma (Steinheim, Germany) 
 
Homogenization 
 
Homogenizer       Heidolph (Kelheim, Germany) 
Homogenizing pistil      Merck (Darmstadt, Germany) 
 
Microscopy 
 
Inverse phase-contrast microscope    Leica (Wetzlar, Germany) 
Confocal laser-scanning microscope TCS SL  Leica (Wetzlar, Germany) 
 
Photometers 
 
Shimadzu UV-2100      Shimadzu (Düsseldorf, Germany) 
Microplate reader MR700     Dynatech (Denkendorf, Germany) 
 
Radioactive work 
 
Scintillation counter      Beckmann (München, Germany) 
Cellulose acetate 0.45 M filters    Sartorius AG (Göttingen, Germany) 
Others 
 
Agfa Curix 60 Film Processor    Agfa (Leverkusen, Germany) 
Balance       Sartorius (Göttingen, Germany) 
Magnetic particle concentrator    Dynal Biotech (Oslo, Norway) 
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Milli Q RO 10 Plus clean water device   Millipore (Eschborn, Germany) 
pH meter pH 213      Merck (Darmstadt, Germany) 
Thermomixer comfort     Eppendorf (Hamburg, Germany) 
Vortex    IKA Labortechnik (Staufen,   
               Germany) 
Consumables 
 
Cell culture flasks      Nunc (Wiesbaden, Germany) 
Centrifuge tubes      Greiner (Frickenhausen, Germany) 
Cryo tubes       Nunc (Wiesbaden, Germany) 
Glass coverslips      Roth (Karlsruhe, Germany) 
Microtiterplates      Nunc (Wiesbaden, Germany) 
Multiwell cell culture plates     Nunc (Wiesbaden, Germany) 
Polycarbonate cell culture filter substrate   Costar (Cambridge, UK) 
Petri dishes       Greiner (Frickenhausen, Germany) 
Reaction tubes      Eppendorf (Köln, Germany) 
Rubber policeman      Costar (Cambridge, UK) 
Scalpel       Bayha (Tuttlingen, Germany) 
Sterile filters Minisart 0,2 µm    Sartorius (Göttingen, Germany) 
Whatman-Paper No.1 und No.3    Whatman (Maidstore, UK) 
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7.3 Methods 
 
7.3.1 cDNA cloning and plasmid construction for EAAC1, GLAST and EAAT4 
 
cDNA cloning, plasmid construction and development of stable cell line for EAAC1 and, 
GLAST were performed by Michael Wiessner [127] as follows. The coding sequence of the 
glutamate transporter EAAC1 and GLAST were isolated from complementary DNA (cDNA) 
derived from adult rat retina of both sexes by the polymerase chain reaction (PCR). The sense 
and antisense primers for EAAC1 were 5’CCATCATGGGGAAGCCCACG3’ and 
5’AGTCCCAGGCATCTAAGGCC-3’, encoding for the EAAC1 nucleotide sequences at 
positions 142–161 and 1724–1743. The sense and antisense primers for GLAST 
5’GAGAGCTAGCAAGTTCAAGA-CACTGAAGTGCA3’ and 
5’GAGAGGGCCCGGGAGATGGACACATTGTAGA-3’, encoding GLAST at positions 136-
157 and 1886-1866. The PCR amplification products of  EAAC1 and GLAST were agarose 
gel-purified, ligated into pBluescript KS-plasmid vector (Stratagene, La Jolla, CA), and 
transformed in E.coli XL1-Blue (Stratagene). Inserts from positive recombinants were 
sequenced on both strands and sub-cloned into the modified expression vector pBK-CMV 
([1098-1300]) (Stratagene), creating the plasmid pCMV-EAAC1 and pCMV-GLAST which 
were used for functional analysis in a mammalian expression system. 
The plasmid pCMV-EAAT4 encoding the cDNA sequence of human glutamate transporter 
EAAT4 was a kind gift from S.Amara. 
 
7.3.2 Microbiology 
All microbiological procedures were performed in a laminar flow hood with sterile devices and 
solutions. Liquid cultures were carefully shaken and Luria Bertami (LB) plates were kept in an 
incubator (LB-medium) [173]. Both, liquid cultures and plates were incubated at 37°C in a 
humidified atmosphere. 
 
7.3.2.1 Transformation of E.coli  
 
In order amplify the plasmid DNA for EAAT4 transient transfections, transformation of E.coli 
was performed as follows: 
One aliquot (50 µl) of competent TOP10F´E.coli cells (Clontech, Palo Alto, USA) were thawed 
on ice followed by addition of 1g of isolated plasmid DNA. 
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The mixture was incubated on ice for 30 min. To allow the DNA to permeate the cell 
membrane, cells were heat shocked at 42°C for 30 s in a pre-warmed water bath. After 2 min 
on ice, 250 µl SOC-medium (Clontech, Palo Alto, USA) was added and the mixture was 
incubated at 37°C for 1 h with shaking in a humidified incubator. 50-200 µl of the cell 
suspension was then spread on LB-ampicillin plates and incubated in a humidified incubator at 
37°C until single colonies grew.  
 
7.3.2.2 Stock cultures and storage of E. coli  
 
In order to preserve the transformed bacteria for prolonged times, glycerol stocks were 
prepared. Single colonies were picked and inoculated in 5 ml LB-medium containing ampicillin 
(50µg/ml). The medium was incubated overnight in a humidified shaker incubator at 37°C.700 
l of the bacterial suspension was mixed with 300µl of glycerol (100%), vortexed for 1 min. 
and stored at -70°C. 
 
7.3.2.3 Isolation of plasmid DNA 
 
Plasmid DNA was isolated from the bacterial cultures Jetstar plasmid purification system. The 
method employs unique anion exchange resin combined with a modified alkaline SDS lysis 
procedure for the preparation of plasmid DNA. The lysates were neutralized and applied to the 
column. The plasmid DNA binds to the resin and washing procedures remove RNA and other 
impurities. Thereafter, the purified plasmid DNA is eluted and concentrated by isopropanol 
precipitation. Plasmid DNA was isolated from E. coli culture grown in LB medium overnight 
(O/N). In all cases 50g/ml each of ampicillin was used as a selection marker. For transient 
transfections, jet star midi plasmid isolation kit (Genomed, Bad Oeynhausen, Germany) was 
used as per manufacturer’s protocol. 
 
7.3.2.4 Determination of DNA concentration 
 
UV absorption spectroscopy was used as the DNA and RNA absorption maxima can be 
observed at 260 nm, those of aromatic amino acid residues of proteins at 280 nm. The purity of 
nucleic acids is measured by the ratio OD260/280; ratios of 1.8 to 1.9 and 1.9 to 2.0 indicate 
highly purified DNA and RNA preparations, respectively. An OD260 value of 1 indicates 50 
µg/ml double-stranded DNA. 
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LB-medium 
Peptone    1% (w/v) 
Yeast extract    0.5% (w/v) 
NaCl     1% (w/v) 
pH          7.4 
 
LB-ampicillin plates 
LB-medium 
Agar     1.5% (w/v) 
Ampicillin   50 g/ml 
 
 
7.3.3 Stable transfections and functional characterization 
 
At 50–80% confluency, human embryonic kidney cell (HEK293, ATCC No. CRL 1573) 
cultures were transfected with pCMV-EAAC1 or with pBK-CMV-GLAST ([98]) (40 
g/5dx106 cells) as a control using calcium phosphate-mediated transfection. 24 h post-
transfection, the culture medium was replaced with fresh Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal calf serum, 50 U/ml penicillin, 50 U/ml streptomycin, 
and 2 g/l Geneticin (Invitrogen) (G418 medium). The G418 medium was replaced every 
second day. Cultures with high glutamate uptake and high glutamate transporter protein 
expression were plated at low density in 1mg/ml G418 media for additional 7 days. G418-
resistant cells were chosen for cloning by limiting dilution method.  
Briefly, cells were diluted to 1 cell/well in 96-well tissue culture plates and grown to 
confluency in 0.5 g/l G418 medium. Each clone was screened for maximal glutamate 
uptake, and stability of glutamate transporter expression (20 sub-cultivations).  
 
Cell line termed HEK-EAAC1 is routinely screened by PCR, Western blot analysis and uptake 
assays for the expression EAAC1 and GLAST. 
All the experiments with EAAT4 were carried out after transient transfections in HEK-293 
cells. For cultivation, adherent cells (HEK-293, HEK-EAAC1, HEK-GLAST, and HEK-
EAAT4 and C6 glioma (ATTC) were grown in culture flasks with filter top seals (75 cm2, for 
various experiments cells were also grown in Petri dishes (60mm) and 6-well dishes.  
Cells were separated by trypsinizing and seeding them at different ratios.  
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Cells were washed in PBS and incubated in trypsin (0.05% w/v) EDTA (0.02% w/v) in PBS 
with gentle shaking to release the cells. The reaction was stopped by addition of 10 ml growth 
medium. The cells were centrifuged in a 50 ml sterile tube at 800g for 10 min at RT, 
resuspended in 10 ml of growth medium and plated at a ratio of 1:10 (5x106cells/ml).   
For all the experiments, the cells were harvested at 80-90% confluence. 
 
7.3.4 Transient transfection of pCMV EAAT4 in HEK-293 cells 
 
The cells were transfected using Lipofecamine™ 2000 according to the manufacturer’s 
instructions. HEK-293 cells were cultured in DMEM supplemented with 10% FCS, 1% 
penicillin/streptomycin and 1% L-Glutamine, split in 6-well plates and grown to 90 % 
confluence. Prior to transfection, the growth medium was replaced by transfection medium 
(without antibiotics) 
 
Table 1 Scheme of scaling up the transfection protocol (adapted from Invitrogen 
Corporation). 
 
Culture vessel 
 
 
Surface area 
(cm2) 
 
Volume of  plating 
Medium 
 
DNA (g) and dilution 
 volume (l) 
 
Lipofectamine™2000 and 
dilution volume (l) 
96-well 0.2 100 l 0.2 g in 25 l 0.5 l in 25 l 
24-well 1 500 l 0.8 g in 50 l 2.0 l in 50 l 
12-well 2 1 ml 1.6 g in 100 l 4.0 l in 100 l 
35-mm 5 2 ml 4.0 g in 250 l 10 l in 250 l 
6-well 5 2 ml 4.0 g in 250 l 10 l in 250 l 
60-mm 10 5 ml 8.0 g in 0.5 ml 20 l in 0.5 ml 
10-cm 30 15 ml 24.0 g in 1.5 ml 60 l in 1.5 ml 
 
 
7.3.5 Cell passage and storage 
 
HEK-EAAC1, HEK-GLAST, HEK-EAAT4, HEK-293 and C6 glioma cells were cultivated in 
75cm2 culture flasks in Dulbecco’s minimum essential medium(DMEM) supplemented with 
10% fetal calf serum (FCS), 2mM L-Glutamine, 100 µg/ml Penicillin und 100 U/ml 
Streptomycin at 37ºC for 2-3 days until 80% confluent.  
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Once confluent, he cells were passaged by washing twice in 10 ml each of PBS (140 mM NaCl, 
2.4 mM KCl, 8.1 mM Na2HPO4, pH 7.4) and incubating with 4 ml trypsin/ EDTA trypsin 
0.05% w/v, EDTA 0.02% w/v) for 1 min at room temperature shaking the flask until the cells 
were released from the surface. The reaction was stopped by the addition of 10ml growth 
medium. The cells were collected in 10 ml sterile tube and centrifuged at 400xg for 10 min at 
RT. the supernatant was discarded ant the pellet resuspended in 10 ml of growth medium. For 
further cultivations, the cells were cultivated in fresh flasks at a ratio of 1:10. 
For storage of stock cultures, cells from 1 flask were trypsinized and resuspended in 1 ml of 
growth medium supplemented with 10% di-methylsulfoxide (DMSO). The cells were 
transferred into a cryotube and cooled overnight in -70°C freezer at the rate of 1°C/min and 
stored in liquid nitrogen until further usage. 
 
7.3.6 Membrane Vesicle Preparation 
 
The cells, grown on 75 cm2 flasks were harvested at 80% confluence, washed twice with 10 ml 
of ice cold cell washing buffer (0.32 M mannitol, 1mM Na-EDTA, pH 7.4) and collected by 
centrifugation at 400xg for 10 min at 4°C. The cell pellet was resuspended in 5 ml ice cold 
loading buffer (0.32 M Mannitol, 0.5 mM K-EDTA, 1 mM MgSO4 in 0.6 M phosphate buffer, 
pH 6.8) and homogenized by passing through a Dounce homogenizer 40 times at 350 rpm. The 
homogenate was centrifuged at 400xg for 10 min at 4 °C to remove the cell debris and the 
supernatant was centrifuged again at 30,000xg for 30 min at 4 °C. The pellet was collected as 
the crude membrane fraction. The pellet was resuspended in homogenization buffer, divided 
into aliquots (1-2 g protein/l; see section 7.3.10.1), frozen in liquid nitrogen and stored at -
20°C until used. Under these conditions, transport activity of the membrane vesicles was stable 
for at least 2 months. 
 
7.3.6.1 Kinetic experiments for glutamate uptake 
 
For uptake of radiolabelled substrate, 20 µl (1-2 g protein/l) of  membrane vesicles were 
diluted at room temperature into 180 µl external transport solution (0.32 M mannitol, 150 mM 
NaCl) supplemented with 1 µCi of L-[3H1]Glutamic acid (42-56 Ci/mmol). The compositions 
of the various external solutions are given in the figure legends.  
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The L-[3H1] glutamate uptake was terminated by addition of 2 ml of an ice cold stopping 
solution (0.15 M NaCl, 0.32 M mannitol) and rapid filtration through cellulose acetate filters 
(0.4 m), which were immediately rinsed with thrice with 1 ml each of ice cold stopping 
solution. Parallel incubations were carried out at 4° C to correct uptake rates for background 
and nonspecific uptake. All concentration-dependent assays contained 1 µCi of L-[3H1] 
glutamate diluted as necessary with cold substrate. After filtration and washing, radioactivity 
was measured using liquid scintillation counting. All experiments were performed in triplicates 
and the results expressed as ± SD. 
                                   
                                                               1000*(cpm sample-cpm blank) 
pmol glutamate/mg protein= ------------------------------------------------------------------------ 
                                             (20*cpm 1Ci 3H1glutamate*specific activity of 3H1glutamate) 
 
 
7.3.7 Cell Lysis and preparation of SDS samples for SDS-PAGE 
 
7.3.7.1 Total cell protein fraction preparation from cultured cells 
 
Cells grown in a 25 cm2 culture flask ad harvested at 80% confluence. The cells were washed 
twice in 5 ml ice cold PBS Ca/Mg containing protease inhibitor cocktail (Roche). The cells 
were harvested by scratching the flask surface with a rubber policeman and collected in a pre-
chilled sterile tube. The cells were then centrifuged at 400xg for 10 min. The supernatant was 
discarded and the pellet was lysed in 500 l cell lysis buffer (150 mM NaCl, 5 mM Na-EDTA, 
50 mM Tris, 1% Triton X-100, pH 7.5) containing protease inhibitor cocktail. The cells were 
incubated at 4°C for 30 min. with intermittent shaking. 
The lysates was centrifuged at 6500xg for 10 min. at 4°C the pellet was discarded and the 
supernatant was collected as the total cell lysates. The relative protein concentration protein 
content of the lysates was determined using Bradford assay (see section 7.3.9.1). 
The lysates was diluted in equal volume of two fold SDS buffer (125 mM Tris/HCl, 4% (w/v) 
Sodium-Dodecyl Sulfate (SDS), 36% (v/v) Glycerin, 10% (v/v) 2-Mercaptoethanol), heated at 
95 °C for 5 min. and immediately frozen in liquid nitrogen and stored at -20 °C at a known 
protein concentration of 1 g/l. 
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7.3.7.2 Total cell protein fraction preparation from tissue 
 
All steps were carried out at 4°C to avoid protease activity. Preparation of total cell protein 
fractions from rat brain tissue was performed according to the following protocol. Rat brain 
cortex and cerebellum was collected from freshly killed rats and immediately transferred to a 
tube with 10 ml of ice cold SPBS buffer (0.05 M sodium phosphate buffer, 0.32 M sucrose, 
1mM sodium EDTA, 150 mM NaCl and protease inhibitor cocktail).  
The tissue was then homogenized using Dounce   homogenizer for 3 min 350 rpm. Tissue 
debris was removed by centrifuging at 400xg for 10 min at 4°C. The supernatant was collected 
as total protein. The protein concentration was determined using the Bradford assay (see 
section 7.3.9.1). The samples were diluted in two fold SDS buffer (see section 7.3.7.1), heated 
at 95°C for 5 min. and immediately frozen in liquid nitrogen and stored at -20 °C at a protein 
concentration of 2mg/ml. 
 
7.3.8 Deglycosylation of EAAC1 
 
7.3.8.1 Deglycosylation by PNGase F 
 
Peptide-N-Glycosidase F (PNGase F) is one of the most widely used enzymes for the 
deglycosylation of glycoproteins. The enzyme releases asparagines-linked oligosaccharides 
from glycoproteins and glycopeptides by hydrolyzing the amide of asparagine (Asn) side chain. 
A tripeptide with the oligopeptide linked asparagines as the central residue is the minimal 
substrate for PNGase F. The enzyme provides an excellent tool to analyse the N-linked 
glycosylations of glycoproteins. 
For in vitro deglycosylation of EAAC1, the cells were harvested at 80% confluence, washed in 
1ml of ice cold PBS Ca/Mg and lysed in 200 l lysis buffer (see section 7.3.7.1) containing 
protease inhibitor cocktail for 30 min at 4 °C.  
Cleared lysate was collected by centrifugation at 6500xg for 10 min. protein concentration of 
the lysate was determined by Bradford assay (see section 7.3.9.1). After determining the 
protein content of the lysate, the lysate was denatured in two fold SDS buffer see section 
7.3.8.1), followed by addition of 15% Triton-X 100 and 5 l (500 U/ml) of PNGase F.  
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The samples were incubated at 37 °C for 15min, 30 min, 1 hr, 2hrs and 3 hrs. After the desired 
incubation time, the reaction was stopped by heating the mix at 100 °C. Samples were 
separated by 10% SDS-PAGE (see section 7.3.10) and analyzed by immunoblotting (see 
section 7.3.11). 
 
7.3.8.2 In vivo deglycosylation 
 
The cells were grown to 80-90% confluence and the medium was supplemented with leupeptin 
(100 g/ml) to inactivate serine and cysteine proteases and Tunicamycin (10 g/ml medium). 
Tunicamycin is a mixture of homologous antibiotics which contain the following common 
building blocks: uracil, N-acetyl glycosamine, an 11-carbon aminodialdose called tunicamine 
and a fatty acid linked to the amino group. Tunicamycin is an inhibitor of bacterial and 
eukaryote N-acetylglucosamine transferases; preventing formation of N-acetylglucosamine 
lipid intermediates and glycosylation of newly synthesized glycoproteins. It blocks the 
formation of protein N-glycosidic linkages by inhibiting the transfer of N acetylglycosamine 1-
phosphate to dolichylmonophosphate. 
Cells were incubated in tunicamycin   for 30 min-24 hrs. After the specific time periods 
mentioned in figure legends, the cells were harvested by washing in PBS Ca/Mg followed by 
lysis in 200l lysis buffer (7.3.7.1) containing protease inhibitor cocktail. The Relative Protein 
concentration of the lysate was determined by Bradford assay (see section 7.3.9.1). The protein 
was denatured in two fold SDS buffer, separated on 10% polyacrylamide gel and analyzed by 
immunoblotting (see section 7.3.11). 
 
7.3.9 Determination of protein concentration 
 
7.3.9.1 Bradford assay 
 
In order to determine the protein concentration of the solubilized proteins, the Bradford assay 
was performed as described by Bradford [174]. The assay is based on the specific binding of 
Coomassie Brilliant Blue G-250 dye (Fig.7.1) to arginine, tryptophan, tyrosine, histidine and 
phenyl alanine residues in proteins.  The dye binds approximately 8 times as well to arginine 
residues as the other listed aromatic residues. 
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The dye in solution is in the cationic form and has an absorption maximum at 470 nm (red).  
The protein bound (anionic) form shifts the absorption maximum to 595 nm. Thus the assay is 
monitored in the spectrophotometer at 595 nm. 
 
 
 
                      
 
 
 
Fig.7.1. Structure of Coomassie Brilliant Blue G-250 
 
The comparison to a standard curve using BSA solution of varied concentrations provides a 
relative measurement of protein concentration. The assay was performed using 800 l double 
distilled (dd) H2O and 200 l Bradford dye along with a defined volume (1-5 l) of total 
lysates of unknown protein concentration. The samples were incubated for 5 min at room 
temperature and the absorbance measured at 595 nm using a spectrophotometer.  
For a blank, a parallel assay was performed without any protein. All the samples were analysed 
in triplicates and the average optical density (OD) was taken for the calculations of the protein 
content.  
 
7.3.9.2 Bicinchoninic acid  (BCA) test 
 
The BCA assay is a popular choice for the assay of protein concentration due to its high 
sensitivity, linearity over a broad range of protein concentration, compatibility with detergents 
and compatibility with a wide range of common buffer components and its overall simplicity. 
The assay is based on the reduction of Cu2+ to Cu1+ by protein in alkaline conditions (the biuret 
reaction).  The cuprous ion formed during the reduction reaction is chelated by two molecules 
of BCA and the result is a purple-colored product having an absorption maximum of 562 nm.   
The macromolecular structure of the protein, the number of peptide bonds, and the presence of 
four specific amino acids (cysteine, tryptophan and tyrosine) are responsible for color 
formation with BCA. 
For samples containing excess SDS, BCA test was performed for the determination of protein 
concentration.  
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The reagent was prepared by addition of 1 volume of CuSO4 (4%) and 50 volumes of BCA 
(Sigma-Aldrich, Deisenhofen, Germany) The reagent was mixed with the protein solution of 
unknown protein concentration and the final volume was maintained at 2 ml.  
A standard curve was also calibrated in parallel using 5, 10, 20, 30, 40 and 50 g/l bovine 
serum albumin (BSA). The reaction was allowed to proceed at 37 °C for 1 hr and the 
absorbance was then measured at 562 nm. The protein concentration was determined by 
comparing the optical density (OD) with the standard. 
 
7.3.10 SDS-polyacrylamide gel electrophoresis 
 
Discontinuous sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed in order to separate complex mixtures of proteins according to their molecular 
weight Laemmli et al [175].  
The sample buffer, containing the anionic detergent SDS denatures the proteins to a so called 
random-coil conformation. SDS also masks the intrinsic protein charge and gives all proteins a 
net negative charge which is proportional to their molecular weight. The sample buffer also 
contains -mercaptoethanol which reduces the disulphide linkages in the sample protein. When 
loaded onto a gel matrix and placed into an electric field, the negatively charged proteins 
migrate towards the anode and are separated by a molecular sieving effect.  
Discontinuous gels contain a short stacking gel with a low percentage of acrylamide and low 
pH (6.8) to concentrate the sample followed by a resolving gel with a higher percentage of 
acrylamide and pH (8.8). 
The lower pH of stacking gel allows for the concentration of proteins between the glycinate and 
chloride ions boundaries. The degree of protein separation depends on the concentration of 
polyacrylamide as well as the length of the gel, and so the concentration of the separating gel 
must be chosen according to the molecular weight of the proteins of interest. 
Before gel electrophoresis protein samples were denatured for 10 min at 95°C. For a 10x10 cm2 
gel, electrophoresis was performed with electrophoresis buffer at 80 V per gel. The voltage was 
increased to 150 V when proteins reached the interface between the stacking and the resolving 
gel. 
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Separating gel 
 
Tris /HCl   0.375 M 
Acrylamide/bis Acrylamide 10% (v/v) 
SDS    0.1% (w/v) 
TEMED   0.1% (v/v) 
APS    0.1% (w/v) 
pH    8.8 
 
Stacking gel 
 
Tris /HCl   0.125 M 
Acrylamide/bis Acrylamide 4% (v/v) 
SDS    0.1% (w/v) 
TEMED   0.1% (v/v) 
APS    0.1% (w/v) 
pH    6.8 
 
SDS Running Buffer 
Tris    0.025 M 
Glycine   192 mM 
SDS    0.1% (w/v) 
 
 
 
7.3.11 Western detection method: protein blotting, immunodetection and  
    stripping. 
 
Western Blotting is the transfer of proteins separated by SDS-PAGE on an immobilizing 
membrane. Proteins are usually blotted electrophoretically. 
The transferred proteins are bound to the surface of the membrane, providing access for 
reaction with immunodetection reagents. All remaining binding sites are blocked by immersing 
the membrane in a skim milk solution.  
After probing with the primary antibody the membrane is washed and the antibody-antigen 
complexes are identified with the secondary anti-IgG antibody coupled to peroxidase. A light 
reaction with a substrate for peroxidase is then used to visualize the proteins. 
The expression of proteins was detected by separating the protein lysate on 10% SDS- PAGE 
(see chapter 2.3.11) and transferring the gel onto a positively charged nitrocellulose membrane 
(Shleicher and Shuell, Dassel, Germany) by semi-dry blotting method as described by Towbin 
et al [176].The nylon membrane was pre-wetted with transfer buffer and the gel was transferred 
onto the membrane. The gel and the membrane were positioned between Whatman™ paper 
soaked with transfer-buffer and an electrical field (0.25 A/cm2) was applied for 90 min.  
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Subsequently, the separated proteins were visualized by Ponceau S staining. The membrane 
was then washed in TBST (150 mM NaCl, 10 mM Tris, 0.05 % Tween-20, pH 8.0) and the 
blocking solution containing 5% milk powder diluted in TBST for 1 hr to block the unspecific 
binding sites. The membrane was the washed 3 times for 10 min each in TBST and then, the 
primary antibody, diluted in TBST supplemented with 0.5% skim milk powder (SMP) was 
added for 1 hr with continuous shaking the dilutions used for various antibodies are listed in 
table 3.  
The membrane was again washed 3x in TBST and incubated with secondary antibody diluted 
in TBST labeled with peroxidase (POD) for 1 hr at RT followed by washing 3 times in TBST 
for 10 min. each. The detection of the signal was performed by applying Amersham 
Biosciences Innovative Enhanced Chemi-luminiscence (ECL) Kit™ (Amersham Biotech) and 
exposure of the membrane to Hyperfilms (Amersham Biotech).The Prestained broad range 
molecular weight marker (New England Biolabs, table 2) was used to evaluate the relative 
molecular weights of the separated proteins. 
 
 
Blotting Buffer 
Tris    25 mM   
Glycine   192 mM  
Methanol   20% (v/v) 
 
TBST buffer 
TRIS    10 mM 
NaCl    150 mM 
Tween®- 20   0.05% 
 
 
20% PVP Blocking Buffer 
PVP 10   10g 
PVP 40   10g 
PVP 120   2g 
 
Made upto 120ml in TBST buffer 
 
SMP Blocking Buffer 
Skim milk powder  5% (w/v)in TBST buffer 
 
 
 
Protein stripping buffer 
Glycine    2 M 
SDS     0.1% (w/v) 
Tween®-20   1%(v/v) 
pH     2.2 
   7.Materials and Methods 
- 107 - 
 
Table2. Molecular weight proteins used as reference for the calculation of the relative 
 molecular weight 
 
No. Protein Apparent molecular weight (kDa) 
1 MBP--galactosidase 175 
2 MBP-paramyosin 83 
3 Glutamic dehydrogenase 62 
4 Aldolase 47 
5 Triosephosphate isomerase 32 
6 -lactoglobulin A 25 
7 Lysozyme 16 
8 Aprotinin 6 
 
 
Table.3 Antibodies used for western blotting 
 
Primary antibody Dilution Time of incubation 
rabbit anti-EAAC1 (Biotrend) 1: 3000 1h 
rabbit anti-EAAT4 (Biotrend) 1: 1000 1h 
rabbit anti-GLAST (N-terminal, from D.Pow) 1: 10,000 1h 
rabbit anti-phospho serine(Zymed Laboratories) 1: 1000 1h 
mouse anti-phospho threonine (ZymedLaboratories) 1: 400  1h 
rabbit anti-phospho tyrosine (Zymed Laboratories) 1: 1000 1h 
  rabbit anti-actin (Sigma) 1:3000                 1h 
Secondary antibody   
goat anti-mouse IgG (POD) (Amersham ) 1:3000                  1h 
goat anti-rabbit IgG (POD) (Amersham ) 1:3000                  1h 
 
 
The membranes were recycled for further applications by incubating in stripping buffer (2 M 
glycine, 150 mM NaCl, 0.05% Tween-20, pH 2.2) overnight at 4 °C to remove adherent 
antibodies. After stripping, the blot was re-incubated in blocking buffer for 1 hr. at RT and re-
probed with phospho-specific antibodies. 
 
After the last immunodetection step the protein loading was determined by the Protogold 
Detection Kit™ (BBI International, Plemington, NJ, USA). The membranes were washed 
thrice for 5 min each in 5 ml of dd H2O and incubated with 5 ml of Protogold solution for 1 
hour with continuous shaking at RT. The blots were then dried at RT and sealed in 
polyethylene films. 
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7.3.12 Immunocytochemistry 
 
Fluorescence microscopy and confocal laser scanning microscopy (CLSM) 
Fluorescence microscopy was used for the detection of proteins in cultured cells stained by 
fluorophor labeled antibodies. Analysis was performed using either a conventional fluorescence 
microscope (Leica DMIRB) or a confocal laser scanning microscope (CLSM) (Leica TCS), that 
additionally provides the determination the three dimensional distribution of stained cellular 
structures. In CLSM, a laser light beam is expanded to make optimal use of the optics in the 
objective. Through x-y deflection mechanism this beam is turned into a scanning beam, 
focused to a small spot by an objective lens onto a fluorescent specimen.  
The reflected light and emitted fluorescent light is captured by the same objective and, after 
conversion into a static beam by the x-y scanner device, is focused onto a photo detector via a 
dichroic mirror. The reflected light is deviated by the dichroic mirror while the emitted 
fluorescent light passes through in the direction of the photomultiplier. 
A confocal aperture, the detection pinhole, is placed in front of the photo detector, such that the 
fluorescent light and not the reflected light from points on the specimen that are not within the 
focal plane where the laser beam was focused will be largely obstructed by the pinhole. In this 
way, out of- focus information is greatly reduced. A two-dimensional image of a small partial 
volume of the specimen centered on the focal plane, referred to as an optical section, is 
generated by performing a raster sweep of the specimen at that focal plane.  
As the laser scans across the specimen, the analogue light signal, detected by the 
photomultiplier, is converted into a digital signal, contributing to a pixel-based image displayed 
on a computer monitor attached to the CLSM. The plane of focus (z-plane) is selected by a 
computer-controlled fine-stepping motor which moves the microscope stage up and down. A 
three-dimensional reconstruction of a specimen can be generated by stacking two-dimension 
optical sections collected in series. 
 
Indirect Immunofluorescence staining of cultured cells 
Immunofluorescence staining was used for the detection and localization of proteins in cultured 
cells. The cells were washed twice with PBS Ca/Mg and then fixed using 4% 
paraformaldehyde (PFA) in PBS Ca/Mg for 5 min at RT. After fixation, the cells were washed 
thrice for 5 min each in PBS Ca/Mg to remove excess PFA.  
The cells were then preincubated and permeabilized in 10% normal goat serum (NGS) and 
0.5% TritonX-100 containing PBS Ca/Mg for 1hr at RT. 
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After Permeabilisation, the cells were washed thrice in PBS Ca/Mg and incubated in primary 
antibody diluted in 3% NGS, 0.3% TritonX-100 in PBS Ca/Mg for 1hr at RT. Thereafter, the 
cells were washed thrice, for 5 min each in PBS Ca/Mg and incubated with the fluorophor 
labeled secondary antibody diluted in 3% NGS, 0.5% Triton-X-100 in PBS Ca/Mg for 1 hr at 
RT. Subsequently, the cells were washed in PBS Ca/Mg and mounted on glass slides using 
aqua polymount® (Polyscience) on cover slips and stored in dark at 4°C to avoid bleaching. 
 
Table 4. Antibody specifications used for immunocytochemistry 
 
Primary Antibody Dilution   Time of incubation 
rabbit anti-EAAC1 (Biotrend) 1: 500 1hr 
rabbit anti-EAAT4 (Biotrend) 1: 500 1hr 
rabbit anti-GLAST (N-terminal, D.Pow) 1:1000                    1hr 
Mouse anti-PKC(BD transduction labs.) 1: 100 1hr 
Rabbit anti-GM130(BD transduction labs.) 1: 100 1hr 
   
Secondary Antibody   
goat anti-mouse IgG Alexa Fluor 546  1: 1000   O/N 4 °C 
goat anti-rabbit IgG Alexa Fluor 488  1: 1000 O/N 4 °C 
 
 
7.3.13 Cell surface Biotinylation 
 
Cell surface Biotinylation offers a novel method to label the surface proteins of live cells as 
described by Daniels and Amara [177]. The method employs use of membrane impermeant 
sulfosuccinimidyl-2-(biotinamido) ethyl-1, 3-dithiopropionate (NHS-SS- Biotin) (Pierce, 
Rockford IL, USA) to attach to proteins of the membrane at the extracellular face of live cells. 
The biotinylated proteins can then be separated from the non-biotinylated cytoplasmic proteins 
by avidin precipitation. 
Cells were cultivated on 7 cm2 culture dishes and harvested at 80-90% confluence. The cells 
were washed in 1ml ice cold PBS Ca/Mg and transferred on ice. The cells were then incubated 
in 1ml Biotinylation buffer (2 mM CaCl2, 150 mM NaCl, 10 mM triethanolamine in PBS 
Ca/Mg) containing1 mg/ml NHS-SS-Biotin for 1 hr at 4°C to label the membrane proteins, 
followed by washing with 1 ml ice cold PBS Ca/Mg and quenching of unreacted biotin with 
1ml of 100 mM glycine in PBS Ca/Mg for 15 min. at 4°C   Thereafter, the cells were lysed in 
200 l lysis buffer (150 mM NaCl, 5 mM Na-EDTA, 50 mM Tris, 1% Triton X-100, pH 7.5) 
containing protease inhibitor cocktail at 4°C for 30 min.  
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The remaining cell debris was separated by centrifugation at 6500xg for 15 min at 4°C. 100 g 
(50 l) protein from the cleared lysates was precipitated with 50 l of neutravidin beads (50% 
slurry) (Pierce, Rockford IL, USA) overnight at 4°C with slow tilt rotation. Beads were 
separated from the lysates by centrifugation at 6500xg at 4°C. The supernatant was collected as 
the non-biotinylated fraction. The beads were washed twice in 1ml each of ice cold lysis buffer, 
once in 1ml ice cold high-salt washing buffer (500 mM NaCl, 5 mM Na-EDTA, 50 mM Tris, 
1% Triton X-100, pH 7.5 containing protease inhibitor cocktail) and once in 1ml ice cold no-
salt washing buffer (50 mM Tris pH 7.5).  
The biotinylated protein fraction was eluted directly in 50 l of 2 fold concentrated SDS buffer 
(see section 7.3.7.1). SDS probes of total cell lysates, non-biotinylated fractions as well as 
biotinylated fractions were stored at -20°C until used. All samples were separated by 10% 
SDS-PAGE (see section 7.3.10) and analyzed by immunoblotting (see section 7.3.11) 
 
7.3.14 Endocytosis of EAAC1 
 
To test for endocytosis of membrane bound EAAC1 cell membrane proteins were biotinylated 
for 1 hr at 4°C (see section 2.3.14), quenched for unreacted biotin by incubation with 100mM 
glycine in PBS Ca/Mg twice, 15 min each and then incubated in serum free medium (to avoid 
influence of any serum derived factors on the endocytotic process) for different time spans (2, 
5, 10, 20 and 30 min) at 37 °C/5 % CO2. After incubation, the cells were transferred at 4°C and 
the remaining non-endocytosed surface biotin was cleaved in 1ml glutathione cleavage buffer 
(50 mM glutathione, 75 mMNaCl, 10 mM Na-EDTA, 1% BSA, 0.075 N NaOH, pH 7.5) per 
7cm² culture dish for 15 min at 4 °C.  The cells were then lysed in 200 l lysis buffer (see 
section 2.3.7.1) and the protocol identical to cell surface biotinylation (see section 2.3.12) was 
followed thereafter.  
 
The biotinylated and non-biotinylated fractions were separated by 10% SDS-PAGE (see 
section 7.3.10) and analyzed by immunoblotting (see section 7.3.11) and the rate of endocytosis 
was calculated by densitometry as the decrease of the biotinylated pool with respect to time. 
Densitometry was performed using Phoretix total lab software (Biostep GmbH, Jahnsdorf, 
Germany) Curve fitting for the Densitometric data was done using Sigma Plot 8 software.  
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7.3.15 Recycling of EAAC1 
 
Recycling experiments were carried by an indirect method using membrane Biotinylation 
principle. 
For the recycling experiments, the cells were cultivated on 7cm2 dishes biotinylated in 1 ml of 
Biotinylation buffer (see section 2.3.14) containing 1mg/ml NHS-SS-Biotin at 4°C, quenched 
of unreacted biotin by incubating the cells in 1ml of 100mM glycine (in PBS Ca/Mg) at 4°C for 
15 min.  Thereafter, the cells were incubated at 37 °C and 5% CO2 in serum free medium for 20 
min. to allow for the endocytosis of biotinylated surface proteins. The cells were then 
transferred on ice at 4°C.  
The surface biotin was cleaved in 1ml ice cold glutathione cleavage buffer for 15 min at 4°C 
and the cells were stimulated again using 100 nM PMA in 2 ml serum free medium at 37°C and 
5% CO2  supplemented with 50mM reduced glutathione. Samples were collected after time 
intervals of 2, 5, 10, 20 and 30 min. The biotinylated proteins recycled to the surface were 
cleaved with 1ml of glutathione cleavage buffer for 30 min at 4°C for a second time.  
The cells were then lysed in lysis buffer (see section 7.3.7.1) and the proteins not recycled and 
hence still tagged with biotin were separated by avidin precipitation. The proteins were further 
separated by 10% SDS-PAGE (see section 7.3.10) and analyzed by immunoblotting (see 
section 7.3.11). 
The Densitometric analysis of the data was performed using Phoretix Total lab software 
(Biostep GmBH , Jahnsdorf, Germany)  and the curve fitting was done using SigmaPlot 8 
software. 
 
7.3.16 Immunoprecipitation 
 
The immunoprecipitation technique is been used to specifically isolate proteins from a whole 
mixture of cell proteins.  
In this thesis immunoprecipitation was used for the isolation of phospho-specific proteins as 
well as EAAC1 and the subsequent analysis of the phosphorylation state of the protein. The 
covalent binding of the antibody to tosyl-activated dynabeads (Dynal, Oslo, Norway) was 
performed as follows: 107 tosyl-activated dynabeads ®M-280 were washed thrice in 1ml bead 
washing buffer.  
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The beads were then mounted on the separator for 5 min and the supernatant removed. 3 g of 
the desired antibody was diluted in 100 l of antibody dilution buffer was added to the beads 
and vortexed for 1 min. The beads were then incubated at 37°C for 24 hrs to ensure covalent 
binding of antibody to the beads.  
After incubation, the beads were concentrated on the magnetic separator and the supernatant 
was discarded. The coated beads were then washed twice in 1ml each of washing buffer and 
once in 1ml blocking buffer. The beads were again incubated in 1ml blocking buffer for 24 hrs 
at 4 °C to block the free tosyl groups. The beads were stored at concentration of 30 µg/ml in 
bead washing buffer. For the immunoprecipitation of desired protein from the lysates, cells 
were cultivated in 7 cm2 culture dishes and harvested at 80-90% confluence (with or without 
treatment with different agents). The cells were washed twice in ice cold PBS Ca/Mg and 
collected by scraping in PBS Ca/Mg.  
The cells were pelleted by centrifugation at 400xg for 10 min. at 4°C the pellet was 
resuspended in 200 l lysis buffer at 4°C (with 10 l/ml phosphatase inhibitor cocktail to avoid 
dephosphorylation of phosphorylated proteins) (see section 7.3.7.1) and incubated on ice for 30 
min. the lysates was centrifuged again at 6500xg for 10 min at 4 °C and the supernatant was 
incubated with 20 l coated beads with slow tilt rotation for 1 hr at RT.  
After incubation, the beads were concentrated using the magnetic concentrator. The beads were 
washed 4 times in 1 ml each of lysis buffer and twice in PBS Ca/Mg. For analysis by SDS-
PAGE, the beads were suspended in 20 l SDS loading buffer in incubated at 95 °C for 10 min 
to elute the proteins from the beads. For each sample, 10 l of the eluted sample was analyzed 
by SDS-PAGE (see section 7.3.10).  
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